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Respiratory ailments are major human killers, especially in developing countries including 
South Africa. Tuberculosis is one of the most prevalent infectious respiratory tract disease 
posing a major threat to human healthcare worldwide. This disease is a highly contagious 
airborne bacterial disease that usually infects the lungs and sometimes other body parts. 
Tuberculosis spreads easily in overcrowded conditions from one person with an active 
respiratory disease to another via droplets that are emitted when they sneeze or cough. 
Approximately two million deaths that occur worldwide per annum are caused by 
tuberculosis and about 285,000 cases occur in South Africa. This is the seventh highest total 
number in the world. The emergence of drug-resistant tuberculosis and other pathogenic 
diseases over the past decades makes this disease a serious threat to human health worldwide. 
Emerging drug-resistant tuberculosis strains and the long duration of treatment has 
established an urgent need to search for new effective agents. According to a 2012 report by 
the World Health Organisation (WHO), South Africa, China, India and Russia are the 
countries with the highest prevalence of multi drug-resistant (MDR) tuberculosis.  
 
Most researchers in South Africa have focused on evaluating the antimycobacterial activity of 
medicinal plants against bacterial strains that cause tuberculosis, but there has not been 
sufficient focus on the related ailments. Therefore, one of the aims of the present study was 
the evaluation of the antimicrobial properties of the selected medicinal plants against 
Mycobacterium species and other bacterial strains related to respiratory infection. The floral 
diversity of South Africa has a potential for yielding new bioactive compounds, therefore 
pharmacological screening of plant extracts from this region is important. The aim of this 
study was the pharmacological evaluation of plants that are used traditionally in South Africa 
to treat tuberculosis and related symptoms against microorganisms that cause respiratory 
ailments, and the identification of compounds from antimicrobial active plant extracts. 
  
Ten plants: Abrus precatorius subsp. africanus (leaves and seeds), Asparagus africanus 
(leaves), Asparagus falcatus (leaves), Brunsvigia grandiflora (bulb), Ficus sur (bark and 
roots), Indigofera arrecta (leaves and roots), Leonotis intermedia (leaves and stem), 
Pentanisia prunelloides (leaves and roots), Polygala fruticosa (whole plant), and Terminalia 
phanerophlebia (leaves, roots and twigs) were selected based on a survey of available 
2 
 
literature of medicinal plants used in South Africa for the treatment of tuberculosis and 
related symptoms. Ground plant material from different plant parts of the 10 plants were 
extracted sequentially with four solvents: petroleum ether (PE), dichloromethane (DCM), 
80% ethanol (EtOH) as well as water, and a total of 68 extracts were produced. The plant 
extracts of the selected plants were evaluated for antibacterial activity against four 
microorganisms (Klebsiella pneumoniae, Staphylococcus aureus, Mycobacterium aurum A+ 
and Mycobacterium tuberculosis H37Ra) associated with respiratory infections using the 
microdilution assay. Cyclooxygenase-2 (COX-2) enzyme was used to evaluate the anti-
inflammatory activity of the extracts. The Ames test and mitochondrial reduction (MTT) 
assays were used to establish toxicity of the extracts that showed noteworthy antimicrobial 
activity against the tested bacterial strains (Klebsiella pneumoniae, Staphylococcus aureus, 
Mycobacterium aurum A+ and Mycobacterium tuberculosis H37Ra). The extracts were 
tested for genotoxicity against Salmonella typhimurium (TA98 and TA100 strains) and 
cytotoxicity using monkey kidney Vero cells. Based on good antimicrobial activity observed, 
compounds were isolated from Terminalia phanerophlebia (leaves). Crude extracts obtained 
from 80% methanol (MeOH) of Terminalia phanerophlebia were successively extracted with 
hexane, DCM, ethyl acetate (EtOAc) and n-butanol. The fractions and isolated compounds 
obtained were tested for their antibacterial activity against Mycobacterium aurum A+, 
Mycobacterium tuberculosis H37Ra, Staphylococcus aureus and Klebsiella pneumoniae. 
Structure elucidation was carried out using NMR (1D and 2D) spectroscopic methods. 
 
This investigation revealed the pharmacological potential of the 10 plants used in South 
Africa for traditional treatment of tuberculosis and related symptoms: Abrus precatorius 
subsp. africanus (leaves and seeds), Asparagus africanus (leaves), Asparagus falcatus 
(leaves), Brunsvigia grandiflora (bulb), Ficus sur (bark and roots), Indigofera arrecta (leaves 
and roots), Leonotis intermedia (leaves and stem), Pentanisia prunelloides (leaves and roots), 
Polygala fruticosa (whole plant), and Terminalia phanerophlebia (leaves, roots and twigs). 
The minimum inhibitory concentration (MIC) values of the tested plant extracts ranged from 
0.098 to 12.5 mg/ml. Out of 68 extracts tested from different plant parts of the 10 plant 
species, 18 showed good antimicrobial activity against at least one or more of the microbial 
strains tested with MIC values ranging from 0.098 to 0.78 mg/ml. For anti-inflammatory 
results, only three extracts showed high inhibition (˃ 70%) of the COX-2 enzyme. In the 
Ames test using Salmonella typhimurium (TA98 and TA100 tester strains), all the extracts 
tested were non-genotoxic. However, in the MTT assay nine extracts demonstrated 
3 
 
cytotoxicity. Bioguided fractionation of the EtOAc fraction of Terminalia phanerophlebia 
(leaves) afforded two bioactive compounds: methyl gallate (methyl-3,4,5-
trihydroxybenzoate) (1) and a phenylpropanoid glucoside; 1,6-di-O-coumaroyl 
glucopyranoside (2). These compounds are reported from Terminalia phanerophlebia for the 
first time. Both compounds showed good antimicrobial activity against all bacterial strains 
tested with MIC values ranging from 0.063 to 0.25 mg/ml. Inhibition of Mycobacterium 
tuberculosis by 1,6-di-O-coumaroyl glucopyranoside (2) at a MIC value of 0.063 mg/ml was 
noteworthy, as this bacterial strain is reported to be the leading cause of tuberculosis 
worldwide.  
 
The good antimicrobial property of Abrus precatorius subsps. africanus, Asparagus 
africanus, Asparagus falcatus, Terminalia phanerophlebia, Indigofera arrecta, Ficus sur, 
Leonotis intermedia and Pentanisia prunelloides partially authenticate their traditional use in 
the treatment of respiratory diseases. However, these plants must be used with caution as 
some of their extracts showed cytotoxicity against Vero cells. The results observed in this 
study indicate that Abrus precatorius subsp. africanus, Asparagus africanus, Asparagus 
falcatus, Ficus sur, Pentanisia prunelloides and Terminalia phanerophlebia could be 
investigated further against drug-resistant tuberculosis strains. Good antimicrobial activity 
exhibited by the compounds isolated from Terminalia phanerophlebia (leaves) authenticate 
the traditional use of this plant in treating tuberculosis and its related symptoms. Compound 
(2), 1,6-di-O-coumaroyl glucopyranoside showed noteworthy activity against a 
Mycobacterium tuberculosis strain H37Ra (0.063 mg/ml), therefore this compound could 











Over the centuries, humans have depended on different parts of plants for basic needs such as 
food, clothing, and shelter (PHILLIPSON, 2001). Plants have been used as medicine since 
antiquity to cure various human diseases and ailments, they have also been used for other 
purposes such as production of fertilisers, flavours, and fragrances (HALBERSTEIN, 2005; 
GURIB-FAKIM, 2011). Traditional medicine systems like the Chinese, Ayurvedic, Native 
American, and African ones have been in existence for centuries and they continue to provide 
mankind with new remedies (SALIM et al., 2008). This is evident from archaeological proof 
indicating that people regularly used medicinal plants in ancient times for curative and 
psychotherapeutic purposes (HALBERSTEIN, 2005). According to NEWMAN et al. 
(2000) “the first annals on the therapeutic properties of medicinal plants dates back to 2600 
BC”. The annals were written on clay tablets in cuneiform, from Mesopotamia (DIAS et al., 
2012). The oils of Cedrus species and Cupressus sempervirens L., Glycyrrhiza glabra L., 
Commiphora species and Papaver somniferum L. are among the substances that were used, 
all of which still continue to be used today for the treatment of coughs, colds, parasitic 
infections and inflammation (GURIB-FAKIM, 2006). In developing countries people still 
use medicinal plants as their primary source of medicine and approximately 60-80% of the 
world’s population use plants for their healthcare needs (PALOMBO, 2006). Although there 
has been universal, cross-cultural utilisation of medicinal plants, scientific research validating 
their efficacy is being conducted on a worldwide scale (KONG et al., 2003). There are many 
research journals available, highlighting the biological activities and constituents of 
medicinal plants. Some of the therapeutic properties accredited to plants have been proven to 
be noteworthy, whereas others erroneous, yet the interest in plants as a source of potential 
chemotherapeutic agents continues (GURIB-FAKIM, 2011).  
 
1.2. History of the medicinal use of plants by humans 
 
The commencement of the use of medicinal plants by humans was instinctive, based on 
experience, as there was no information concerning which plant to use and how it could be 
used (PETROVSKA, 2012). As time passed, reasons for specific medicinal plant usage in 
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treating certain illnesses became available; therefore, the use of plants as medicine gradually 
abandoned the empiric basis and became founded on descriptive facts. Plants were used as 
the source of treatment and prophylaxis until the advent of chemical medicine in the 16 th 
century. However, the decreasing effectiveness of synthetic drugs make the use of natural 
remedies interesting once more. 
 
According to CRABTREE (2013), the Sumerian clay slab from Nagpur (about 5000 years 
old) contained written proof of the use of plants for preparation of drugs. It contained 12 
methods for drug preparation referring to over 250 plants. Camphor, the great yellow gentian, 
ginseng, jimson weed, cinnamon bark, and ephedra are some of 365 dried plant parts 
recorded in ‘Pen T’Sao’, a Chinese book on roots and grasses written by Emperor Shen Nung 
approximately 2500 BC (BENDER et al., 1966). Spices used today such as nutmeg, pepper, 
and clove originate from India, and are recorded in Indian holy books ‘Vedas’, as used for 
treatment of illnesses. A collection of 800 prescriptions referring to 700 plant species and 
drugs used for therapy such as pomegranate, castor oil plant, aloe, senna, garlic, onion, fig, 
willow, coriander, juniper, and common centaury are recorded on the Ebers Papyrus written 
approximately 1550 BC (BENDER et al., 1966).  
 
According to information from the Bible and the holy Jewish book (The Talmud), aromatic 
plants such as myrtle and incense were used by humans during various rituals accompanying 
a treatment (PETROVSKA, 2012). Medicinal plants such as wormwood and common 
centaury were applied against fever; and garlic against intestinal parasites. Opium, henbane, 
deadly nightshade, and mandrake were used as narcotics; fragrant hellebore and haselwort as 
emetics. Sea onion, celery, parsley and asparagus were found in the works of the Hippocrates, 
classifying plants based on their physiological action (PETROVSKA, 2012).  
 
Theophrastus was considered the founder of botanical science with his books “De Causis 
Plantarium”- Plant Etiology and “De Historia Plantarium”-Plant History (THANOS, 2005). 
He produced a classification of more than 500 medicinal plants known at the time and 
amongst those plants there were cinnamon, iris rhizome, false hellebore, mint, pomegranate, 
cardamom, fragrant hellebore and monkshood (THANOS, 2005).  
 
In early history, Dioscorides was the most prominent writer on plant drugs and is today 
known as the father of pharmacognosy, who studied medicinal plants wherever he travelled 
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while working as Nero's army military physician and pharmacognosist (PETROVSKA, 
2012). Paracelsus was one of the advocates of chemically prepared drugs from plants and 
minerals. His beliefs were based on observations, and he simultaneously supported the 
“Signatura doctrinae”-signature doctrine (PETROVSKA, 2012).  
 
Although the early use of medicinal plants by ancient people was as simple pharmaceutical 
forms, infusions, decoctions and macerations, between the 16th and 18th centuries, the 
demand for compound drugs was increasing. The compound drugs contained medicinal 
plants along with drugs of an animal and/or plant source. The early 19th century saw the 
turning point in the use and knowledge of medicinal plants as there was the discovery, 
substantiation and isolation of alkaloids, glycosides, tannins, saponosides, etheric oils, 
vitamins and hormones (ZENK and JUENGER, 2007). Today, almost all pharmacopoeias 
worldwide describe plant drugs of medicinal value.  
 
1.3. An overview of traditional medicine systems 
 
Traditional medicine (TM), variously known as ethnomedicine, folk medicine, native healing, 
or complementary and alternative medicine (CAM) is an ancient and culture-bound method 
of healing that humans have used to cope and deal with various diseases that have threatened 
their existence and survival (ABDULLAHI, 2011). Several classifications have been 
attempted for defining and classifying TM (WACHTEL- GALOR and BENZIE, 2011). 
However, the World Health Organisation (WHO) defined TM as the “sum total of the 
knowledge, skills, and practices based on the theories, beliefs, and experiences indigenous to 
different cultures, whether explicable or not, used in the maintenance of health, as well as in 
the prevention, diagnosis, improvement or treatment of physical and mental illness” (WHO, 
2000). 
 
Traditional medicine is used by a large proportion of the population either due to the system 
being accepted from a cultural and spiritual perspective or to the high cost of western 
pharmaceuticals (TAYLOR et al., 2001). There are many forms of TM systems that exist 
within cultures and in different regions (WACHTEL-GALOR and BENZIE, 2011). 
Regarding raw material, production methods and quality control of products, in South Africa 
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and many other developing countries, there is currently no standardisation of TM (TAYLOR 
et al., 2001).  
 
African and Latin American TM is marked strongly by an oral tradition of sharing 
information about medicinal plants even though training exists in various forms (from self-
education to teaching by an expert practitioner) (UNESCO, 2013). On the other hand 
traditional Chinese medicine (TCM) has a formal structure and documentation is supported 
by the government (TAYLOR et al., 2001).  
 
Traditional Chinese medicine is an ancient system (more than 3000 years) of medicine that is 
based on two separate theories about the natural laws that govern good health and longevity, 
namely ‘yin’ and ‘yang’, and the five elements (‘wu xing’) (WACHTEL-GALOR and 
BENZIE, 2011; YAO et al., 2013). Traditional Chinese medicine was incorporated into the 
national healthcare system by providing academic training and emphasising research and 
today it is taught in local medical schools and universities as part of a mixed curriculum 
(GURIB-FAKIM, 2006). In TCM, 60% of the curriculum is devoted to TM and the 
remaining 40% to modern medicine (WACHTEL-GALOR and BENZIE, 2011). Up to 
40% of healthcare delivered in China is TCM and more than 90% of general hospitals have 
TM units (WACHTEL-GALOR and BENZIE, 2011). 
 
Among the systems of medicine, African traditional medicine (ATM) is perhaps the most 
diverse. However, in the past the knowledge was usually transferred orally from one 
generation to the next, thus it is poorly recorded when compared to the TCM 
(MAHOMOODALLY, 2013). African traditional medicine in its diverse forms, is holistic 
involving both the body and the mind, with the healer typically diagnosing and treating the 
psychological basis of an illness before prescribing medicines to treat the symptoms 
(GURIB-FAKIM, 2006). The majority of the African population (80%) use TM for their 
primary healthcare needs (RICHTER, 2003). Some people in Africa utilise only TM, while 
others combine it with conventional drugs. Traditional medical practitioners (TMPs) are an 
important aspect of the health-care delivery system (ADEDEJI et al., 2013).  
 
Africa is known to have a rich biological and cultural diversity with marked regional 
difference in healing practices, and is considered as the cradle of mankind (DA SILVA et al., 
2011). There is an estimated 68000 plant species that are found in the African region of 
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which about 35000 are known to be endemic (ADEDEJI et al., 2013). More than 5000 plants 
are known to be used for curing various diseases and ailments, but only a few have been 
studied extensively (IWU, 1993). 
 
In the recent past, there has been a growing interest in TM and its relevance to public health 
both in developed and developing countries. There is also a critical need to mainstream TM 
into public healthcare to achieve the objective of improved access to healthcare facilities 
(UNESCO, 2013). Traditional medicine practice is also spreading significantly in some 
developed countries as people become disillusioned by modern medicine and lose confidence 
in it. Almost half the population in industrialised countries use TM, either because they are 
convinced that this type of medicine is risk free and more natural (UNESCO, 2013). 
Although many developing and developed countries recognise TM, not all of them make it an 
important part of the healthcare system. However, a few countries such as China and India 
have reached a level of offering TM as a healthcare option.  
 
Due to the fact that TM lacks a scientific basis, although contributing significantly in 
healthcare it seldom cooperates with modern healthcare (TAYLOR et al., 2001). Other 
problems associated with TM are that its methods, and training are often kept secret, and does 
not keep pace with advances in science and technology (TAYLOR et al., 2001). The 
developed world initially showed rather little attention to indigenous traditional knowledge 
and provided minimal help to developing regions for preservation, collection and 
systemisation of the knowledge until the late 1980s (TAYLOR et al., 2001). However, 
recently there is an interest in natural products, this has led to an increasing respect for 
indigenous people and their customs and beliefs. 
 
1.4. South Africa’s traditional plant based medicines 
 
South Africa is estimated to have more than 24 000 plant species that occur within her 
borders, representing 10% of the world’s species. Thus, the South African region is 
considered to be a biodiversity hot spot (COETZEE et al., 1999). About 3000 plant species 
have been recorded by various cultural groups in South Africa as part of their materia medica 
(DE WET et al., 2013). Traditional medicine still forms an important part of the healthcare 
system of the South African population as is the case in most developing countries. It was 
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estimated that up to 60% of the South African population consult a traditional healer in 
addition to western trained doctors (TAYLOR et al., 2001). The South African population 
does not only use plants as medicine due to the rich biodiversity that exist in this region, but 
also because of coexisting diverse cultural groups with their associated beliefs and practices 
(PRETORIUS, 1999). Each culture in this region uses medicinal plants for preventing and 
curing various diseases and ailments. Traditional medicine treatment used in South Africa is 
holistic, it does not only deal with the physical aspect of the disease but also deals with 
psychosocial aspects (PRETORIUS, 1999).  
 
A traditional healer is defined as a competent and community recognised person who 
provides healthcare using natural resources and has relevant knowledge about attitudes and 
beliefs regarding physical, mental and social well-being and the causation of disease 
(PRETORIUS, 1999; ELUJOBA et al., 2005). Although diverse cultural groups within 
South Africa subscribe to their own traditional systems of therapy, there are structural 
similarities that are evident. With different African cultures TM practitioners are classified 
into different categories as they do not perform the same functions. Among practitioners of 
TM are the diviner, they are known by different names in the different cultures of South 
Africa, for example, amagqirha in Xhosa, izangoma in Zulu, ngaka in Northern Sotho, selaoli 
in Southern Sotho and mungome in Venda and Tsonga (PRETORIUS, 1999; TRUTER, 
2007). The popular press terms the diviner as isangoma, and the herbalist inyanga. However, 
nowadays the distinction between the diviner and the herbalist is not clear as a result of 
overlapping duties amongst the two. The prophet or faith healer that divines and heals within 
the framework of the African independent church is a more recent category of traditional 
healers. The interim coordinating committee (ICC) of traditional medical practitioners in 
South Africa has proposed to include traditional surgeons (iingcibi in Xhosa), and traditional 
midwives/birth attendants (ababelethisi in Zulu) in the proposed legislation. The healer: 
population ratio in South Africa is estimated to be 1:200. There are approximately 200 000 
traditional healers in South Africa (TAYLOR et al., 2001; TRUTER, 2007). However, this 
is likely to be an underestimation of people who provide medicinal plants-dependent services, 
as there are chances of ignoring people who do not identify themselves as full-time traditional 
healers, although they use medicinal plants to provide healthcare. Traditional healers are 
unlike medical doctors who only treat the disease, but also try to relink the social and 
emotional equilibrium of patients based on community rules and relationships. In many 
communities, traditional healers usually determine how to bring the sick person back into 
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harmony with the ancestors by acting as intercessors amongst the visible and invisible 
worlds; the living and the dead or ancestors, determining which spirits are working 
(ABDULLAHI, 2011). However, a significant turning point in the history of this old 
tradition and culture was marked by the influx of Europeans. Western medicine and culture 
introduction gave rise to a cultural-ideological clash which had previously created an unequal 
power relation that undermined and stigmatised the indigenous African way of medicine that 
included the use of medicinal plants (ABDULLAHI, 2011). However, that is no longer the 
case as medicinal plants are known to have great potential in human healthcare. 
 
The majority of South Africans first call traditional healers when illness strikes (TRUTER, 
2007; VAN NIEKERK, 2012). The reason for calling traditional healers first might be 
because they are easily accessible as they reside within the communities and that people 
believe in their healing abilities or in alleviating illnesses. Traditional healers are involved in 
activities such as tuberculosis control, nutritional, and social plant use programmes, and are 
part of student training programmes, thus playing a significant role in dealing with health 
problems in South Africa. Additionally, the acquired immunodeficiency syndrome (AIDS) 
foundation of South Africa, which supports human immunodeficiency virus (HIV) and AIDS 
education for traditional healers recognises that they are engaged in educating people and 
providing counselling (VAN NIEKERK, 2012).  
 
Due to the fact that traditional healing techniques vary among geographic regions and 
cultures, the methods of healing need to be standardised. Standardisation of TM in South 
Africa has recently become a topic of discussion based on the fact that there is loss of oral 
information and there is a rapid pace of urbanisation in this country (TAYLOR et al., 2001). 
National governments have made moves to encourage research into medicinal plants and the 
development of good policies, regulations and standards (trade or use of medicinal plants and 
training of traditional healers) by setting up research institutes and funding. In 1995, the 
South African government took the initiative for making ATM legitimate. The provincial 
governments were called by the national health minister and the provincial Members of 
Executive Council (MECs) for health to conduct public hearings on traditional healthcare 
availability (PRETORIUS, 1999). In 2011, a call was made by the president of the Republic 
of South Africa for standardisation of ATM. A follow up conference was held in South 
Africa in 2013 to determine how other countries such as China and Ghana standardised their 
traditional medicines and to use that as a guide to standardise the ATM in this region. Greater 
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interest in research of South Africa’s natural resources is being promoted by the country’s 
government through agencies such as the National Research Foundation (NRF) and Medical 
Research Council (MRC). 
 
1.5. Secondary metabolites 
 
A plant is similar to a factory, as it produces a vast and diverse range of organic compounds 
classified as primary and secondary metabolites (CROZIER et al., 2006). Primary 
metabolites are defined as compounds that have essential roles in processes such as 
photosynthesis, respiration and plant growth and development (CROTEAU et al., 2000; 
CROZIER et al., 2006). Examples of primary metabolites include phytosterols, acyl lipids, 
nucleotides, amino acids and organic acids. On the other hand, secondary metabolites are 
structurally diverse compounds and vast numbers are distributed among plant species. 
Examples of secondary metabolites include terpenes, phenolic compounds, and alkaloids, 
classified based on their biosynthetic origin (AGOSTINA-COSTA et al., 2012). Although 
ignored for some time, their role in plants is now attracting attention as some of these 
compounds have key roles in plant protection from microbial infection. Secondary 
metabolites are also of interest as they are viewed as potential sources of new natural drugs, 
antibiotics, and insecticides (CROZIER et al., 2006). A vast number of plant based natural 
products have been reported to provide a beneficial role in human health. This has inspired 
more research focusing on searching for new drugs and antibiotics (CROTEAU et al., 2000). 
 
1.6. Drug discovery from medicinal plants 
 
Natural products with therapeutic properties have been utilised as the main source of drugs 
for a long time (RATES, 2001). Between 1981 and 2002, about 28% of new chemical 
entities were natural product derivatives (BALUNAS and KINGHORN, 2005). Various 
infectious diseases and ailments are known to be treated by the use of herbal remedies. 
Presently natural products and their derivatives represent more than 50% of all drugs in 
clinical use and 25% of that, originate from higher plants (MARIDASS and DE BRITTO, 
2008). Out of 252 drugs considered by the WHO as basic and important, 25% are exclusively 
of plant origin (RATES, 2001). Examples of some 100 plant-based drugs that were 
introduced in United States of America (USA) drug market during 1950-1970 include 
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deserpidine, reseinnamine, reserpine, vinblastine and vincristine which are derived from 
higher plants. Other plant derived drugs such as artemisinin appeared worldwide from 1971-
1990 (VERMA and SINGH, 2008). Early drugs such as cocaine, codeine, digitoxin, 
morphine and quinine, some of which are still in use, were derived from medicinal plants 
(BALUNAS and KINGHORN, 2005).  
 
In developing countries, about 33% of drugs that were produced in the early 1970s were 
derived from plants. This accounted for up to 40% of all prescriptions at that time (KONG et 
al., 2003). In 1980, more than US $1800 million was paid by consumers to the American 
economy in prescriptions containing plant-derived drugs (FARNSWORTH et al., 1985). In 
1985 the annual production of traditional plant remedies contributed US $571 million dollars 
to the Chinese economy and sales of crude drugs in the country amounted to $1400 million 
(AKERELE, 1993). This shows the importance of plant-derived drugs in boosting the 
economy of developed and developing countries. 
 
Ethnobotany and plants provide a rich resource of natural drugs for scientific development. 
However, a very small percentage (about 15%) of plants have been investigated for their 
potential as sources of drugs and only about 5% for one or more biological activities (KONG 
et al., 2003; VERPOORTE et al., 2006). Even though there is a lot of research on medicinal 
plants that is published yearly, there are only a few plants that have been studied broadly for 
pharmacological properties (KONG et al., 2003). Due to these facts, medicinal plants 
obviously represent a great source of future new leads for the development of drugs. 
 
Drugs discovered from plants benefit humans even today, although earlier, it was mostly a 
result of coincidence based on human practices (WANG et al., 2007). The isolation and 
characterisation of pharmacologically active compounds from medicinal plants continues and 
recently, drug discovery techniques have been applied to the standardisation of herbal 
medicines, to elucidate analytical marker compounds (BALUNAS and KINGHORN, 2005). 
Natural products, particularly medicinal plants continue to be important sources of new drugs 
in spite of the current interest in molecular modelling, combinatorial chemistry, and other 
synthetic chemistry techniques by pharmaceutical companies (DIAS et al., 2012). These 
compounds can be used as leads for new drugs and new chemical entities other than being 
used directly as drugs (SALIM et al., 2008). However, in some situations these compounds 
13 
 
are not the first choice in treatment of severe life-threatening infections, but can be useful in 
many other ways (VAN WYK and WINK, 2004). 
 
1.7. Respiratory tract infections 
 
The respiratory system is made up of two parts classified as the upper and lower respiratory 
tract (FILE, 2002). Infectious diseases of the respiratory tract are common and they present a 
challenge in precise diagnosis and management, and are among the leading causes of 
mortality and morbidity worldwide (ELLIS, 1998; FILE, 2000). These infections occur 
among both the young and elderly with aged humans having a greater mortality from 
pneumonia, influenza, tuberculosis, infective endocarditis, urinary tract and intraabdominal 
infections (FILE, 2002). Depending on the part of the respiratory tract that is affected, 
infections can be caused by a huge variety of microorganisms. Most upper respiratory tract 
infections are caused by viral pathogens, they are not severe, and are self-limiting. In 
contrast, the lower respiratory tract infections are more likely to have a bacterial etiology, are 
more severe, and more often require antimicrobial intervention (FILE, 2002). Annually, 
about 7 million people die worldwide as a direct consequence of acute and chronic 
respiratory infections from the common cold to many life-threatening conditions such as 
tuberculosis (AKINGBADE et al., 2012). Infectious diseases of the respiratory tract are a 
widespread problem and will likely remain a problem for the future (ELLIS, 1998). 
 
Globally, lower respiratory tract infections are a common reason for hospital outpatient visits 
and antimicrobial prescriptions (FILE, 2002). In 1998, the WHO reported that 3.7 million 
deaths were due to lower respiratory tract infections (CARROLL, 2002). Despite all the 
advances made by medical science, lower respiratory tract infections are still the most 
frequent among infectious causes of mortality worldwide (AKINGBADE et al., 2012). 
Pulmonary tuberculosis is one of respiratory tract infections that arise from pathogens in the 
lower respiratory tract. According to WHO, tuberculosis is one of the most prevalent causes 
of death in Africa, responsible for about 1.5 million deaths in 2008 (BATES et al., 2013).  
 




Tuberculosis is an airborne bacterial disease that is highly contagious mostly infecting the 
lungs and sometimes other body parts like the central nervous system, adnexa, prostate 
seminal vesicles, bladder, ureter, adrenal glands, spleen, liver, peritoneum, bones, spine, 
psoas muscles, intestine, tonsils and middle ear (OKUNADE et al., 2004). The disease can 
be classified as pulmonary or extrapulmonary tuberculosis, and is usually caused by a human 
tubercle bacillus called Mycobacterium tuberculosis but occasionally by the bovine tubercle 
bacillus, Mycobacterium bovis or by Mycobacterium africanum (TRIPATHI et al., 2004). 
Tuberculosis is one of the most prevalent infections of mankind having a major challenge in 
public health contributing considerably to illness and death worldwide (AHMAD, 2011). In 
the case of pulmonary tuberculosis, the bacterium usually destroys the soft tissue of the lungs, 
resulting in difficulty with breathing, and this cause cavities or holes in the lungs, and blood 
can be coughed up. If untreated it can cause death. The bacterium is very resistant to sunlight, 
antiseptics and disinfectants and can survive in dry sputum for weeks. Tuberculosis spreads 
easily in overcrowded conditions from one person to another via droplets from the throat and 
lungs of people with the active respiratory disease when they sneeze or cough (GREEN et 
al., 2010; TEKWU et al., 2012). Transmission of tuberculosis occurs after prolonged close 
contact with a person that tested smear positive for the bacteria. The symptoms of 
tuberculosis vary depending on the part of the body that is infected. However, the most 
common tuberculosis symptoms may include persistent cough (for three weeks or more), 
chest pains, tiredness and weakness of the body, loss of appetite and weight, night sweats 
even when it’s cold and coughing up blood or mucus, fever, easy fatigability, stiffness of the 
neck, headache, vomiting and skin rash (MOORE et al., 2009). Tuberculosis infection can 
be latent (showing no symptoms of tuberculosis infection while the bacteria remains alive 
and dormant) or active (have symptoms of tuberculosis infection). Tuberculosis infection is 
latent at the initial stage of infection and may progress to an active disease in later life 
particularly if a person’s immune system becomes weakened, for example in the case of 
HIV/AIDS or due to chemotherapy. The majority of tuberculosis infected people are unaware 
of their infection as they appear not to be sick. However, when the disease starts to be active 
they may die if they do not receive effective treatment immediately.  
 
1.7.2. Historical viewpoint of tuberculosis 
 
Historically, tuberculosis is one of the oldest, most prevalent and diverse health problems of 
mankind known since time immemorial (AHMAD, 2011; FYHRQUIST et al., 2014). 
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Scientists believe that the disease established itself in human populations about 8000 B.C. at 
the time of transition of humans from nomadic tribes to settled, agricultural based societies 
(DANIEL, 2006). Tuberculosis has been detected in prehistoric skeletons and Egyptian 
mummies, and reference was found in ancient Babylonian and Chinese writings (PAVAN et 
al., 2012). Many of the human remains found in Egypt show vertebrae erosion and fusion due 
to infection by tuberculosis. By the time the Europeans reached East Africa in the 19th 
century tuberculosis was already well established (DANIEL, 2006). During the emergence of 
Europe from the dark ages, a renewed interest in science coincided with an tuberculosis 
epidemiology that began in early 1600 and continued for the next century (BASEL, 1998). 
Tuberculosis became known as the white death and was almost as feared as the black death 
also known as bubonic plague. In America, just like in Egypt, there is archeological evidence 
of early tuberculosis in Peruvian mummies. There is evidence that tuberculosis in America 
occurred prior to the arrival of the first European explorers (DANIEL, 2006). In ancient 
Greece, tuberculosis was called phthisis (consumption) and was noted by a Greek physician, 
Hippocrates (BASEL, 1998; DANIEL, 2006). In the beginning of the 20th century despite 
the rapid spread of tuberculosis in Europe, Nilotic North Africa, and America, in sub-Saharan 
Africa tuberculosis remained unknown, as has been reported by a number of medical 
observers (BLOOM, 1994). As noted by the army medical officers from Britain in places 
where immigration of Europeans had not occurred, tuberculosis was unknown. Livingstone 
and Lichtenstein also found no trace of tuberculosis in parts of South Africa in the first half 
of the 20th century (BLOOM, 1994). 
 
In the Biblical books of Deuteronomy and Leviticus, tuberculosis is noted clearly using the 
ancient Hebrew word schachepheth (DANIEL, 2006). René Théophile Hyacenthe Laennec 
clearly identified the pathogenesis, described the physical signs of tuberculosis and also 
unified its concept whether pulmonary or nonpulmonary. By the time of Laennec, 
tuberculosis had surged across Europe, with London, Stockholm and Hamburg having a death 
rate approaching 800-1000 per 100000 annually (DANIEL, 2006). American cities also had 
similar death rates. During such tuberculosis incidences, the society responded by 
romanticising the disease with victims wan and pallid faces thought to be attractive (BASEL, 
1998). Hermann Heinrich Robert Koch changed the history of tuberculosis when he produced 
evidence that the disease was caused by a specific microbe. Using a staining technique he 
visualised slender rods which he called tubercle bacilli. Wilhelm Conrad von Röntgen also 
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contributed to the diagnosis of tuberculosis by discovering X-rays that showed the 
development, course and severity of the disease (BASEL, 1998).  
 
In the mid-19th century the mortality rate of tuberculosis began to decrease due to advanced 
knowledge about the disease and the use of vaccines and several antibiotics to control it 
(DANIEL, 2006). The decline of tuberculosis is still evident in Europe and America with the 
incident rate continuing to be low (DANIEL, 2006; WHO, 2013). However, Africa remains 




Mycobacteria, belonging to the family Mycobacteriaceae are made up of Gram-positive, 
aerobic, non-motile and slightly curved or straight rod shaped bacteria that are characterised 
by a complex cell envelope containing a high percentage of lipids which includes mycolic 
acid (PARISH and STOKER, 1998; ROGALL et al., 1990; DOSTAL et al., 2003; 
HASAN et al., 2013). The cell envelope isolates the cell from the environment and protects it 
from adverse conditions as well as making the bacteria relatively impermeable to antibiotics 
(PARISH and STOKER, 1998). Mycobacteria appear phenotypically most closely related to 
Nocardia, Rhodococcus and Corynebacterium (DOSTAL et al., 2003). It can infect most 
animal species, however most interest resides in the fact that it includes major human 
pathogens like Mycobacterium tuberculosis (the most disease infectious cause of mortality 
worldwide) and Mycobacterium leprae (PARISH and STOKER, 1998). Naturally and 
taxonomically mycobacteria falls into two major groups: the slow growers and fast growers, 
the former includes most of the human and animal pathogens whereas the latter consist of 
non-pathogenic species such as Mycobacterium aurum. The pathogenic species of 
mycobacteria that cause tuberculosis in humans and animals include Mycobacterium 
tuberculosis, Mycobacterium bovis, Mycobacterium canetti, Mycobacterium africanum, and 
Mycobacterium microti (McGAW et al., 2008a). The non-tuberculous group of 
mycobacteria that are mostly wide spread in the environment include Mycobacterium avium, 
Mycobacterium intracellulare, Mycobacterium paratuberculosis and Mycobacterium 
lepraemurium. The nonpathogenic strains of mycobacteria are encountered after surgery and 




1.7.4. Global effect of tuberculosis 
 
Tuberculosis has reemerged in recent years as a serious world health problem (CAMACHO-
CORONA et al., 2007; MANN et al., 2008; McGAW et al., 2008a; SHUBLADZE et al., 
2013). It is the most common cause of morbidity and mortality; more especially in HIV 
infections, and is becoming pandemic in some parts of the world (GANDHI et al., 2006). 
There is estimation that one-third of the world’s population is infected with the tubercle 
bacillus (KAMATOU et al., 2007; BANSAL et al., 2009; BUENO et al., 2011; JENA et 
al., 2013). Approximately eight million new cases and two million deaths per annum are 
caused by tuberculosis (BUENO et al., 2011). In 2008, South-East Asia was declared by the 
WHO as a region having the largest number of new tuberculosis cases with 35% of newly 
reported cases globally. The sub-Saharan Africa had over 350 cases per 100000 members of 
the population killing both adults and children (WHO, 2010; RAMOS et al., 2013). Africa 
also has the worse death rate of tuberculosis patients. This is due to failing tuberculosis 
programs (GANDHI et al., 2006; MAKOMBE, 2006). Out of an estimated 1.7 million 
people that died from tuberculosis in 2009, the African region had the highest number 
(WHO, 2010). Tuberculosis remains a world health problem (WHO, 2009a; WHO, 2011). 
 
Africa which is home to approximately 11% of the world’s population reports more than a 
quarter of the global tuberculosis burden and the spread of this disease is still rising in the 
continent (MAKOMBE, 2006). Between 1993 and 2003, the report rate of new smear 
positive tuberculosis increased from 20 cases per 100000 members of the population to 75 
(MAKOMBE, 2006). The prevalence of tuberculosis in many parts of the world has 
stabilised with the exception of Africa, South-East Asia and the Western Pacific region. 
There are sub-regional differences in the burden of tuberculosis in Africa with southern and 
eastern parts having the highest per capita burden (MAKOMBE, 2006). In the Southern 
African region, seven countries report approximately 400 to 700 cases per 100000 members 
of the population while North Africa has comparatively the lowest tuberculosis burden of less 
than 65 cases per 100000 members of the population. In the Central African countries, six out 
of seven countries reported between 100-200 cases per 100000. Most Eastern African 
countries report less than 200 cases per 100000 members of the population with the exception 
of Kenya. More than 60% of Western African countries report fewer than 100 cases per 




In South Africa, tuberculosis is the most commonly notified disease and the country was 
ranked number four in the list of 22 countries that were affected by tuberculosis (LALL and 
MEYER, 1999; SEMENYA and MAROYI, 2013). An estimated 285,000 cases of 
tuberculosis are found in South Africa and this is the seventh highest total number in the 
world and the second in Africa (GREEN et al., 2010). The incidence rate of tuberculosis was 
reported to be high in mines exceeding 4000 per 100000 members of the population per 
annum. This is mainly a result of high prevalence of silica dust exposure (SEMENYA and 
MAROYI, 2013). In 2009, approximately 407000 tuberculosis cases were notified in South 
Africa, with KwaZulu-Natal and the Eastern Cape provinces accounting for almost 50% of all 
cases. In South Africa, the tuberculosis and HIV co-infection rate is high, about 58% of those 
infected with tuberculosis are co-infected with HIV (GREEN et al., 2010; CDC, 2011). In 
the North West province of South Africa, tuberculosis was ranked fourth as being responsible 
for death in all genders, and in Mpumalanga the disease was ranked the sixth cause of death 
of people (SEMENYA and MAROYI, 2013). In Limpopo province, tuberculosis was 
ranked as the fifth cause of death of people for all races and genders (SEMENYA and 
MAROYI, 2013). Of the numerous factors responsible for the tuberculosis epidemic in South 
Africa, late and inadequate detection of tuberculosis cases; and ineffective diagnostic 
techniques are of utmost causes (BADASI, 2011). Tuberculosis is still a serious infectious 
disease in South Africa and effective strategies are needed to control it. Figure 1.1 depicts 







Figure 1.1: Number of tuberculosis cases reported by district in South Africa, 2008. EC, 
Eastern Cape; FS, Free State; GP, Gauteng province; KZN, KwaZulu-Natal; LP, 
Limpopo province; MP, Mpumalanga province; NC, Northern Cape; NW, North West, 




1.7.5. Modern treatment of tuberculosis 
 
Before the advent of modern tuberculosis chemotherapy, therapeutic strategy was based on 
bed rest, surgical removal and isolation of the effected part of the lungs. However in 1952, 
due to research and extensive clinical trials done for many years, the modern treatment for 
tuberculosis was discovered. The beginning of tuberculosis chemotherapy showed the 
importance of nature in fighting against the diseases (DE SOUZA, 2009). Tuberculosis 
treatment was not only effective for curing the disease, but is among the most cost effective 
ways of prolonging healthy human life (GRANGE and ZUMLA, 2002). After the discovery 
of streptomycin several synthetic drugs were introduced to the market (DE SOUZA, 2009).  
 
There are two stages of tuberculosis treatment and these are the first line and second line anti-
tubercular drugs (WHO, 2006). The drugs commonly used for tuberculosis treatment include 
rifampin, isoniazid, pyrazinamide, ethambutol, kanamycin and fluoroquinolones which are 
often used in combination (LAI et al., 2011). 
 
1.7.5.1. First line anti-tuberculosis therapy 
 
The first line anti-tuberculosis drugs include isoniazid, rifampin, pyrazinamide and 
ethambutol that are used in combination based after considering the needs of an individual 
patient, sputum culture and sensitivity test results (ARCANGELO and PETERSON, 2006). 
Using the first line anti-tuberculosis drugs in combination is the single most important factor 
to be considered when deciding on a tuberculosis treatment, except in the case of latent 
tuberculosis (SENSI et al., 1959). It is recommended that patients must receive four drugs on 
a regular basis until culture and sensitivity testing is complete. Isoniazid and rifampin are the 
pillars of tuberculosis therapy as they have bactericidal effects to both rapidly growing and 
replicating Mycobacterium tuberculosis organisms. Rifampin (Figure 1.3) has a broad 
spectrum of activity acting on both the extracellular and intracellular bacilli. The mode of 
action of rifampin is to inhibit bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic 
acid (RNA) polymerase by blocking the initiation chain formation of RNA (SENSI et al., 
1959). Isoniazid (Figure 1.2) is used in both prevention and treatment of tuberculosis. This 
antibiotic is only bactericidal when there is rapid growth of mycobacteria, but bacteriostatic 
in the case of slow growing bacteria (AHMAD et al., 2009). Rifampin must be activated by 
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KatG, a bacterial catalase-peroxidase enzyme to Mycobacterium tuberculosis. Isonicotinic 
acyl and NADH are coupled by KatG to form an isonicotinic acyl-NADH complex that 
tightly binds to the enoyl-acyl carrier protein reductase, thereby blocking the action of fatty 
acid synthase and the natural anoyl-AcpM substrate. This process inhibits mycolic acid 
synthesis in the mycobacterial cell and that leads to death of the bacteria (AHMAD et al., 
2009). Pyrazinamide (Figure 1.4) is a bacteriostatic drug, but can be bactericidal on 
replicating tuberculosis bacteria. It is a prodrug that is activated to pyrazinoic acid by the 
pyrazinamidase enzyme of Mycobacterium tuberculosis. This drug is only active at acidic pH 
ranging between 5.5 to 5.8, and under normal culture conditions shows little or no activity 
(LORIAN, 2005). Pyrazinamide is for the initial treatment of active tuberculosis for both 
adults and children, and should be used in combination with other antibiotics. Ethambutol 
(Figure 1.5) is a bacteriostatic drug and works in combination with other drugs such as 
isoniazid, rifampin and pyrazinamide. This drug works by obstructing cell wall formation 
(ARCANGELO and PETERSON, 2006). 
 
                                           
Figure 1.2: Isoniazid                                                 Figure 1.3: Rifampin 
                             




1.7.5.2. Second line anti-tuberculosis therapy 
 
When tuberculosis strains show no sensitivity to the first line drugs, then other antibiotics are 
recommended. However, before the recommendations to take second line drugs are made, the 
patient must be monitored by a specialist (ARCANGELO and PETERSON, 2006). Second 
line drugs include fluoroquinolones and kanamycin. Fluoroquinolones are important 
antimycobacterial agents that are used in cases of resistance to first line tuberculosis drugs. It 
inhibits synthesis of bactericidal DNA through bacterial topoisomerase inhibition ii (DNA 
gyrase) and topoisomerase iv inhibition, which are responsible for super coiled DNA 
relaxation and replicated chromosomal DNA separation. Fluoroquinolones eradicate bacteria 
by interfering with DNA replication, and are ineffective against intracellular pathogens. 
There are different types of fluoroquinolones, they include ciproflaxin, levofloxacin, 
gatifloxacin, moxifloxacin, ofloxacin and norfloxacin (HOOPER, 2001). Kanamycin 
(Figure 1.6) is produced during fermentation of Streptomyces kanamyceticus. This drug 
interferes with protein synthesis in bacterial cells. The mechanism of action is that defective 
protein synthesis results through its irreversible binding to 30S and 50S ribosomal subunits 
(WAKSMUNDZKA-HAJINOS and SHERMA, 2011). 
 
 
                                                           Figure 1.6: Kanamycin 
 
As common with other medications, anti-tuberculosis drugs have side effects. For example 
pyrazinamide, rifampin and isoniazid can induce hepatoxicity. Liver injury induced by drugs 
is a long standing cause of concern in tuberculosis treatment and its rate ranges from 5 to 
33%. Rifampin may cause renal failure, hemolysis and thrombocytopenia (due to platelets 
absorbing anti-rifampin antibodies resulting in damage of the platelet) (LAI et al., 2011). 
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Furthermore, rifampin and pyrazinamide can cause arthalgias which is evident when the 
patient experiences pain, and has swelling joints. Ethambutol causes retrobulbar neuritis and 
the symptoms of this are blurred vision, decreased visual acuity, central scotoma and colour 
blindness. Other side effects of anti-tuberculosis drugs are hypersensitivity reactions such as 
acneform skin rash or systemic lupus erythematosus (tissue damage to segments of the 
vascular tissue and various surfaces) these are caused by isoniazid (LAI et al., 2011). 
 
Tuberculosis treatment consists of a combination of anti-tuberculosis drugs, as a single drug 
would be less capable of killing a typical tuberculosis bacterium in some patients. 
Nonetheless, this interaction could have positive and negative effects to the patient’s health. 
Besides tuberculosis drugs having to interact with each other, they also interact with 
antiretroviral treatment and this makes tuberculosis very difficult to treat when there is an 
HIV infection (LAI et al., 2011). For instance, when HIV protease inhibitors (antiretroviral) 
react with rifampin, its serum concentration is decreased by 35 to 92%. Thus, there is a need 
to find new anti-tuberculosis drugs without or with less side effects (LAI et al., 2011). 
 
As with other infectious diseases, pathogens have developed resistances to drugs known to 
treat them, and tuberculosis is no exception. Resistance to the first discovered anti-
tuberculosis drug was found in the middle of 1950s (NEGI et al., 2009). Many cases of 
multi-drug resistant (MDR) tuberculosis are treatable by means of prolonged therapy with 
more expensive and more toxic drugs given under strict supervision (MANN et al., 2008). 
This raises the cost of therapy as it takes more time to cure the disease (two years and more) 
than the usual 6 months, furthermore not all patients are cured (MOLINA-SALINAS et al., 
2006). Additionally, the spread of tuberculosis in patients infected with HIV is increasing. 
The directly observed treatment strategy has not been responding according to expectations 
as the success rate has been reported to be 67% instead of the expected 85% (GANDHI et 
al., 2006). This, however increases the need to find new drugs that will not only shorten the 
duration of treatment but will also be active against latent tuberculosis, MDR and extensive 
drug-resistant (XDR) tuberculosis and be of use to patients infected with HIV. Since the 
drugs sometimes cannot inhibit a typical tuberculosis pathogen or drug-resistant strain, new 
treatments must be found.  
 
The known currently available vaccine for tuberculosis is Bacillus Calmette-Guèrin (BCG) 
which is usually used in children for protecting them against extrapulmonary forms of 
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tuberculosis such as meningitis (ZELADA et al., 2006; LAI et al., 2011). The effectiveness 
of the vaccine has been proven in clinical trials and case studies to be 70-80% effective 
against tuberculosis meningitis in children, the most severe form of the disease. However, the 
efficacy of the vaccine wanes 10 to 15 years post vaccination, thus adults are not protected 
against pulmonary forms of tuberculosis and may only be protected against primary forms of 
infection (ZELADA et al., 2006; DOROKHOV et al., 2007; LAI et al., 2011). Only a few 
cases have shown BCG vaccine affording protection when given to adults (16 years and 
older) and virtually no data on persons over 35 years old are available.  
 
1.7.6. Measures taken to control tuberculosis worldwide 
 
In almost all countries, there are tuberculosis control programmes that includes the directly 
observed treatment short course (DOT) (AL-HAJOJ and VARGHESE, 2013). The DOT 
programme was recommended by the WHO enabling the patients to be monitored daily by a 
healthcare worker during treatment (AL-HAJOJ and VARGHESE, 2013). In the United 
States of America, DOT is a standardised approach that is currently based in communities 
(FLOYD et al., 1997). Directly observed treatment short course has been reported to be cost 
effective, it is less expensive than hospital admission, and has achieved a high cure rate 
(FLOYD et al., 1997). Even in very poor African countries, the cost of hospital care is 
unlikely to decrease enough to make DOT treatment comparatively inexpensive. However in 
a study that was done in KwaZulu-Natal, South Africa by FINLAY et al. (2012), half of all 
patients interviewed reported to be unsupervised when taking their medication. Poor 
programme implementations were observed more especially where there were high case 
loads (FINLAY et al., 2012). Previous research noted the delay of tuberculosis treatment by 
rural patients due to being unable to travel to centres of treatment daily as they could not 
afford to (MOORE et al., 2009). Some patients often change their living places or 
experience side effects of drugs or are not knowledgeable about the treatment course. This 
makes DOT services implementation a challenge and may be an ineffective strategy for 
tuberculosis control in South Africa. The national coordination of this programme has been 
improving with greater visibility of political leaders raising support and awareness on 
tuberculosis (MAKOMBE, 2006). In April 2001, 16 African heads of state and governments 
showed their commitment in the Abuja declaration and plan of action on HIV/AIDS, 
tuberculosis and other related infectious diseases to develop strategies that will ensure 
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adequate prevention and cure of the diseases (MAKOMBE, 2006). However, despite this 
improvement the rates of case detection and treatment are still low, because DOT services are 
still not accessible to all segments of the population (MAKOMBE, 2006). Although the 
DOT remains essential for controlling tuberculosis, according to global statistics the strategy 
alone will not be enough to achieve the 2015 “stop tuberculosis target” especially on the 
African continent (MAKOMBE, 2006). 
 
1.7.7. Overview of medicinal plants in treating tuberculosis 
 
Antimycobacterial activity has been tested on a large number of plants worldwide, this is 
evident from the reports on in vitro inhibition of different species of mycobacteria that have 
been produced, however, more plants still need to be investigated for their efficacy (LALL 
and MEYER, 1999; MOLINA-SALINAS et al., 2006; GREEN et al., 2010; LUO et al., 
2011). Mycobacteria species were found to be sensitive against extracts of Maerua edulis 
Gilg & Gilg-Ben. DeWolf, Securidaca longipendunculata Fresen., Zanthoxylum capense 
(Thunb.) Harv and Tabernaemontana elegans Stapf (MOLINA-SALINAS et al., 2006; 
LUO et al., 2011). In South Africa, research on documenting and evaluating medicinal plants 
that are used for treating tuberculosis and its related symptoms has been done. Such research 
includes ethnobotanical studies that were conducted in Limpopo by GREEN et al. (2010), 
and in rural Maputaland and in KwaZulu-Natal by YORK et al. (2011) to select medicinal 
plants used in treating tuberculosis. Other studies were conducted by MATIVANDLELA et 
al. (2008), LALL and MEYER (1999), BUWA and AFOLAYAN (2009) screening 
randomly selected medicinal plants against strains of Mycobacterium. In a study by GREEN 
et al. (2010), out of a total of 21 medicinal plants screened against Mycobacterium 
tuberculosis H37Ra and a clinical strain resistant to first line drugs, four plants showed 
noteworthy minimum inhibitory concentration (MIC) values. These were Berchemia discolor 
(Klotzsch) Hemsl., Bridelia micrantha (Hochst.) Baill., Terminalia sericea Burch. ex DC and 
Warburgia salutaris (G.Bertol.) Chiov with a MIC value of 25 µg/ml. Artemisia afra Jacq. ex 
Willd., Galenia africana L. and Drosera capensis L. exhibited inhibition of Mycobacterium 
segmatis with MIC values ranging from 0.78 to 6.25 mg/ml, respectively 
(MATIVANDLELA et al., 2008). Extracts from Drosera angustifolia F.Muell. and Galenia 
africana were found to have activity against Mycobacterium tuberculosis with MIC values of 
5 and 12 mg/ml (MATIVANDLELA et al., 2008). The acetone extracts of Euclea natalensis 
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A.DC. exhibited some activity against Mycobacterium bovis with MIC value of 26 µg/ml 
(McGAW et al., 2008b). The acetone extracts of Euclea natalensis, Helichrysum melanacme 
DC. and Polygala myrtifolia L. were found to have a MIC value of 0.1 mg/ml (LALL and 
MEYER, 1999). According to ELDEEN and VAN STADEN (2008) the ethanol (EtOH) 
extracts of Acacia seyal Delile, Combretum krausii Hochst., Kigelia africana (Lam.) Benth. 
and Ziziphus spina-christi (L.) Desf. showed MIC values between 0.19 and 1.56 mg/ml 
against Mycobacterium aurum. Coleonema album (Thunb.) Bartl. & H.L.Wendl. was 
reported to have activity against Mycobacterium smegmatis in the bioautography assay; and 
the acetone extract from this plant showed antimycobacterial activity against drug sensitive 
Mycobacterium tuberculosis inhibiting more than 99% of the bacterial population at a 
concentration of 1 mg/ml (McGAW et al., 2008a). 
 
Compounds with antimycobacterial activity have been isolated from plants (FYHRQUIST et 
al., 2014). Thus, drugs used in tuberculosis therapy might be found from medicinal plants 
that are used for tuberculosis and other bacterial infection treatments (NEGI et al., 2009). 
The plant derived compounds with antimycobacterial activity, include aegicerin isolated from 
Clavija procera B.Ståhl which demonstrated good activity against Mycobacterium 
tuberculosis H37Rv and MDR tuberculosis strains (EARL et al., 2010). Diospyrin isolated 
from Euclea natalensis showed activity against a strain of Mycobacterium tuberculosis with 
an MIC value of 100 µg/ml in a study done by LALL and MEYER (2001). Oleanolic acid 
was isolated from Buddleja saligna Willd., and both oleanolic acid and ursolic acids isolated 
from Leysera gnaphalodes (L.) L. showed good antimycobacterial activity when tested 
against Mycobacterium avium, Mycobacterium scrofulaceum, Mycobacterium microti and 
Mycobacterium tuberculosis H37Rv. The flavone, 5,7,2-trihydroxyflavone isolated from the 
EtOH extract of Galenia africana was found to have activity against Mycobacterium 
segmatis and Mycobacterium tuberculosis with MIC values of 0.031 mg/ml and 0.10 mg/ml 
respectively (MATIVANDLELA et al., 2008). A new compound, termilignan B and arjunic 
acid isolated from Terminalia sericea were reported by ELDEEN et al. (2008) to have 
displayed insignificant activity against Mycobacterium aurum A+. The naphthoquinone 7-
methyljuglone and diospyrin isolated from chloroform extract of Euclea natalensis (root) 
showed activity at MIC values ranging from 0.5 to 8.0 µg/ml against drug sensitive and 
resistant Mycobacterium tuberculosis strains (McGAW et al., 2008b). Thus, screening of 
diverse South African plants for antimycobacterial activity offers much potential in the search 
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for new active metabolites that may have activity against tuberculosis and other opportunistic 
infections. 
 
1.8. Medicinal plant trade 
 
Due to the healing role attributed to medicinal plants, many cities have become centers of 
demand for plants from rural areas and across the borders of South Africa. A major source of 
income in Africa are medicinal plants. They are not only traded locally but are also widely 
exported in bulk for the international market. In terms of export figures, the African continent 
comes second to Asia (ICS-UNIDO, 2004). It was reported by ICS-UNIDO (2004) that 
more than 10% of the African region’s floristic diversity is likely to be exploited for 
commercial purposes and half of it is underutilised at present.  
 
There are relatively few plants in South Africa that are utilised economically despite the 
enormous plant species richness (COETZEE et al., 1999). However, attempts have been 
made to use plants in boosting the economy of the nation with permission from the legal 
owners. Most households in South Africa spend between 4-8% of their annual income on TM 
and services (MANDER, 1998). BOTHA et al. (2004) expressed the opinion that the actual 
economic value of medicinal plant trade in South Africa may be more than estimated by 
various researchers, the reason being that in informal trade the volume of sales are not 
quantified easily due to lack of records and the often illegitimate nature of the trade. 
 
In South Africa, medicinal plant traders conform to two generalised market systems: a 
primary informal and more formal market (MANDER and MCKENZIE et al., 2005). The 
marketing is driven primarily by largely informal economics and dominated by simple 
technologies enabling a wide range of community members to be involved in various trade 
aspects. The major players involved in harvesting and trading of medicinal plants for the 
informal sector are rural people, especially women and children (MANDER, 1998). A large 
informal trade business has been established with medicinal plants as a result of urbanisation. 
Herb traders trading from fixed licensed premises called herbal muthi shops are 
representatives of the formal market and this includes phytomedicine, nutraceuticals and 
cosmeceuticals (COETZEE et al., 1999). Economical exploitation of natural plant resources 
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is limited, with only the indigenous industry that has managed to successfully establish small 
and medium scale entrepreneurs.  
 
During the last 10 years, research on southern African medicinal plants has been gaining 
momentum (VAN WYK, 2008). About 38 indigenous plant species have been 
commercialised in South Africa and made available in modern packaging and various forms 
of tea, tinctures, tablets, capsules as well as ointments with several others produced for the 
multi-million rand informal market (VAN WYK, 2008). In 1998, an estimated 20 000 tonnes 
of medicinal plants were repeatedly used in TM trade in South Africa. This huge volume has 
increased pressure on habitats, resulting in many local extinctions (VAN WYK, 2008). 
Research by in 1997, BOTHA et al. (2004) revealed that approximately 70 different plants 
representing 40 families were traded in the low-veld of Limpopo province. WILLIAMS et 
al. (2000) surveyed 50 herbal muthi shops, and reported that 69% of traded medicinal plants 
were harvested from Gauteng, North West, Limpopo and Mpumalanga. In KwaZulu-Natal, 
23 of the 70 traded plants are protected species in the province. In 1998, an estimated 4000 
tonnes of plant material was said to have been traded in KwaZulu-Natal. In the same year, 
Eastern Cape was said to have traded 505 tonnes of plant material (MOENG and 
POTGIETER, 2011).  
 
1.9. Conservation of medicinal plants 
 
Conservation of medicinal plants involves their preservation and protection, through planned 
management to prevent neglect, over-exploitation or even destruction (OKIGBO et al., 
2008). The income and living standards of rural people that are economically vulnerable in 
developing countries depends on utilisation and commercialisation of medicinal plants 
(WILLIAMS et al., 2000). Therefore, wild resource harvesting is an economic activity 
recognised by developing countries. The demand of medicinal plants whether for scientific 
evaluation or commercialisation has led to indiscriminate harvesting of the wild flora and has 
resulted in traditional medicines becoming unavailable to people who have relied on them for 
years (ROBERSON et al., 2008). As there is continued demand for medicinal plants, there is 
a need for species conservation through sustainable harvesting and cultivation methods as 
their overharvesting has placed them at extinction risk (ROBERSON et al., 2008; 
NJOROGE et al., 2010). According to ROBERSON et al. (2008), about 15000 medicinal 
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plant species may be threatened with extinction worldwide with experts estimating the loss of 
at least one potential drug every two years. All these reasons justify the urgent need to study 
and conserve medicinal plants. Governments and non-profit organisations are expected to act 
to meet the challenge. 
 
Interest in medicinal plants has been based on the assumption that they will continuously be 
available for use (ZSCHOCKE et al., 2000). However, slow growing and slow seed 
reproducing species are more vulnerable to excessive collection as a consequence there are 
many plants that are threatened to extinction. Medicinal plant management has become an 
urgent matter because of the rapid increase in informal trade. Destructive harvesting of barks, 
roots, bulbs and whole plants is of huge concern to resource managers.  
 
Approximately 5400 wild harvested medicinal plant species are utilised in Africa as TM 
(NAHASHON, 2013). The majority of these medicinal plants are collected from the wild 
through uncontrolled and unsustainable harvesting. This unsustainable harvesting of 
medicinal plants has resulted in some species becoming threatened, if not extinct, despite 
their importance in human healthcare and livelihood. The importance of conserving 
medicinal plants rose from the cultural, livelihood and economic roles they have in human 
life (HAMILTON, 2004). However, these resources are disappearing at a disturbing rate, not 
only because of unsustainable harvesting but also due to natural habitat destruction, thus 
endangering the lives and livelihoods of the African population as well as the traditional 
healthcare system (MAUNDU et al., 2006). 
 
The medicinal plants of South Africa are threatened due to uncontrolled harvesting by 
chopping, ring-barking as well as up-rooting plants, and this has raised a lot of concerns in 
terms of conservation (MUANALO, 2007). The most commonly utilised medicinal plants in 
South Africa are trees, from these trees the bark is reported to be used often (ZSCHOCKE et 
al., 2000). Overharvesting of slow growing bulbous plants result in them being threatened 
and, they are recognised by the traditional healers as being scarce (MUANALO, 2007). 
Encouraging traditional healers to collect and use alternative plant parts such as leaves and 
twigs instead of bark, roots or bulbs could be solutions for these problems. 
 
South Africa does not have devoted laws encouraging connectivity to conservation, however 
there are several legislations and policies that contain the tools for realising the concept in as 
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far as biodiversity is concerned (PATERSON, 2012). These legal tools place restrictions on 
collection and harvesting of protected resources, such as plants, and prescribe the 
arrangement of permits for research purposes. According to the EEUSA (2012) 28 legal 
instruments for conservation of nature exist at provincial level in this region. Many of the 
laws are out-dated and the nine provinces are at different stages of developing and 
implementing new ones. These legal instruments generally allow establishment and 
protection of nature reserves and conservation of threatened species. Examples of some of the 
laws include the constitution Act 108 of 1996 that recognises the right of South Africans to a 
healthy, well conserved environment and to benefit from the natural resources economically 
and socially (EEUSA, 2012). In addition the national environmental Act number 107 of 1998 
promotes sustainable use of natural resources and access as well as cooperative governance in 
environmental management (EEUSA, 2012). The biodiversity Act number 10 of 2004 
provides for the management and conservation of South Africa’s biodiversity within the 
framework of the National Management Act (NEMA) of 1998 that seeks protection of 
species and ecosystems that warrant national protection (EEUSA, 2012). It also provides for 
the sustainable use of indigenous biological resources, the fair and equitable sharing of 
benefits arising from bioprospecting involving indigenous biological resource. In South 
Africa, there are nature conservation ordinances which place strict limits on the trade of 
plants (MOENG and POTGIETER, 2011). For example, the Limpopo environmental 
management Act prohibits any person without a permit to pick, sell, purchase, donate, receive 
as a gift, be in possession of, import to, export or remove protected plants in the province  
(MOENG and POTGIETER, 2011). Therefore, through these conservation tools, South 
Africa is trying to conserve her unique biodiversity and indigenous medicinal plants as they 
are a valuable resource. 
 
1.10. Aims and objectives 
 
Africa remains the only continent where tuberculosis rates are still increasing (KAMATOU 
et al., 2007). The problem is worsened by the emergence of drug resistance and coinfection 
with HIV (WALUSIMBI et al., 2013). Although drugs for treating tuberculosis have been 
available for many years, due to a number of reasons many patients fail to complete 
treatment. The reasons that lead to failure to comply with the rules of treatment are that, 
drugs used have unpleasant side effects, patients are unaware of the consequences of stopping 
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treatment, standard anti-tuberculosis therapy takes longer (six months), and patients feel 
better after several weeks of treatment. Patients remain infectious for longer due to poor 
compliance and are most likely to suffer relapse and die (AL-HAJOJ and VARGHESE, 
2013). Thus, new treatments from various sources that takes less time and are without side 
effects are required to alleviate the problems at hand. 
 
The idea that certain plants have healing potential was well accepted a long time ago before 
the existence of microbes was discovered by mankind (RÌOS and RECIO, 2005). The 
ethnobotanical studies done in South Africa do not only boost the natural products economic 
subdivision, but are a means of preserving indigenous knowledge, with medicinal plants 
playing an important role in both improving health and the livelihood of many indigenous 
populations. The illnesses that occur as a result of respiratory tract infection such as colds, 
flu, hay fever, pneumonia, asthma, bronchitis, emphysema, tuberculosis are one of the scope 
of traditional healing practices in South Africa. Due to the important role that medicinal 
plants play in the process of drug discovery and development they are recognised as sources 
of active antimycobacterial metabolites (McGAW et al., 2008a). Thus, the aims of this study 
were to evaluate the pharmacological properties of plants that are used in South Africa in the 
traditional treatment of tuberculosis and related symptoms. These tests include antibacterial 
activity and enzyme inhibition bioassays [cyclooxygenases enzymes (involved in anti-
inflammatories)]. Genotoxicity and cytotoxicity evaluation of the plant extracts that showed 
good antimicrobial activity to test for their safety. This study was also aimed at isolating and 
identifying compounds from plant extracts that showed good antimicrobial activity. The 
information obtained from this study could go a long way in validating the use of the plants 
used in traditional treatment of tuberculosis and related symptoms and offer scientific 
credence to the ideas of integrating such plants in healthcare systems which in turn will be 
helpful to the population.  
 
1.11. Plant selection 
 
Ten plants were selected based on available literature of medicinal plants used by various 
South African tribes in the treatment of tuberculosis and related symptoms (MABOGO, 
1990; HUTCHING et al., 1996; VAN WYK et al., 1997; McGAW et al., 2008a; VAN 
WYK et al., 2009). The plant materials were collected from the University of KwaZulu-
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Natal (UKZN) Botanical garden and Ukulinga Research Farm. Voucher specimens were 
deposited in the UKZN (Pietermaritzburg) Herbarium (NU) for botanical authentication if 
required in future. 
 
1.12. Botanical description and distribution of the plants selected 
 
1.12.1. Abrus precatorius subsp. africanus Verdc. 
 
This plant is known by a variety of names in South Africa. The common names of Abrus 
precatorius subsp. africanus in English are coral-bead plant, crab's eye, jecquirty bean, love 
bean, lucky bean creeper, minnie-minnies, prayer bean, rosary pea, paternostertjie in 
Afrikaans, umkhokha in Zulu or umuthi wenhlanhla, umuthi wentlahla in Xhosa, nsisani in 
Tswana and amabope in Ndebele (BARCELOUX, 2008).  
 
 
Figure 1.7: Abrus precatorius subsp. africanus  
 
This plant is a perennial climber that twines around trees, shrubs, and hedges without any 
special organs of attachment (BHUTIA and MAITI, 2011). The plant has slender branches, 
a cylindrical wrinkled stem with a smooth-textured brown bark and glabrous alternate 
compound paripinnate leaves with stipules. It bears oblong and obtuse leaflets, and each is 
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about 12-18 mm long. Both leaf ends are blunt, glabrous on top and slightly hairy below. It 
has small and pale violet flowers with a short stalk that are arranged in clusters. The fruit (a 
pod) is silky in texture, flat, oblong and truncate shaped with a sharp, deflexed beak. The pod 
contains from three to five oval shaped seeds that are about 6 mm long, bright red with 
smooth, glossy texture and a black patch on top (IWU, 1993). In South African, the plant is 
found in KwaZulu-Natal, Gauteng, and some parts of the Limpopo province (FODEN and 
POTTER, 2005a). 
 
1.12.2. Asparagus africanus Lam. 
 
The common names of Asparagus africanus are wild asparagus in English, Haakdoring in 
Afrikaans, isigoba in Zulu, ubulawu obumhlope or umthunzi in Xhosa, and Lelala-tau-le-
leholo in Sotho.  
 
 
Figure 1.8: Asparagus africanus (DEEDI, 2011) 
 
Asparagus africanus is a fast-growing plant that can climb up trees and can grow as a 
scrambling low shrub without a host, with stems that can be up to 12 m in height. It has 
thorny leaves and stems (UMBERTO-QUATTROCCHI, 2012). The roots of this plant do 




and bell shaped (IWU, 1993). Asparagus africanus produces berries that contain one seed. 
The colour of Asparagus africanus berries is green, but when ripening it turns orange. This 
plant species is native to southern Africa, and prefers bushland and rainforests (UMBERTO-
QUATTROCCHI, 2012). In South African the plant species is found along the Eastern Cape 
coast to KwaZulu-Natal, Limpopo, Mpumalanga, and Western Cape provinces (VON 
STADEN, 2012). 
 
1.12.3. Asparagus falcatus (L.) Oberm. 
 
The common names for this plant are thorny creeper in English, doringtou in Afrikaans, 
imbelekazana in Zulu, and isigoba in Xhosa. 
 
 
Figure 1.9: Asparagus falcatus 
 
Asparagus falcatus is an evergreen climbing shrub that grows up to 7 m in height. The older 
stems are light grey and have sharp, hard thorns that are curved backwards for protection 
against predators and to grip onto the host plant to reach sunlight. The leaves are sickle 
shaped, shiny dark green, feature a prominent vein and are up to 8 cm long. It has roots that 
are swollen tubers resembling sweet potatoes. The flowers are attractive, small, white and 
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fragrant. The fruit is a red berry and the seeds are round, shiny and black. The plant occurs in 
the Eastern Cape, through KwaZulu-Natal into the low-veld of South Africa in forest and 
forest edges of these locations (FODEN and POTTER, 2005b). 
 
1.12.4. Brunsvigia grandiflora Lindl. 
 
Brunsvigia grandiflora is commonly known in South Africa as the candelabra flower in 
English, kandelaarblom in Afrikaans, umqhele-wenkunzi in Zulu, and isichwe in Xhosa. 
  
 
Figure 1.10: Brunsvigia grandiflora (McMASTER et al., 2010) 
 
Brunsvigia grandiflora is a large perennial bulb that can reach up to 20 cm in diameter 
(MANNING et al., 2002). The bulb is covered usually with tan coloured and brittle tunics 
(MANNING et al., 2002). The flowers of this plant are star shaped, 30 mm in diameter, and 
deep pink in colour. The flower heads are large and can grow up to 40 cm in diameter with 30 
to 60 individual flowers on stalks joined together on a thick stem. The leaves are decorative, 
grey-green, and upright, often spiraled with waxy margins and dry off during flowering 
(MANNING et al., 2002). When the seeds are dry, the main stem dries and the head falls off, 




plant is distributed in grasslands of the Eastern Cape, Free State, KwaZulu-Natal and 
Mpumalanga provinces (SNIJMAN and VICTOR, 2004).  
 
1.12.5. Ficus sur Forssk. 
 
The common names for Ficus sur are broom cluster fig, bush fig, cape fig, wild fig, fire 
sticks, kooman fig, malabar tree in English; besembosvy, besemtrosvy, bosvyeboom, 
grootvy, koeman, suurvy, wildevyeboom in Afrikaans; amakhiwane, ingobozweni, intombi 
kayibhinci,  umkhiwane in Zulu; ikhiwane, umkhiwane, umkwane in Xhosa; mogo, mogo-
tshetlo, mphai, mphayi in Sotho; nkuwa xinkuwana in Tswane; muhuyu, muhuyu-lukuse, 
muhuyu-ngala in Vhenda; ikuwu, likwani, mouwane, umkhiwa, umkiwa in Ndebele; and 
umkiwane in Swati. 
 
 
Figure 1.11: Ficus sur. Inset shows the fruit of Ficus sur. 
 
 Ficus sur is a large, semi-deciduous, fast-growing tree with a short trunk. The tree grows 
approximately 35 m high (VAN WYK et al., 2008). The leaves are alternate, large, oval, 
green, hairless, tip usually tapering, and borne on a massive, spreading crown. Figs are 20-40 
mm in diameter borne in large leafless clusters mostly low down on the trunk and can even 
appear at ground level arising from the roots. The figs are smooth or slightly hairy orange-red 
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or red when ripe. This species is widely distributed in the Western Cape in South Africa 
usually on riverbanks or in riverine forest but also in drier woodlands (BURROWS and 
VICTOR, 2005). 
 
1.12.6. Indigofera arrecta Benth. ex Harv. & Sond. 
 
The common names for this plant are Natal indigo in English, verfbossie in Afrikaans and 
umphekambedu in Zulu. 
 
 
Figure 1.12: Indigofera arrecta (HYDE et al., 2014) 
 
Indigofera arrecta is an erect, woody, large shrub up to about 3 m in hieght. The leaves are 
spirally arranged, 2 to 9 mm long, and have about seven to 21 leaflets usually smooth above 
and hairy beneath (ORWA et al., 2009). Inflorescence is up to 5 cm long but usually much 
shorter. Flowers are about 5 mm long, pinkish or reddish, brown strigulose outside. The fruit 
of Indigofera arrecta is a linear pod about 12 to 25 mm long and 2 mm wide, brown when 
ripe and has four to eight seeds. In South African the plant is found in KwaZulu-Natal, 





1.12.7. Leonotis intermedia Lindl. 
 
The common name of Leonotis intermedia in English is the wild dagga plant. Leonotis 
intermedia is a woody shrub.  
 
 
Figure 1.13: Leonotis intermedia  
 
This shrub is multi-stemmed, with stems rising from a woody base, unbranched, pale brown 
in colour and square in section (SCHMIDT et al., 2002). The leaves are dark green above 
and paler below, arranged in opposites, broadly ovate, densely hairy with coarsely toothed 
margins. It has orange to reddish flowers. This species is distributed in South Africa, and 
found in the Eastern Cape, KwaZulu-Natal, and Northern provinces (MANYAMA and 
KAMUNDI, 2006). 
 
1.12.8. Pentanisia prunelloides Schinz 
 
The common names for this plant are wild verbena and broad-leaved pentanisia in English, 





Figure 1.14: Pentanisia prunelloides. Inset shows the flowers of Pentanisia prunelloides. 
 
Pentanisia prunelloides is an erect perennial herb that grows up to about 30 cm in height and 
60 cm wide with stout hairy stems sprouting from a tuberous root. It has oblong leaves, that 
are usually hairy and in pairs (VAN WYK et al., 2009). The flowers of this plant species are 
small, pale purple occurring in dense groups on the branch ends. This plant is found in South 
Africa, provinces such as Eastern Cape, Free State, Gauteng, KwaZulu-Natal, Limpopo and 
Mpumalanga (FODEN and POTTER, 2005d). In Eastern Cape, Pentanisia prunelloides is 
an important part of the grassland (VAN WYK et al., 2009). 
 
1.12.9. Polygala fruticosa P. J. Bergius 
 
The common names for Polygala fruticosa are featherdusters, heart-leaved polygala, and 




Figure 1.15: Polygala fruticosa (VILJOEN and HITCHCOCK, 2002) 
 
Polygala fruticosa is a shrublet that can grow up to 2 m in height and has numerous erect 
branches (VAN WYK et al., 2009). The leaves are arranged opposite to each other on the 
stems, lance or heart-shaped and greyish-green in colour. It has purple flowers that are similar 
to those of the legume family but distinguished by a tufted outgrowth near the tip of the 
bottom petal. This plant is distributed in South Africa along the coastal parts of Western 
Cape, Eastern Cape and KwaZulu-Natal provinces (VAN WYK et al., 2009). 
 
1.12.10. Terminalia phanerophlebia Engl. &Diels 
 
Bastergeelhout in Afrikaans, amangwamhlophe or amangwansundu in Zulu are the common 





Figure 1.16: Terminalia phanerophlebia. Inset shows the fruit of Terminalia 
phanerophlebia 
 
Terminalia phanerophlebia is a shrub or small deciduous tree that is approximately 3-7 m 
high with a rounded crown (SCHMIDT et al., 2004). The stem is about 300 mm in diameter 
with a dark grey-brown to blackish bark. Leaves are fresh green to dull grey green or dark 
olive green above and paler below, closely placed along stems and are hairy beneath 
(SCHMIDT et al., 2004). The flowers are small about 4 mm wide, and are white to creamy 
white in colour. Fruits are held in clusters with a central nut that is surrounded by a hard 
ribbed wing, with a pale green colour when young and brown or pinkish brown when ripe 
(SCHMIDT et al., 2004). The distribution of Terminalia phanerophlebia in South African is 






Chapter 2: In vitro antimicrobial activity of extracts from plants 
used traditionally in South Africa to treat tuberculosis and 
related symptoms 
 
2.1. Infectious diseases 
 
When pathogens such as bacteria, viruses, or parasites invade and multiply in the cells and 
tissues of a body, an infectious disease may occur. Infectious diseases have been present 
since antiquity, thus critically shaping the history of mankind (BELTZ, 2011). Evidence of 
the presence of an infectious disease such as tuberculosis was found on human bones from 
about 5000 BC with Hippocrates describing a disease characterised by lung nodules matching 
the tubercles found in tuberculosis in about 1000 BC (BELTZ, 2011). A few decades ago, 
there was enormous optimism about the decline of life threatening infectious diseases due to 
advances in technology and science (COHEN, 1998). However, due to a rise in the 
transitional nature of infectious diseases, such optimism has not yet been met. Worldwide, 
infectious diseases are still the leading causes of death, especially in developing countries, 
claiming millions of lives yearly despite the enormous improvements made in human 
healthcare (YORK et al., 2011). On a global scale, infectious diseases are the second leading 
cause of death, disabling and disfiguring many lives, thus having a huge negative effect on 
the human population (HAMBURG, 2008; YORK et al., 2011). This rise in infectious 
disease mortality is credited to the increase in diarrhoea, respiratory tract infections and 
HIV/AIDS which account for about half of all deaths (PINNER et al., 1996). The rise in the 
transitional nature of infectious diseases is the greatest challenge of the present era 
(HAMBURG, 2008).  
Death due to infectious diseases on both children and adults under the age of 50, places a 
severe burden on developing parts of the world (HAMBURG, 2008). There has been an 
emergence of 30 life threatening infectious diseases that have been discovered within the last 
few decades with the majority being zoonoses or human diseases (HAMBURG, 2008). A 
few examples of such infectious diseases are HIV, acute respiratory syndrome, H5N1 avian 
influenza, Ebola and the Nipah virus. Re-emergence of old diseases like WestNile disease, 
monkeypox, dengue fever, malaria and tuberculosis more especially in new geographic 
regions have been witnessed (HAMBURG, 2008). Almost all nations have been affected by 
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the emergence or reemergence of infectious diseases such as malaria and tuberculosis that 
have occurred in new and more dangerous forms that are resistant to drugs. Presently this is a 
serious world health concern (HAMBURG, 2008). 
Several factors have contributed to the explosion in emerging as well as reemerging 
infectious diseases worldwide, and these include increasing numbers of immunocompromised 
individuals and microbial evolution. Many of the emerging diseases appear new to 
humankind, whereas reemerging ones represent an increasing threat (BELTZ, 2011). Tools 
such as the discovery of antimicrobials and a better understanding of infectious diseases have 
been developed to prevent and cure illnesses. This had decreased the incidence and severity 
in developed countries. However, this is again increasing worldwide (BELTZ, 2011). 
Overcrowded conditions such as slums of urban areas, homeless shelters, prisons and nursing 
homes, contribute to the rapid spread of infectious diseases such as tuberculosis. Addressing 
the problem of infectious diseases is now an important and urgent requirement.  
 
2.1.1. Bacterial infections 
  
Bacteria are microscopic unicellular organisms that are able to adapt and live in different 
ranges of environments such as soil, water, air and even in bodies of other organisms 
(SLEIGH and TIMBURY, 1998). They are one of the most abundant group of organisms on 
earth and can either be beneficial or harmful. These micro-organisms are prokaryotes that 
reproduce by fission or forming spores. Major forms of bacteria can be recognised as spheres, 
rods (bent or curved rods) as well as spirals and they are nearly colourless and transparent 
with a refractive index that is close to that of the surrounding liquid (RYAN and RAY, 
2004). Based on whether the organisms do or do not stain with Gram's stain, bacteria can be 
classified generally as either Gram-positive or Gram-negative (LEE and SCHNEENWIND, 
2001). When bacterial cells are stained with crystal violet, Gram-positive’s are those that 
retain the crystal violet after being decoloured with alcohol, treated with safranin and washed 
in water. Those that do not retain the dye are Gram-negative. Gram-positive and Gram-
negative bacteria differ from each other in many ways and they can be broadly differentiated 
based on the structure of their cell walls. The function of the cell wall is to provide structural 
support, protection against osmotic damage and act as a filtering mechanism determining 




Gram-positive bacteria have a relatively simple cell wall structure that is composed of 
peptidoglycan polymers cross-linked by polypeptides to form a rigid protective coat 
(SLEIGH and TIMBURY, 1998). They also have a single plasma membrane followed by a 
thick cell wall layer that functions as a surface organelle for carbohydrate and protein display 
(O'LEARY and CAPOTE, 2008). Gram-negative bacteria have a more complex cell wall 
structure with an inner wall that is interposed between the outer and inner membrane (RANG 
and DALE, 1987). Both the inner and outer membranes have a characteristic lipid bilayer, 
but the outer membrane has a lipopolysaccharide component that permits or excludes certain 
macromolecules.  
 
Human beings are infected with, and are constantly exposed to bacteria. Most bacterial 
strains that humans are exposed to on a daily basis are not harmful, constitute the commensal 
flora, and are beneficial (HERITAGE et al., 1999). Only a few bacterial strains interact with 
humans to cause disease, and they can cause a wide range of different infections ranging from 
inaparent to fulminating, causing infections to be widespread (AVILA et al., 2008). In 
immunocompromised patients, normal bacterial strains that are known to be harmless often 
cause opportunistic infectious diseases (MACKOWIAK, 1982). Examples of common 
bacteria found in the upper respiratory tract that are part of the normal flora include 
Staphylococcus aureus, Staphylococcus epidermis, Haemophilus species, Neisseria species, 
Corynebacterium species, Propiorubacterium acnes, and many anaerobes such as 
Bacteriodes as well as members of the Enterobacteriaceae (HERITAGE et al., 1999). 
Although, bacteria from the upper respiratory tract are washed downwards towards the lower 
respiratory tract, the action of the ciliated epithelium and sticky mucus that covers the lining 
of the bronchial tubes keeps the lower respiratory tract free of these microorganisms 
(MACKOWIAK, 1982). The relative pathogenicity of a bacterium to cause disease depends 
on its capacity. Pathogens can be opportunistic, for example the ones isolated from 
immunocompromised individuals, or they may be agents of disease just like in the case of 
Escherichia coli (PETERSON, 1996). Worldwide, approximately 17 million deaths per 
annum are reported to be caused by bacterial infections especially in children (DEMAIN and 
SPIZEK, 2012). Bacterial infections of the lower respiratory tract include Streptococcus 
pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas species, 
Legionella pneumophila, Mycoplasma pneumoniae, as well as Chlamydia pneumoniae. These 
are known to infect HIV/AIDS patients. However, in sub-Saharan Africa, the most common 
cause of respiratory tract bacterial infection in HIV-infected patients is tuberculosis, although 
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Infectious disease treatment is currently facing a major challenge, with many microbes 
developing resistance to widely used antibiotics. Both Gram-negative and Gram-positive 
bacteria have acquired resistance to antimicrobial drugs used worldwide (WILSON et al., 
2002). This in turn has led to a rise in morbidity, mortality and cost of healthcare (DE 
SOUZA, 2009). Drug-resistance is defined as the ability of an organism to withstand 
antibiotic treatment by either making it inactive or less effective.  
 
Antimicrobial resistance mechanisms in bacteria can either be natural or acquired (WILSON 
et al., 2002). Natural resistance entails that the bacteria have ‘intrinsic’ resistance; for 
instance, some bacterial strains have genes that cause resistance to an antibiotic known to kill 
them, while others lack transport systems or targets for antibiotics (GEORGIEV and 
FAUCI, 2009). Acquired resistance refers to bacteria that usually show sensitivity to 
antibiotics, but are likely to develop resistance, and this occurs through spontaneous gene 
mutation, or mobile genetic element acquisition, which carry the antibiotic resistance genes 
(WILSON et al., 2002). A mutation altering the binding site of a drug decreases antibiotic 
sensitivity, thus increasing drug-resistance. Resistance of Mycobacterium tuberculosis to 
streptomycin is an example of such a kind of mechanism (WILSON et al., 2002). There are a 
lot of bacterial strains that have acquired antimicrobial resistance, and they include 
respiratory pathogens such as Klebsiella pneumoniae, Staphylococcus aureus and 
Mycobacterium tuberculosis (WILSON et al., 2002). Resistance of bacteria to drugs is 
linked to usage of antimicrobial agents in clinical practice (GIEDRAITIENĖ et al., 2011). 
The use of therapeutic antibiotics for a long time can result in microorganisms that showed 
drug sensitivity prior to the development of resistance through adaptation. Resistance of 
Staphylococci species to penicillin marked the beginning of antimicrobial resistance. 
 
The past two decades have seen the emergence of pathogenic infectious diseases, such as 
AIDS and drug-resistant tuberculosis which represent a substantial global threat to human 
health. Tuberculosis is presently one of the most serious bacterial infectious diseases that 
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causes a threat to healthcare of humans globally (CHEN et al., 2011). There has been an 
emergence of resistant tuberculosis strains to first line antibiotics known as single drug-
resistant, MDR tuberculosis and XDR tuberculosis (WHO, 2009a). It is estimated by the 
WHO that 50 million people may be infected with drug-resistant tuberculosis worldwide 
(WHO, 2009a). Additionally, in the next few years emerging diseases will probably increase 
due to travel, urbanisation, overcrowding, inadequate healthcare, continuing globalisation of 
trade leading to new interactions between human beings and animals as well as other disease 
vectors  (HAMBURG, 2008; ALIROL et al., 2011). Thus, addressing the problems of 
infectious diseases now is an important and urgent requirement (HAMBURG, 2008). 
 
2.2.1. Multi drug-resistant tuberculosis 
 
Multi drug-resistant tuberculosis is highly contagious and it is due to resistance to rifampin 
and isoniazid (SINGH et al., 2011). Multi drug-resistant tuberculosis was recognised by the 
WHO-International Union against tuberculosis and lung disease in nearly every country 
surveyed from 1994 to 2000 as part of the global drug-resistance surveillance project 
(SINGH et al., 2011). According to surveys from 184 countries, 458000 new MDR 
tuberculosis cases occurred worldwide in 2003 and out of these cases, 60% were reported 
from China and India constituting 3.2% of all new tuberculosis cases (SINGH et al., 2011). 
In 2012, a report was issued by the WHO which stated that China, India, Russian and South 
Africa represents 60% of the total cases of MDR tuberculosis, thus referred to as the burden 
countries out of 27 nations (SOTGIU et al., 2013). Multi drug-resistant tuberculosis is 
widespread and is recognised as a threat to tuberculosis control as it may result in death 
unless treated quickly and effectively (ALEXANDER and DE, 2007). It is estimated that at 
least 4% of tuberculosis patients have MDR tuberculosis, with 40% of them having been 
previously treated for tuberculosis (ALEXANDER and DE, 2007). For a person with MDR 
tuberculosis short term chemotherapy is ineffective and its treatment requires 
multidisciplinary care for more than a year (ALEXANDER and DE, 2007). The situation of 
increasing incidence of MDR tuberculosis worldwide, highlights the urgent need to search for 
newer anti-tuberculosis agents or drugs. Figure 2.1 shows a report by the WHO (2013) on 





Figure 2.1: Percentage of global new tuberculosis cases with MDR tuberculosis in 2012 
(WHO, 2013). 
 
2.2.2. Extensive drug-resistant tuberculosis  
 
Due to improper treatment and management, XDR tuberculosis emerged, which is defined as 
resistance of pathogens to first line antibiotics as well as fluoroquinolones and at least 1 of 3 
injectable second-line drugs such as capreomycin, kanamycin or amikacin (DE SOUZA, 
2009). The outbreak of XDR tuberculosis was observed for the first time in September, 2006; 
in a rural hospital in Tugela Ferry, South Africa where 53 cases were diagnosed, out of which 
52 patients died (SINGH et al., 2011). Among four countries estimated to have the leading 
number of XDR tuberculosis, South Africa is included (FYHRQUIST et al., 2014). There is 
growing proof that drug-resistant tuberculosis is transferred from one person to the next, thus 
supporting the conclusion that the estimated number of cases here in South Africa are only a 
portion of a larger phenomenon. Extensive drug-resistant tuberculosis is threatening to make 
the disease untreatable, more especially in the case of co-infection with HIV. All South 
African provinces have reported cases of XDR tuberculosis, since the Tugela Ferry outbreak 
was discovered, and Western Cape in particular has a very high rate of tuberculosis bacterial 
strains resistance to drugs (OLSON et al., 2011). It has been reported that throughout 
KwaZulu-Natal, there are MDR and XDR tuberculosis cases, thus causing the province to 
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have an enormous tuberculosis burden (OLSON et al., 2011). The latest estimations have 
reported that more than 60 facilities in KwaZulu-Natal have at least one case of XDR 
tuberculosis (OLSON et al., 2011).  
 
The disturbing epidemiology of MDR and XDR tuberculosis strains and difficulty in treating 
the disease that is spreading throughout South Africa creates an urgent reason for solving the 
problem. According to the WHO, this is a new serious global public health problem (DE 
SOUZA, 2009). In fact, reports from all over the world have shown that XDR tuberculosis 
treatment outcomes are poor. It is likely that more resistant strains of Mycobacterium that 
will exhaust the current chemical defence that are available at present will emerge in the 
future. Therefore, there is need for new and alternative ways of counteracting this problem. 
 
2.3. Ethnopharmacological approach to drug resistance problem 
 
Ethnopharmacology is a specially designated field of science defined as the evaluation of 
natural products from medicinal plants, to expand their knowledge base in order to further 
develop the use of this information (HEINRICH and GIBBONS, 2001). The evaluation of 
medicinal plants is done by observing, identifying, describing and further conducting 
experimental investigations of the ingredients and their effects. Thus, making 
ethnopharmacology a truly interdisciplinary field of research which is very important in the 
study of TM (LEONTI, 2011). Ethnopharmacology in a modern sense, only became possible 
with the scientific ability to study the effects of substances and extracts on model systems 
(HEINRICH and GIBBONS, 2001). Ethnopharmacological approaches have generally 
followed a practical approach and are aimed at the experimental investigation and biological 
validation of medicinal plants from traditional ethnic groups (LEONTI, 2011; NOVAES 
and LEITE, 2011). Thus, the broad perception of ethnopharmacology contextualises ecology 
and addresses the perception of plants, plant use, pharmacology and physiology in human 
communities.  
 
Which method to use when selecting plants for biological evaluation is one of the main 
challenges at present, because this process is the first research step. Various methods are used 
in selecting plants for pharmacological evaluation. These methods include: random selection 
of the species without consideration of taxonomic and ethnobotanical information (NOVAES 
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and LEITE, 2011); ethnodirected selection, which encompasses ethnobotanical and 
ethnopharmacological approaches and applies information about the traditional use of plants 
to treat specific diseases; chemotaxonomic approaches that are based on studying plants from 
the same family or genus of a species from which bioactive secondary metabolite have been 
isolated already (SILVER et al., 2013). However, an ethnopharmacological approach in 
selecting plants has previously shown to be advantageous towards discovering plants with 
compounds that have pharmacological properties (NOVAES and LEITE, 2011). In 
bioprospecting, medicinal plants are selected based on the idea that they are used for treating 
specific illnesses and may have an associated biological activity (AHMAD et al., 2006).  
 
2.4. Bacterial strains related to respiratory ailments that were selected in 
this study 
 
Conducting research on anti-tuberculosis plants against MDR and XDR tuberculosis strains is 
rather a challenge, due to the fact that growth of Mycobacterium tuberculosis is slow and that 
the bacteria is highly dangerous to work with and requires strict biosafety conditions. All 
these problems pose considerable obstacles, but in alleviating the critical issues at hand, non-
pathogenic fast growing mycobacteria, like Mycobacterium aurum have been introduced as 
test organisms in the drug screening process. Additionally, among non-pathogen strains of 
Mycobacterium, Mycobacterium aurum is the closest to Mycobacterium tuberculosis in terms 
of mycolate components (GUPTA et al., 2009). The structural similarities in mycolate 
components are responsible for cell wall envelope permeability to antimicrobials, thus the use 
of Mycobacterium aurum in anti-tuberculosis research is recommended. The ability of this 
strain to survive in an intracellular environment is another advantage for the use of this 
bacterial strain for the second step of drug screening.  
 
2.4.1. Klebsiella pneumoniae 
 
Klebsiella pneumoniae is a Gram-negative, aerobic, non-motile, rod shaped, lactose 
fermenting bacteria. This bacterium is the most prevalent and clinically important bacterial 
strain found in normal flora of the mouth, skin and intestines of humans. It has cells that are 
surrounded by a gelatinous capsule inhibiting phagocytosis and produces large, moist and 
often very mucoid colonies (DAVIS et al., 1990). Infection due to Klebsiella pneumoniae if 
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not treated can cause destructive changes to human lungs and often becomes fatal (PRICE 
and FREY, 2003). Klebsiella infections are seen mostly in people with a weakened immune 
system, most often illness affects middle-aged and older men with debilitating diseases. 
Klebsiella pneumoniae tends to affect people with diabetes or chronic pulmonary disease. In 
the USA, approximately 3% of all bacterial pneumonia whether nosocomial or community 
acquired are caused by Klebsiella pneumoniae (PRICE and FREY, 2003). Infection with 
Klebsiella pneumoniae can also cause mild respiratory tract infections such as bronchitis and 
sometimes lobar pneumonia, and meningitis. Klebsiella pneumoniae is thus, a secondary 
invader in the lungs of humans suffering from chronic pulmonary disease (PRICE and 
FREY, 2003). The bacterium is highly resistant to antibiotics attributable to acquiring 
plasmids and changes to its chromosomal gene structure (PRICE and FREY, 2003). 
 
2.4.2. Staphylococcus aureus 
 
Staphylococcus aureus is a Gram-positive, facultative anaerobe that grows rapidly and 
abundantly under aerobic conditions as grape like-structures. Species of the genus 
Staphylococcus are prominent inhabitants of the human respiratory tract and skin, and may be 
highly pathogenic when they invade the underlying tissues (FUERST, 1978). Staphylococcus 
aureus is a dangerous coagulase producing bacteria that typically produces boils and 
carbuncles. This bacterial strain can invade the human system, causing fatal septicemia, 
meningitis, endocarditis, puerperal sepsis, pneumonia, multiple absesses and osteomyelitis. 
The strain is of special importance in hospitals, causing epidemics of antibiotic resistance, 
and can therefore remain alive for several months under favorable conditions. 
 
2.4.3. Mycobacterium aurum  
 
Mycobacterium aurum is a fast growing, non-infectious, Gram-positive bacterium. This 
bacterium belongs to a different category of mycobacteria that do not cause tuberculosis 
(HONARVAR et al., 2012). This bacterial species also called non-tuberculous mycobacteria 
(NTM), is also known as an environmental mycobacteria since it is particularly found in the 
environment, mostly in wet soils, rivers, lakes, and swamps. In contrast to typical 
tuberculosis infections, this mycobacterial infection is non-communicable. The high level of 
resemblance in the susceptibility profile of cell wall inhibitors in Mycobacterium aurum and 
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Mycobacterium tuberculosis, makes it a recommended organism for use in the search for new 
inhibitors. The ability to survive in an intracellular environment is another advantage for 
using Mycobacterium aurum for drug screening (GUPTA et al., 2009).  
 
2.4.4. Mycobacterium tuberculosis H37Ra 
 
Mycobacterium tuberculosis H37Ra is a non-motile, rod-shaped bacterium and one of the 
causative agents of tuberculosis. This bacterium is the avirulent counterpart of the virulent 
strain H37Rv derived from H37 which is a virulent parent strain, and was originally isolated 
by Edward R. Baldwin in 1905 from a 19 year-old male patient with chronic pulmonary 
tuberculosis (ZHENG et al., 2008). H37Ra (“a” for avirulent) has been widely used as a 
reference strain for studying virulence and pathogenesis of Mycobacterium tuberculosis 
worldwide since 1940s and is also used as an adjuvant to boost immunogenicity during 
immunisation (ZHENG et al., 2008). A large part of the success of this pathogen is due to its 
ability to persist in a dormant or latent form for years without showing clinical symptoms. 
Despite being considered as Gram-positive, mycobacteria have an unusual outer membrane 
approximately 8 nm thick. The outer membrane and the mycolic acid-arabinoglactan-
peptidoglycan polymer form the cell wall and constitutes an efficient permeability barrier in 
conjunction with the cell inner membrane. 
 
The traditional use of medicinal plants has been documented extensively in many regions of 
South Africa by various researchers. This is evident from the books written by WATT and 
BREYER-BRANDWIJK (1962); HUTCHINGS et al. (1996) and VAN WYK et al. (1997 
and 2009). Though, the effectiveness of the plant preparations may be reported by traditional 
practitioners, their scientific validation is required for confirmation. Most studies done in 
South Africa on plants used traditionally to treat respiratory ailments have focused only on 
evaluating their antimycobacterial activity against tuberculosis-causing bacterial strains 
(LALL and MEYER, 1999; GREEN et al., 2010; MATIVANDLELA et al., 2008) but 
with little emphasis on the related symptoms (BUWA and AFOLAYAN, 2009; YORK et 
al., 2012). Therefore, this current study was aimed at evaluating the antimicrobial activity of 





2.5. Materials and methods 
 
2.5.1. Preparation of plant extracts 
 
Immediately after collection, plant materials were oven dried at 50 ºC. The dried plant 
materials were ground into fine powders using an ultra centrifugal mill (ZM 200, Retsch® 
Germany) and stored in airtight containers. Dried plant material (10 g) was extracted 
sequentially with 200 ml of each of four solvents; in the following order petroleum ether 
(PE), dichloromethane (DCM), 80% ethanol (EtOH) and water (from non-polar to polar) by 
sonication for 1 h in an ice water bath. Organic extract samples were then filtered through 
Whatman No. 1 filter paper and concentrated to dryness under reduced pressure using a 
rotary evaporator to obtain crude extracts. The aqueous extracts were freeze-dried under 
reduced pressure. Crude extracts were then stored in the dark at 10 ºC until use. The 
percentage yields for each extract were determined. 
 
2.5.2. Bacterial strains and culture conditions 
 
Four bacterial strains were used in this study to evaluate the plant extracts. Klebsiella 
pneumoniae (ATCC 13883), Staphylococcus aureus (ATCC 12600), Mycobacterium 
tuberculosis H37Ra (ATCC 25177) obtained from the American Type Culture Collection 
(ATCC), and Mycobacterium aurum A+ from the Microbiology Laboratory, Division of 
Pharmacology, University of Cape Town were used for the assay. The test organisms were 
selected because of their respiratory pathogenesis (ELDEEN and VAN STADEN, 2007; 
BUWA and AFOLAYAN, 2009; GREEN et al., 2010; YORK et al., 2012). The strains 
were maintained on Mueller-Hinton (MH) (Merck, South Africa) agar except for 
Mycobacterium aurum A+ and Mycobacterium tuberculosis H37Ra that were maintained on 
Middlebrook 7H10 agar (Sigma-Aldrich, Steinheim) supplemented with either 0.5% or 0.2% 
glycerol and 10% OADC (oleic acid, albumin, dextrose, and catalase; Sigma-Aldrich, 
Steinheim) 
 
2.5.3. Procedure for microorganism long term storage 
 
Prior to storage, MH agar (Merck, South Africa) and Middlebrook 7H10 agar supplemented 
with 0.5% or 0.2% glycerol and 10% OADC were prepared, sterilised and poured (25 ml) 
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into sterile plastic Petri dishes and allowed to gel. After gelling of the agar, the Petri dishes 
were kept at 4 °C. 
 
The Kwik-stikTM unit was removed from 2-8 °C storage and allowed to equilibrate to room 
temperature. The middle of the ampoule cap of the Kwik-stikTM unit was pinched to break the 
ampoule and that was followed by release of the hydrating fluid which was then allowed to 
flow through the swab shaft and into the bottom portion of the unit containing the gelatine 
pellet. The bottom portion of the pellet was crushed by pinching it repeatedly to form a 
homogeneous suspension. The fluid-hydrated swab was saturated and transferred to Petri 
dishes with MH agar (Klebsiella pneumoniae and Staphylococcus aureus) or Middlebrook 
7H10 agar supplemented with 0.5% or 0.2% glycerol and 10% OADC (Mycobacterium 
aurum A+ and Mycobacterium tuberculosis H37Ra). For each bacterial strain, the same swab 
was used repeatedly to streak the inoculated area. The inoculated agar plates were then 
incubated for 24 h (Klebsiella pneumoniae, Staphylococcus aureus), or 72 h (Mycobacterium 
aurum A+) at 37 °C to allow bacterial colonies to grow. For Mycobacterium tuberculosis 
H37Ra, the agar plates were incubated in a 5% carbon dioxide incubator at 37 °C for four 
weeks.  
 
After incubation, the bacteria were kept as stocks in sterile cryovials (Greiner, Germany) 
containing glycerol solution for Klebsiella pneumoniae and Staphylococcus aureus. Whereas 
Mycobacterium aurum and Mycobacterium tuberculosis H37Ra stocks were kept in sterile 
Middlebrook 7H9 broth supplemented with a 0.5% glycerol and 10% OADC supplement. 
The cryovials with stock cultures were then stored in an ultra-freezer at -70 ºC until required 
for antibacterial assay. 
 
2.5.4. Subculturing for bioassays 
 
Bacterial stock strains were streaked and sub-cultured in sterile MH agar (for Klebsiella 
pneumoniae and Staphylococcus aureus) or Middlebrook 7H10 agar supplemented with 0.5% 
glycerol and 10% OADC supplement (for Mycobacterium aurum and Mycobacterium 
tuberculosis). The plates were incubated for 24 h for Klebsiella pneumoniae and 
Staphylococcus aureus, 72 h for Mycobacterium aurum and 3 to 4 weeks for Mycobacterium 
tuberculosis H37Ra to allow bacterial colonies to develop. When the bacterial colonies had 
developed, the plates were then stored at 4 °C to prevent further bacterial growth. The same 
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procedure was followed to sub-culture stocks on a monthly basis in order to maintain 
viability. 
 
2.5.5. Antibacterial activity using microdilution 
 
The minimum inhibitory concentrations (MIC) of plant extracts were determined using the 
microdilution method in 96 well microtitre plates against Staphylococcus aureus and 
Klebsiella pneumoniae as described by ELOFF (1998a). The extracts were dissolved in 10% 
dimethylsulfoxide (DMSO) except for aqueous extracts that were dissolved in sterile distilled 
water. The test organisms (Staphylococcus aureus and Klebsiella pneumoniae) were cultured 
in MH broth for 24 h at 37 °C. Neomycin was used as the positive control whereas broth 
(negative), 10% DMSO, and water (solvent controls) were used as negative and solvent 
controls, respectively. For antibacterial testing against Staphylococcus aureus and Klebsiella 
pneumoniae, one hundred microlitres of water were added in each well of the 96 well 
microtitre. One hundred microlitres of solvent controls and test samples were added to the 
first wells of the column at an initial concentration of 100 mg/ml of extracts and 50 mg/ml for 
the positive control and then two-fold serially diluted down the wells. The optical density of 
Staphylococcus aureus and Klebsiella pneumoniae was adjusted with MH broth to match that 
of McFarland standard, equivalent to 108 colony forming units/ml (CFU/ml) at 600 nm. One 
hundred microlitres of the diluted culture were added to all the wells. The microtitre plates 
were then incubated for 24 h at 37 °C. After incubation, 40 𝜇l of p-iodonitrotetrazolium violet 
(INT) indicator was added to evaluate growth inhibition. The results were observed following 
30 min incubation at 37 °C. The lowest concentration containing clear wells were considered 
as the MIC values. The assay was repeated twice with two replicates per assay. 
 
2.5.6. Antimycobacterial activity using the resazurin microplate assay 
 
The resazurin microplate assay (REMA) and broth microdilution method as described by 
JADAUN et al. (2007) modified by GREEN et al. (2010), to determine the 
antimycobacterial activity of the extracts, were performed against Mycobacterium 
tuberculosis H37Ra and Mycobacterium aurum A+. Mycobacterium tuberculosis H37Ra was 
subcultured in Middlebrook 7H9 broth supplemented with 10% OADC and 0.2% glycerol, 
and then incubated at 37 ºC for 4 weeks in 5% carbon dioxide until logarithmic growth was 
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reached. Turbidity equivalent to that of McFarland’s No. 1 standard solution for 
Mycobacterium tuberculosis H37Ra was achieved by mixing the culture with a sufficient 
volume of sterile supplemented Middlebrook 7H9 broth. The test inoculum was obtained by 
further dilution (1:20) of the suspension with the same culture medium to approximately 
6×106 CFU/ml immediately prior to use. Mycobacterium aurum A+ was subcultured in 
Middlebrook 7H9 broth supplemented with 10% OADC and 0.5% glycerol, and incubated for 
72 h at 37 ºC. The optical density of Mycobacterium aurum A+ was adjusted to 0.125 at 550 
nm using Middlebrook 7H9 broth enriched with 0.5% glycerol and 10% OADC growth 
supplement. Rifampicin and streptomycin were used as positive controls whereas broth 
(negative), 10% DMSO and water (solvent) were used as negative and solvent controls, 
respectively. The extracts were dissolved in 10% DMSO to a concentration of 100 mg/ml and 
maintained at room temperature for 1 h to assure their sterilisation. For antimycobacterial 
testing, 100 µl of Middlebrook 7H9 broth supplemented with 0.5% glycerol, and 10% OADC 
were then added in each well.  Solvent controls and test samples (100 µl) were added to the 
first wells of the column starting with a concentration of 100 mg/ml of extracts and 50 mg/ml 
for the positive control and then two-fold serially diluted down the wells. One hundred 
microlitres of the adjusted bacterial cultures were added to all the wells. The organic and 
aqueous extracts from each plant were assayed in duplicates. Each microplate with 
Mycobacterium tuberculosis H37Ra as a test organism was incubated for 5 days at 37 ºC in a 
5% carbon dioxide atmosphere, while the microplates with Mycobacterium aurum A+ were 
incubated for 72 h at 37 ºC. After incubation, 32 µl of freshly prepared filter sterilised 
0.002% resazurin solution was added to each growth control well only. For Mycobacterium 
tuberculosis H37Ra, the microplates were incubated again at 37 ºC in a 5% carbon dioxide 
atmosphere for 24 h. When a color shift from blue to pink was observed in the growth control 
sample, 32 µl of resazurin solution was added to each of the remaining wells, and the 
microplate was further incubated for 24 h. For Mycobacterium aurum, the results were 
observed after 30 min of incubation after adding the indicator. A well-defined pink colour 
was interpreted as positive bacterial growth, whereas a blue colour indicated the absence of 
growth.  
 




Plants selected in this study are all used in South African TM by various South African tribes 
for the treatment of tuberculosis and related symptoms. Ten plants were selected based on the 
available literature of medicinal plants used. The species name, family, traditional uses, 
voucher specimen numbers, parts used and phamarcological activities of the plants used in 




Table 2.1: Medicinal plants used traditionally in South Africa to treat tuberculosis and related symptoms  
Family, species Voucher 
specimen No. 




Brunsvigia grandiflora Lindl. 
 
BALUNGI 31 Coughs and colds Bulbs Mutagenic and antimutagenic 
activities of bulbs. 
HUTCHINGS et al., 
1996; VERSCHAEVE 








Tuberculosis  Shoots Analgesic and anti- 
inflammatory activities of 
roots. Two antiprotozoal 
compounds were isolated. 
 
HUTCHINGS  et al., 
1996; VAN WYK et al., 
 1997; OKETCH- 
RABAH et al., 1997;  
HASSAN et al., 2008 
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Family, species Voucher 
specimen No. 




BALUNGI 44 Tuberculosis  Leaves, roots Caryophyllene typesesquiterpene lactone  
isolated from the leaves was found to have 
remarkable aspfalcolide effect on the 
proliferation, migration and tube formation 
of human umbilical vein endothelial cells. 
Antibacterial activity of the roots 
 
MABOGO, 1990;  
STEENKAMP et al., 













Leaves, roots Sedative effects of roots. Antibacterial and 
cytotoxicity activity of seeds. Five 
compounds were isolated and identified as 
isoflavan, quinones and hydroquinones. 
 
HUTCHINGS et al.,  
1996; ZORE et al. 2007;  
SIVAKUMAR and  
ALAGESABOOPHATHI 
, 2008; BOLOU et al., 
2011; HATA et al., 2012 
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Family, species Voucher 
specimen No. 




Terminalia phanerophlebia  
Engl. & Diels 
 
BALUNGI 37 Tuberculosis Roots Antibacterial and antifungal 
activities of the leaves. 
 




Benth. ex Harv. & 
Sond. 
 
BALUNGI 41 Tuberculosis  Roots Antibacterial activity of the 
leaves. 
 
MABOGO, 1990;  
TOMANI et al., 2008 
 
Moraceae 
Ficus sur Forssk. 




Bark, roots Antimalarial and antibacterial 
activities of the leaves.  
 
 
HUTCHINGS et al.,  
1996; VAN WYK et al.,  
1997; ELDEEN et al.,  




Family, species Voucher 
specimen No. 
Traditional use Parts used Previously screened 





BALUNGI 35 Tuberculosis, blood  
purification, intestinal  
sores, sinusitis and  
gonorrhoea 
 
Whole plant Antibacterial activity against 
Gardnerella vaginalis and 
toxicity. 
 
McGAW et al., 2008a; 
VAN WYK et al., 1997; 











Tuberculosis, chest  
pain, fever and  
toothache 
 
Roots Antibacterial activity. 
Antiviral activity of leaves 
and roots. 
 
HUTCHINGS et al.,  
1996; VAN WYK et al., 





BALUNGI 38 Colds, coughs, 
bronchitis,  
asthma, tuberculosis, 
high blood pressure 
and jaundice 
Leaves, stems Anti-inflammatory activity. McGAW et al., 2008a ;  




2.6.1. Plant extraction  
 
In the preparation of plant formulations for pharmacological analysis, extraction is one of the 
most important steps, as it is necessary to extract the desired plant constituents (AZMIR et 
al., 2013). Inappropriate extraction methods may result in natural product degradation. The 
percentage yield of the extracts used in this study are presented in Table 2.2. Most scientists 
working on secondary metabolites chemistry use dried plant material for many reasons, and 
one of them is that there are fewer problems associated with large extraction of dried plant 
material than with fresh ones. Additionally, dried plant material is used by many scientist for 
extraction because, many if not most plants are used by traditional healers in dried form 
(ELOFF, 1998b). Hence the use of dried plant materials for preparation of crude extracts in 
this study. 
 
Plants produce a wide range of secondary metabolites with different functional groups and 
polarities. The extraction process of bioactive substances from raw plant material is an 
important stage in the techniques used in natural medicinal preparations. Numerous 
improvements have been put forward in order to perfect the extraction process (IVANOV et 
al., 2004). In this study, plant material was ground into powders to increase the surface area 
for maximum diffusion of the extractable compounds. The plant material was sonicated so as 
to increase the yield of bioactive compounds while reducing extraction time. Additionally, ice 
was added during sonication to lower the temperatures, thus preventing decomposition of 
plant compounds that are sensitive to high temperatures (ELOFF, 1998b). 
 
Although water is used as an extractant in many traditional procedures, organic solvents of 
varying polarities are generally selected in modern methods of extraction to exploit various 
solubilities of plant constituents (SARKER et al., 2005). Four solvents (PE, DCM, 80% 
EtOH and water) were used in this study because of their wide polarity range. The highest 
quantity of extract yield was observed from the EtOH extract of Polygala fruticosa, whilst 
the lowest was from PE extracts of the roots of Terminalia phanerophlebia (Table 2.2.). 
Generally, EtOH was the best extractant giving the highest mass of extracts while PE yielded 
the lowest mass. The masses of all water extracts were second highest to EtOH for most of 
the species extracted. When extracting metabolites to screen plants for antimicrobial activity, 
the effect of the extractant on the subsequent separation is not important, but rather the 
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solvent used should not interfere with bacterial strains in the bioassay (ELOFF, 1998b; 
NCUBE et al., 2008). Nonetheless, when extracting plant material intending to isolate 
chemical constituents only without using a bioassay, solvent toxicity is not important as it can 






Table 2.2: Percentage yields of extracts from plants used in this study 
Plant species Plant part Extract Extract yield % (DW) 
Abrus precatorius subsp. africanus Leaves PE 1.03 
  DCM 1.24 
  80% EtOH 3.54 
  Water 2.66 
Abrus precatorius subsp. africanus Seeds PE 2.28 
  DCM 2.87 
  80% EtOH 3.42 
  Water 2.43 
Asparagus africanus Leaves PE 0.40 
  DCM 0.50 
  80% EtOH 1.50 
  Water 6.80 
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Plant species Plant part Extract Extract yield % (DW) 
Asparagus falcatus Leaves PE 0.80 
  DCM 0.62 
  80% EtOH 2.76 
  Water 1.00 
Brunsvigia grandiflora Bulb PE 2.83 
  DCM 0.98 
  80% EtOH 4.47 
  Water 3.42 
Ficus sur Bark PE 0.50 
  DCM 0.50 
  80% EtOH 0.60 
  Water 0.40 
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Plant species Plant part Extract Extract yield % (DW) 
Ficus sur Roots PE 3.20 
  DCM 0.70 
  80% EtOH 7.70 
  Water 2.10 
Indigofera arrecta Leaves PE 2.66 
  DCM 1.79 
  80% EtOH 11.15 
  Water 9.69 
Indigofera arrecta Roots PE 0.60 
  DCM 0.70 
  80% EtOH 11.40 
  Water 0.80 
Leonotis intermedia Leaves PE 1.02 
  DCM 1.00 
  80% EtOH 5.62 
  Water 3.20 
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Plant species Plant part Extract Extract yield % (DW) 
Leonotis intermedia Stem PE 0.50 
  DCM 0.60 
  80% EtOH 4.80 
  Water 3.00 
Pentanisia prunelloides Leaves PE 1.30 
  DCM 1.40 
  80% EtOH 4.40 
  Water 1.50 
Pentanisia prunelloides Roots PE 0.20 
  DCM 0.20 
  80% EtOH 11.40 
  Water 6.76 
Polygala fruticosa Whole plant PE 0.73 
  DCM 1.04 
  80% EtOH 16.67 
  Water 4.84 
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Plant species Plant part Extract Extract yield % (DW) 
Terminalia phanerophlebia Leaves PE 0.50 
  DCM 1.20 
  80% EtOH 16.00 
  Water 9.80 
Terminalia phanerophlebia Roots PE 0.10 
  DCM 0.30 
  80% EtOH 12.90 
  Water 1.70 
Terminalia phanerophlebia Twigs PE 1.00 
  DCM 0.40 
  80% EtOH 11.00 
  Water 3.70 




2.6.2. Antimicrobial and antimycobacterial assay 
 
The MIC values of 68 extracts from 10 plants used in this study are presented in Table 2.3. 
Analysis of the antimicrobial efficacy of the plant samples was based on the following 
criteria: MIC values of less than 1.00 mg/ml were considered as having good activity 
(YORK et al., 2012). Out of 68 extracts tested from different parts of 10 species, 18 were 
found to have good antimicrobial activity at least against one or more of the tested bacterial 
strains. Twelve extracts showed good activity against Mycobacterium aurum A+, 11 against 
Staphylococcus aureus and eight against Mycobacterium tuberculosis H37Ra. It was 
observed that Mycobacterium aurum A+ was the most susceptible bacterium while Klebsiella 
pneumoniae was the most tolerant with only six extracts showing good activity against the 
bacterium. Due to lipopolysaccharides present on their outer membrane, Gram-negative 
bacteria are usually impermeable to most antibacterial compounds (FENNELL et al., 2004; 
VORAVUTHIKUNCHAI et al., 2004). This can explain the low number of active extracts 
against Klebsiella pneumoniae. The water extract of Terminalia phanerophlebia (leaf) 
showed the best activity with the lowest MIC value of 0.098 mg/ml among the extracts 
tested. Among the water extracts, Terminalia phanerophlebia leaves exhibited good activity 
against all tested bacterial strains, with MIC values ranging from 0.098-0.39 mg/ml. The 
water extracts of Indigofera arrecta (leaf), Pentanisia prunelloides (leaf), and Terminalia 
phanerophlebia (twig and root) also showed good activity against at least one bacterial strain 
with MIC values ranging from 0.098-0.78 mg/ml. This was encouraging as many reports 
often states that water extracts lack bioactivity (MULAUDZI et al., 2009). The evaluation of 
water extracts aims to mimic the traditional use; therefore, the observed antibacterial activity 
exhibited by water extracts is of great interest. 
 
Comparing the root and leaf extracts, the leaf EtOH extracts of Indigofera arrecta, showed 
good antibacterial activity against three bacterial species with MIC values ranging from 0.39-
0.78 mg/ml and generally poor for roots. For Pentanisia prunelloides, the root EtOH extracts 
showed good activity against all bacterial strains tested, with MIC values of between 0.39-
0.78 mg/ml. Additionally, the EtOH extracts from the leaves of Pentanisia prunelloides 
showed good activity against both Mycobacterium aurum and Staphylococcus aureus at MIC 
values of 0.39 and 0.195 mg/ml respectively. This is noteworthy as it indicates the presence 
of bioactive compounds in these plants that might be a potential cure for ailments related to 
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respiratory infection. The palmitic acid previously isolated from roots of Pentanisia 
prunelloides by YFF et al. (2002) may be responsible for the antimicrobial activity of this 
plant observed in this study. YFF et al. (2002) also did an antiviral test on the root decoction 
of Pentanisia prunelloides and reported an inhibition of Influenza A virus. These results make 
this plant a potentially effective remedy against respiratory diseases, and the evaluation of 
palmitic acid against respiratory microbes is required. 
 
For Terminalia phanerophlebia leaf, root, and twig extracts, the EtOH extracts showed good 
activity against the majority of the bacterial strains tested, with MIC values ranging from 
0.195 to 0.78 mg/ml. This, however, was excluding the leaf extract that did not exhibit good 
activity against one strain and root extract that also did not show good activity against two 
strains. In a study on antimicrobial properties done by SHAI et al. (2008) against 
Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, and Pseudomonas 
aeruginosa, the leaf extracts of Terminalia phanerophlebia exhibited good antimicrobial 
activity which was also the case in this study against the tested bacteria. In addition, through 
a literature investigation conducted by NAIR et al. (2012), several alkaloids were reported to 
have been isolated from the stem of Terminalia phanerophlebia which exhibited 
cyclooxygenase-2 enzyme activity. The antimicrobial activity observed from different parts 
of this plant might be due to those sterols (cholestane triterpenoids: 𝛽-sitostenone, stigmast-4-
ene-3,6-dione, and 𝛽-sitosterol). It is, therefore, important to evaluate these compounds in 
bioassays against these microorganisms. Terminalia plants were confirmed to have medicinal 
importance when Terminalia sericea Burch. ex DC. was included in the African herbal 
pharmacopeia representing the top 50 African medicinal plants (ELOFF et al., 2008). The 
leaves and bark of Terminalia phanerophlebia were reported by SIBANDZE (2009) to 
posses high flavonoid and phenolic content. Flavonoids are known to have antimicrobial, 
anti-inflammatory, anti-cancer and antiviral activities (HAVSTEEN, 2002). Reports on 
antimycobacterial activities of flavonoids through inhibiting enzymes involved in 
biosynthesis of mycolic and fatty acid have been made (KUETE et al., 2010a). Additionally, 
flavonoids have been observed to possess the same modulatory properties of isoniazid (INH) 
and hence could be taken with anti-tuberculosis treatment for preventing or counteracting 
INH resistance (MACABEO et al., 2012). The genus Terminalia has been reported to have 
antimycobacterial properties and this was evident in a study done by KUETE et al. (2010b) 
where compounds isolated from Terminalia superba Engl. & Diels inhibited Mycobacterium 
species. Good antimicrobial activity is sometimes associated with toxicity, however, the leaf 
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extracts of Terminalia phanerophlebia demonstrated non-toxicity in a study done by 
SIBANDZE (2009). The interaction or coinfection of tuberculosis microorganisms and 
malarial parasites is of importance. Of particular interest is a study by SIBANDZE (2009) 
which confirmed the activity of Terminalia phanerophlebia as an antimalarial agent and this 
current study has demonstrated the same plant as an anti-tuberculosis agent.  
 
For Ficus sur (bark and root), only the EtOH extract (root) showed good activity with an 
MIC value of 0.78 mg/ml against Klebsiella pneumoniae and Mycobacterium tuberculosis, as 
well as 0.195 mg/ml against Staphylococcus aureus. From a previous study, good 
antibacterial activities were observed on tested extracts of the leaves, roots and bark of Ficus 
sur (ELDEEN et al., 2005b). The activity of this plant could be due to the triterpene 
compounds found in the latex isolated in a previous study by FELEKE and BREHANE 
(2005), which also warrants testing in similar bioassays. 
 
For Leonotis intermedia (leaf and stem), only the EtOH extract (leaf) showed good activity 
with MIC value of 0.195 mg/ml against Mycobacterium aurum A+ and 0.78 mg/ml against 
Staphylococcus aureus. These findings are very interesting as they indicate the antimicrobial 
activity of this plant. Of all the extracts of Asparagus africanus and Asparagus falcatus, good 
activity was observed only in the EtOH extracts with both having an MIC value of 0.39 
mg/ml against Mycobacterium aurum A+. Asparagus species are known to have steroidal 
saponins as their major bioactive constituents; therefore, the antimycobacterial activity of 
these two species could be due to these groups of compounds (NEGI et al., 2010). 
 
For Abrus precatorius subsp. africanus, the leaves showed good antimycobacterial activity 
against both Mycobacterium species tested, with MIC values of 0.195 and 0.78 mg/ml, 
respectively. The leaf is one of the plant parts reported to be used for tuberculosis treatment 
in South Africa, thus the antimycobacterial activity exhibited by the leaf EtOH extracts was 
noteworthy. Additionally, good antibacterial activity was also exhibited against M. aurum by 
the leaf DCM and seed EtOH extracts of Abrus precatorius subsp. africanus, with MIC value 
of 0.78 mg/ml. The stem EtOH extracts of Abrus precatorius subps. africanus was found to 
have partial activity against Mycobacterium tuberculosis in a study done by ANTOUN et al. 
(2001). Phytochemical research done in a previous study by TAUR and PATIL (2011) from 
the root and aerial parts of this plant showed the presence of triterpernoids and saponins. 
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Saponins are known to have a broad spectrum of pharmacological activities, including 
antimicrobial property (SPARG et al., 2004). 
 
In view of the fact that these plants were selected based on their traditional uses against 
tuberculosis and related symptoms, these findings are noteworthy. The antimicrobial activity 
observed from the extracts of Abrus precatorius subsp. africanus, Asparagus africanus, 
Asparagus falcatus, Ficus sur, Indigofera arrecta, Leonotis intermedia, Pentanisia 
prunelloides and Terminalia phanerophlebia advocates that these plants possibly have 
antimycobacterial compounds. Therefore, further studies aimed at isolating bioactive 
compounds of these plants are necessary as the observed findings substantiate that they might 
comprise alternative future candidates for tuberculosis treatment. All the extracts of 
Brunsvigia grandiflora and Polygala fruticosa P.J. Bergius did not display good activity 
against all the screened bacterial strains in these assays despite being reported to be used in 
the treatment of tuberculosis and related symptoms. However, bioactivity cannot be 
completely ruled out from such plant species as they could be active against other bacterial 
strains that cause tuberculosis and related respiratory ailments. The other possible explanation 
could be that antimicrobial effects of these plants are not mediated through direct inhibition 
on microbial growth but rather through immunostimulation or the compounds potentially 




Table 2.3: Antibacterial (MIC values) effects of plants used traditionally as remedies in the treatment of tuberculosis and related symptoms 
in South Africa 
Plant species Plant part Extract Antibacterial activity MIC (mg/ml) 








Abrus precatorius subsp. africanus L PE 12.50 12.50 12.50 12.50 
  DCM 12.50 12.50 0.78 12.50 
  80% EtOH 3.13 1.56 0.195 0.78 
  Water 6.25 3.13 12.50 6.25 
Abrus precatorius subsp. africanus S PE 12.50 6.25 12.50 12.50  
  DCM 12.50 3.13 6.25 12.50  
  80% EtOH 6.25 1.56 0.78 12.50  
  Water 1.56 3.13 1.56 6.25 
Asparagus africanus L PE 12.50 12.50 6.25 12.50  
  DCM 12.50 12.50 6.25 12.50  
  80% EtOH 6.25 6.25 0.39 6.25 
  Water 1.56 12.50 6.25 12.50 
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Plant species Plant part Extract Antibacterial activity MIC (mg/ml) 








Asparagus falcatus L PE 12.50 12.50 3.13 12.50 
  DCM 12.50 12.50 1.56 12.50  
  80% EtOH 6.25 3.13 0.39 6.25 
  Water 3.13 1.56 2.56 3.13 
Brunsvigia grandiflora Blb PE 12.50 12.50 12.50 12.50  
  DCM 12.50 6.25 3.13 12.50  
  80% EtOH 3.13 6.25 3.13 12.50  
  Water 3.13 6.25 3.13 6.25 
Ficus sur B PE 12.50 12.50 6.25 12.50  
  DCM 12.50 12.50 6.35 12.50  
  80% EtOH 6.25 6.25 3.13 6.25 
  Water 6.25 12.50 6.25 1.56 
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Plant species Plant part Extract Antibacterial activity MIC (mg/ml)  








Ficus sur R PE 6.25 12.50 12.5 12.50  
  DCM 6.25 12.50 6.25 12.50  
  80% EtOH 0.78 0.195 3.13 0.78 
  Water 12.50 3.13 3.13 6.25 
Indigofera arrecta L PE 6.25 12.50 12.50 12.50  
  DCM 12.50 12.50 6.25 12.50  
  80% EtOH 0.78 0.39 0.39 6.25 
  Water 12.50 6.25 0.78 6.25 
Indigofera arrecta R PE 12.50 12.50 6.25 12.50  
  DCM 12.50 12.50 1.56 12.50  
  80% EtOH 3.13 1.56 1.56 12.50  
  Water 6.35 12.50 12.50 12.50  
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Plant species Plant part Extract Antibacterial activity MIC (mg/ml) 








Leonotis intermedia L PE 12.50 12.50 6.25 12.50  
  DCM 12.50 12.50 12.50 12.50  
  80% EtOH 6.25 0.78 0.195 3.13 
  Water 3.13 1.56 3.13 3.13 
Leonotis intermedia Stm PE 6.25 12.50 3.13 12.50  
  DCM 6.25 12.50 12.50 12.50  
  80% EtOH 3.13 1.56 1.56 6.25 
  Water 3.13 6.25 1.56 12.50 
Pentanisia prunelloides L PE 6.25 12.50 6.25 12.50  
  DCM 12.50 6.25 12.50 12.50  
  80% EtOH 3.13 0.195 0.39 12.50  
  Water 3.13 0.39 1.56 3.13 
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Plant species Plant part Extract Antibacterial activity MIC (mg/ml) 








Pentanisia prunelloides R PE 6.25 12.50 3.13 12.50  
  DCM 6.25 12.50 12.50 12.50  
  80% EtOH 0.39 0.78 0.78 0.78 
  Water 1.56 1.56 1.56 3.13 
Polygala fruticosa Wp PE 6.25 6.25 1.56 12.50  
  DCM 6.25 6.25 1.56 12.50  
  80% EtOH 3.13 1.56 3.13 6.25  
  Water 3.13 6.25 3.13 3.13 
Terminalia phanerophlebia L PE 6.25 6.25 6.25 12.50  
  DCM 6.25 6.25 6.25 12.50  
  80% EtOH 0.195 0.195 1.56 0.39  
  Water 0.39 0.098 0.39 0.39 
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Plant species Plant part Extract Antibacterial activity MIC (mg/ml) 








Terminalia phanerophlebia R PE 12.50 12.50 6.25 12.50  
  DCM 6.25 6.25 3.13 12.50  
  80% EtOH 1.56 0.195 3.13 0.78 
  Water 3.13 0.39 6.25 12.50 
Terminalia phanerophlebia T PE 6.25 6.25 3.13 12.50  
  DCM 6.25 3.13 1.56 12.50  
  80% EtOH 0.195 0.39 0.195 0.78  
  Water 1.56 1.56 1.56 0.39 
Neomycin - - 0.0975 0.0975 - - 
Streptomycin - - - - 0.195 0.048 
Rifampicin - - - - - 0.024 
L: leaves, R: roots, B: bark, Blb: bulb, S: seeds, Stm: stem, Wp: whole plant, T: twigs, MIC: minimum inhibitory concentration, DCM: 
dichloromethane, PE: petroleum ether, EtOH: ethanol, the values highlighted in bold are considered very active, Neomycin, Rifampicin and 





Two extracts of Abrus precatorius subp. africanus, Terminalia phanerophlebia, Pentanisia 
prunelloides, Indigofera arrecta and one extract of Asparagus falcatus, Asparagus africanus, 
Leonotis intermedia, as well as Ficus sur showed good antimicrobial activity against at least 
one of the bacterial strains tested. The results indicate that some of the plants such as Abrus 
precatorius subsp. africanus, Asparagus africanus, Asparagus falcatus, Indigofera arrecta, 
Leonotis intermedia, Ficus sur, Pentanisia prunelloides and Terminalia phanerophlebia have 
antimycobacterial compounds. Significant in vitro antimycobacterial activities have been 
demonstrated by extracts of South African plant species from different families and genera in 
this study. This provides supporting evidence that South Africa has diverse flora which has a 
potential for the discovery of metabolites that are active against Mycobacterium tuberculosis. 
Additionally, further phytochemical and pharmacological studies (such as isolation of active 
compounds and antimycobacterial evaluation against resistant tuberculosis strains) of these 
plants are worthwhile as they form a good preliminary basis for the selection of candidate 
plants. The fact that some species of the tested plants such as Brunsvigia grandiflora and 
Polygala fruticosa did not display good antimicrobial activity does not mean that they may be 
inactive in vivo; thus, it should be noted that they only demonstrated weak activity in vitro. 
Weak activity might mean that the plant species are used to treat the symptoms of various 
respiratory ailments rather than the disease itself. 
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Chapter 3: Inhibition of cyclooxygenase enzyme as an evaluation 




In order for humans to survive, they have to be able to eliminate foreign invaders such as 
agents of infection and damaged tissues from their system. The elimination of foreign 
material is mediated by a complex response called inflammation. Inflammation is defined as 
a protective reaction evoked by body cells or tissues in response to various factors such as 
bacterial infections, allergic reactions and chemical injury (IWALEWA et al., 2007; 
KUMAR et al., 2013). The inflammation response is an important function of the immune 
system that is required to protect the host against microorganisms and initiate specific 
immunity (SHIN et al., 2010). Inflammation aids in eliminating infections and other harmful 
stimuli and initiates healing. However, the response and the subsequent healing process can 
themselves cause substantial damage (KUMAR et al., 2013). The mechanisms of the 
inflammatory response that destroy and eradicate microorganisms and dead tissues are also 
capable of injuring normal tissues (KUMAR et al., 2013; KATARIA and KAUR, 2013). 
Thus, injury may accompany entirely normal, beneficial inflammatory reactions, and the 
damage may even become the dominant feature when the infection is severe. Some of the 
most complicated human diseases are disorders that result from inappropriate, often chronic, 
inflammation. 
 
Inflammation can be acute or chronic and can be beneficial or harmful (SUGAWARA, 
2009). Acute inflammation is the initial response of the immune system to harmful stimuli 
(VASSILEVA and PIQUETTE-MILLER, 2010). The acute inflammatory response is 
characterised by exudation of fluids and plasma proteins as well as movement of leukocytes 
(neutrophils) into the harmed area (IWALEWA et al., 2007). Acute inflammation is believed 
to be helpful when it occurs under normal circumstances as it results in healing and serves as 
a defence mechanism against bacteria, viruses and parasites (VASSILEVA and 
PIQUETTE-MILLER, 2010). When the body is unable to destroy the invading foreign 
object, chronic inflammation occurs (VASSILEVA and PIQUETTE-MILLER, 2010). 
Chronic inflammation is characterised by mononuclear immune cell infiltration, simultaneous 
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tissue destruction and healing attempts which include angiogenesis and fibrosis. Chronic 
inflammation is evident in the case of persistant infections like tuberculosis, rheumatoid 
arthritis, cancer and chronic lung diseases (KATARIA and KAUR, 2013). 
 
Inflammatory responses are major contributors to diseases and disorders as its symptoms 
appear when the body recognises the injury and repairs the damage (IWALEWA et al., 
2007). Without inflammation, wounds would never heal and infections would go unchecked. 
The symptoms of an inflammation response are redness, pain, and swelling with impaired 
functioning of the inflamed area. Redness of the inflamed area is due to an increased quantity 
of blood so that the smallest capillaries are distended with red particles (VASSILEVA and 
PIQUETTE-MILLER, 2010). 
 
Inflammation treatment usually consists of the use of aspirin and similar anti-inflammatory 
drugs (GALE et al., 2007). However, currently used anti-inflammatory drugs have serious 
side effects. Worldwide, researchers continue the search for new anti-inflammatory drugs and 
there is growing interest by the pharmaceutical and herbal industries in the potential of plants 
as anti-inflammatory agents (GALE et al., 2007). As a result of scientific research taking 
place in various countries at present, a number of anti-inflammatory compounds have been 
isolated from medicinal plants. Thus, evaluating medicinal plants that are used traditionally in 
the treatment of pain related infections in search for potent anti-inflammatory agents with 
reduced or no side effect is proving to be worthwhile. 
 
3.2. Overview of inflammation response 
 
The inflammation response is controlled by a number of chemical mediators. Upon pathogen 
invasion, mammalian monocytes or macrophages identify lipopolysaccharides (LPS) of 
bacteria through transmembrane signaling Toll-like receptor-4 (TLR-4), thus signalling 
commencement of normal host defence mechanisms (SHIN et al., 2010). The chemical 
mediators are released as plasma proteins or come from mast cells, platelets, neutrophils and 
monocytes or macrophages (SHIN et al., 2010). The inflammation process mediators are 
termed pro-inflammatory fundamental factors, and they result in inflammations of different 
severity depending on the duration of the injury (IWALEWA et al., 2007). The chemical 
mediators include nitric oxide, prostaglandins, leukotrienes, vasoactive amines and cytokines 
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(VANE and BOTTING, 1987). These chemical mediators bind to target receptors on the 
cells thereby increasing vascular permeability, promoting neutrophil chemotaxis, stimulating 
smooth muscle contraction, increasing direct enzymatic activity, inducing pain and mediating 
oxidative damage in the process (IWALEWA et al., 2007).  
 
The complex inflammatory response begins with the release of arachidonic acid (AA), a 20 
carbon tetraenoic fatty acid, from the plasma membrane phospholipids following stimulation 
(SIMMONS et al., 2004). Tissue damage activates phospholipase A2 enzyme which cleaves 
AA from cell membrane phospholipids. Upon release, AA proceeds down either the 
lipoxygenase (LOX) or cyclooxygenase (COX) pathway leading to the formation of 
thromboxane or prostaglandins respectively (GARCIA-VALASCO and RIZK, 2010). 
Cyclooxygenase and LOX pathways are responsible for controlling the biosynthesis of 
eicosanoids. The COX-derived eicosanoids are prostanoids, like prostaglandin 12 and E2 
(PG12 and PGE2) that are involved in platelet aggregation regulation of gastrointestinal and 
renal blood flow (SIMMONS et al., 2004). Prostaglandin 12 and PGE2 can however be 
powerful vasodilator agents that play a role in the vascular signs of the inflammation 
response (WISASTRA and DEKKER, 2014). Prostaglandins play a vital role in the 
homeostasis of several tissues and organ system, including the gastrointestinal tract, renal, 
pulmonary, cardiovascular, and the reproductive system (GALE et al., 2007). They also play 
a crucial role in the regulation of blood pressure and coagulation. Prostaglandins are 
produced by most human cells and their overproduction is the main cause of inflammation. 
Cyclooxygenase enzyme/prostaglandin H synthase or LOX are the major enzymes involved 
in the conversion of AA to prostaglandin (SIMMONS et al., 2004). During inflammation 
processes, both leukotrienes and prostanoids are synthesised and released by cells in 
concentrations sufficient to affect their biological processes such as vascular changes, 
increase in body temperature, and migration of leukocytes.  
 
3.3. Cyclooxygenase enzymes 
 
Cyclooxygenase is the key and rate limiting enzyme that catalyses the first step of 
prostaglandin synthesis, which is the main cause of inflammation (VERNIERI et al., 2013). 
There are three forms of COX enzymes that are known to convert AA to prostanoids; they are 
COX-1, COX-2 and COX-3 (GILROY et al., 1999; MENDES et al., 2012). All these COX 
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enzymes are named according to the order in which they were discovered. Cyclooxygenase 
enzymes were initially believed to be expressed constitutively with constant levels in 
individual tissues (PORCHER et al., 2002). However, the discovery of COX-2 between 
1989 and 1992 gave rise to the concept of constitutive COX-1 and inducible COX-2 
(SIMMONS et al., 2004). 
 
Cyclooxygenase-1 and COX-2 are similar in many respects, however there are significant 
differences that distinguishes the two isoenzymes. Cyclooxygenase-1 is a membrane bound 
protein that resides in the endoplasmic reticulum of prostanoid forming cells (MBONYE et 
al., 2006). The amino acids in the structure of COX-1 form a long narrow channel that ends 
with a hairpin-like bend at the end. The mRNA of this enzyme is about 4.5 Kb (POPOVICI 
et al., 2011). Cyclooxygenase-1 is the first isoenzyme that is expressed constitutively in 
resting cells of most tissues and shares 60% homology at the amino acid level with COX-2 
enzyme (PATRIGNANI et al., 2005). This first isoenzyme functions as a house keeping 
enzyme and is responsible for maintaining homeostasis (gastric and renal intergrity) as well 
as normal production of prostaglandins (VERNIERI et al., 2013). This enzyme has a 
molecular weight of 71 Kda. 
 
Cyclooxygenase-2 enzyme is about 82 Kb long and is located on chromosome 1. It consists 
of 10 exons and 9 introns. The mRNA of COX-2 is about 2.8 Kb. Cyclooxygenase-2 is 
mainly located in the lumen of the endoplasmic reticulum where the oxidising conditions 
favor its proper dimerisation (POPOVICI et al., 2011). Just like COX-1, COX-2 has a 
molecular weight of 71 Kda. It is an “inducible enzyme”, upregulated by infection and is 
responsible for the inflammatory response. The constitutive presence of COX-2 has been 
recently highlighted in the central nervous system, kidney, and endothelial cells, but is 
virtually absent in most other tissues (VERNIERI et al., 2013). The expression of COX-2 is 
significantly upregulated in neoplastic tissues and as part of various acute as well as chronic 
inflammatory conditions. The stimulators of COX-2 expression are epidermal growth factors, 
platelet derived growth factors, pro-inflammatory cytokines, tumor promoters, bile acids and 
ultraviolet B irradiation (POPOVICI et al., 2011). Cyclooxygenase-2 enzyme is the main 
target for treatment of inflammatory diseases. 
 
Cyclooxygenase-3 enzyme is a splice variant of COX-1 (PATRIGNANI et al., 2005). 
Although COX-3 enzyme is made from the COX-1 gene, it retains intron 1 in its mRNA and 
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was reported to be expressed in the canine cerebral cortex (PATRIGNANI et al., 2005). 
Cyclooxygenase-3 is pharmacologically different to COX-1 and COX-2 even though it is 
derived from COX-1. This enzyme is less potent and produces less prostaglandin than either 
COX-1 or COX-2. However, research has revealed that COX-3 might have a role in 
remission periods in chronic inflammatory diseases and could be involved in ovarian, colonic 
and cervical cancer (POPOVICI et al., 2011). 
 
3.4. Inflammation and tuberculosis 
 
One of the symptoms of tuberculosis is chest pain caused by inflammation of the membranes 
lining the lungs. Several tuberculosis symptoms are associated with the pronounced host 
inflammatory responses that occur as the immune system attempts to recover (NANDI and 
BEHAR, 2011). In the case of pulmonary tuberculosis, alveolar macrophages control 
persistant inflammatory responses in the lungs by producing chemical mediators that leads to 
granuloma formation (SHINOHARA et al., 2009). The main roles of granulomas formed in 
the lungs during tuberculosis infection are confinement and containment of bacteria, and the 
inflammatory response to the bacteria itself (SHINOHARA et al., 2009). Tuberculosis is 
characterised by inflammation when the disease is latent and active (KAUFMANN and 
DORHOI, 2013). During latent tuberculosis infection, the immune system holds the 
pathogen through controlled inflammation, causing minimal collateral damage. The lungs are 
the entrance route for mycobacteria species, and they allow the bacteria to evade protective 
host defenses, forming pathological lesions that are essential for transmission of the bacterial 
strain from the granuloma lung lesion to the alveoli and aerosols (IVANYI and ZUMLA, 
2013; NANDI and BEHAR, 2011).  
 
The application of tuberculosis anti-inflammatory treatment is for lessening injurious host 
inflammation reactions that results in pathological lung lesions (KAUFMANN and 
DORHOI, 2013). Thus, the target of tuberculosis anti-inflammatory treatment is lung 
granulomatous lesions. These granulomatous lesions are produced by a variety of immune 
cells such as monocytes, lymphocytes and neutrophils which produce prostaglandins 
(IVANYI and ZUMLA, 2013). Therefore, all immune cells that produce granulomatous 




3.5. Anti-inflammatory agents 
 
Anti-inflammation refers to the ability of a substance to alleviate pain by blocking production 
of prostaglandins. There are two types of anti-inflammatory drugs, and they include 
steroidal/or glucocorticoid and non-steroidal anti-inflammatory drugs (NSAIDs) 
(DINARELLO, 2010). Glucocorticoids are used on a wide scale for treatment of several 
inflammatory diseases and they have a unique ability of inhibiting both COX and LOX 
pathways simultaneously (UMARU et al., 2009; DINARELLO, 2010). They inhibit COX-2 
by down regulating its transcription. Non-steroidal anti-inflammatory drugs are compounds 
of non-steroidal origin that are capable of reducing or inhibiting tissue injury associated with 
inflammatory responses, and they include aspirin, and several other selective and non-
selective inhibitors of COX (UMARU et al., 2009). The main benefits of NSAIDs are 
analgesic, antipyretic and anti-inflammatory effects (AWOFISAYO et al., 2008). These 
drugs are generally used for relief of symptoms of rheumatoid arthritis, osteoarthritis, 
dysmenorrhea, pyrexia and post-operative pain (DINARELLO, 2010). Due to the acidic 
nature of NSAIDs, they are easily absorbed in the stomach and intestinal mucosa. Non-
steroidal anti-inflammatory drugs NSAIDs are mobilised in the liver through oxidation and 
conjugation to inactivate metabolites and are excreted partially in bile or urine 
(AWOFISAYO et al., 2008).  
 
However, both NSAIDs and glucocorticoids have the potential to interfere with the healing 
process as they inhibit inflammation (WRIGHT, 2002). Glucocorticoids such as prednisone, 
prednisolone, and hydrocortisone which are naturally secreted by the adrenal glands or 
chemically synthesised are associated with side effects such as retarded growth in children, 
immunosuppression, muscle breakdown, increased blood pressure and glaucoma. The use of 
NSAIDs is associated with a number of adverse effects (GALE et al., 2007). These include 
kidney damage, worsening asthma, cardiovascular ailments, and damage to the 
gastrointestinal tract (DINARELLO, 2010). Non-steroidal anti-inflammatory drugs have 
injurious effects to the upper and lower gut that occur by depleting COX-1-derived 
prostaglandin-causing topical injury to the mucosa. These NSAIDs may be associated with 
gastrointestinal ailments ranging from mild to severe dyspeptic symptoms, development of 
gastric or duodenal ulceration, haemorrhage or perforation and other events which may lead 




As a result of the association of NSAIDs with adverse effects, as an alternative, more 
selective agents of COX were developed. Selective COX-2 inhibitors were introduced in the 
1990s as first line drugs for osteoarthritis and rheumatoid arthritic treatment (DINARELLO, 
2010). This class of drugs includes the widely used rofecoxib, etoricoxib and celecoxib 
(WRIGHT, 2002). The advantages of selective COX-2 inhibitors were in their potent anti-
inflammatory action and lower risk of gastrointestinal problems as they leave COX-1 
gastroprotective prostaglandin unopposed (SOLHEIM et al., 2013). In high risk cancer 
patients, the adenocarcinoma cells overexpress COX-2, and selective COX inhibitors play a 
beneficial role by reducing colon cancer development (SOLHEIM et al., 2013). However, a 
possible link between selective COX-2 inhibitors and increased cardiovascular as well as 
cerebrovasc ular risk has been suggested (WRIGHT, 2002). Recently there have been 
concerns regarding selective COX-2 inhibitors, as they are believed to contribute to the onset 
of acute myocardial infarction and thromboembolic events (HOWARD and 
DELAFONTAINE, 2004; SEGEV and KATZ, 2004; UMARU et al., 2009). Thus, there is 
still a need to develop more effective and safer COX inhibitors. 
 
Due to numerous problems associated with the currently available anti-inflammatory drugs, 
search has intensified on plants for alternative agents (OKOLI et al., 2003). Various plants 
have been used in folk medicine for the treatment of inflammatory disorders (AGNIHOTRI 
et al., 2009). Some of the traditionally used anti-inflammatory plants include Aloe vera (L.) 
Burm.f., Harpephyllum caffrum Bernh., Helichrysum nudifolium (L.) Less, and Leonotis 
leonurus (L.) R.Br. and these have demonstrated varying activity in in vitro inflammatory 
models (TAYLOR et al., 2001; AGNIHOTRI et al., 2009). Worldwide, several scientific 
studies have shown that plants do possess anti-inflammatory effects (TUNÓN et al., 1995; 
AGNIHOTRI et al., 2009; OLUKUNLE et al., 2011). Similarly, many South African 
medicinal plants have been suggested as potential sources of anti-inflammatory agents 
(JÄGER et al., 1996; McGAW et al., 1997; SHALE et al., 1999). Modern allopathic drugs 
are single active components that target one specific pathway. Plants contain more than one 
ingredient that work on targeted elements of the complex cellular pathway (KUMAR et al., 
2013). Various anti-inflammatory compounds such as curcumin, pentacyclic triterpenic acid 
and its derivatives have been structurally and pharmacologically isolated from plants 
(OKOLI et al., 2003). The main chemical classes of anti-inflammatory agents from plants 
include compounds such as polyphenols, flavonoids, terpenoids, alkaloids, anthraquinones, 
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lignans, polysaccharides, saponins and peptides (OKOLI et al., 2003; AGNIHOTRI et al., 
2009). Therefore, plants with anti-inflammatory property and which lack adverse effects can 
be used as therapy in the management of inflammatory conditions.  
 
Plants used for treatment of tuberculosis and related symptoms were selected for this study, 
to evaluate their anti-inflammatory properties since the tuberculosis disease is associated with 
inflammation. Pulmonary tuberculosis often leads to lung injury, pathological and 
inflammatory responses (DAVIES et al., 1997; DEY et al., 2003). Mycobacteria species are 
known to induce expression and induction of matrix metalloproteinase-9 which is suggested 
to be involved with COX-2 reliant signaling events (BANSAL et al., 2009). Therefore the 
development of selective COX-2 inhibitors could be an important step in the therapeutic 
treatment of inflammatory pulmonary tuberculosis. Thus, the COX-2 enzyme was selected 
for this study. Additionally, it is important to screen medicinal plant extracts in different in 
vitro assays, because there is a possibility of losing other potentially useful bioactive 
compounds when there is evaluation of only a single biological activity. Unlike drugs which 
are single active components that target one specific illness, herbal medicines work in a way 
that depends on an symphonic method (KUMAR et al., 2013). Thus, the plants screened for 
their antimicrobial properties in Chapter 1, were selected for anti-inflammation screening in 
this Chapter. 
 
3.6. Materials and methods 
 
Preparation of plant extracts and COX-2 bioassay were performed as detailed below. 
 
3.6.1. Preparation of plant extracts 
 
The extracts were prepared as described in Section 2.5.1. The stored dried sample extracts 
were resuspended in 70% EtOH for organic solvent extracts (PE, DCM and EtOH) and in 
water for aqueous extracts to a concentration of 10 mg/ml. 
 




The substrate 14C-arachidonic acid (radio labeled AA) was obtained from Amersham (GE 
Healthcare, UK). Radio-labeled AA (100 μl) were diluted with unlabelled AA (6.75 μl) 
(Sigma-Aldrich, Germany) to obtain the final concentration (17 Ci/mol, 30 μM) required for 
the bioassay. 
 
The COX-2 enzyme used in this study was obtained from Sigma-Aldrich (USA). A stock 
solution of the enzyme was kept at -70 ºC until use. The COX enzyme was diluted with 
Tris(hydromethyl)aminomethane (TRIS) storage buffer (pH 8.0) to obtain 60 μl of 75 units 
enzyme concentration per aliquot. The prepared COX enzyme (50 μl, 75 units) was kept in an 
ultra-freezer at -70 ºC until required. 
 
3.6.3. Cyclooxygenase inhibitory activity  
 
The COX-2 inhibition assay was performed as described by JÄGER et al. (1996) and 
modified by ZSCHOCKE and VAN STADEN (2000). Prepared stock solution of COX-2 
enzyme (60 µl) at -70 oC was activated with 1250 µl of co-factor solution (3 mg/ml 
epipherine, 6 mg/ml glutathione in 10 ml Tris buffer pH 8.0, and 100 µl hematin solution) 
and incubated on ice for 5 min. Plant extracts (2.5 µl) were added to 17.5 µl of distilled 
water, (for water extracts only 20 µl of the extract were added) to give a final concentration 
of 250 µg/ml of each organic extract per test solution (2 mg/ml for water extract per tester 
solution) and this was done in duplicates. A similar 200 µM indomethacin was used as a 
positive control. Solvent blank and background (2.5 µl ethanol and 17.5 µl of water) were 
used as negative controls. The enzyme solution (60 µl) was added to the test solution and pre-
incubated at room temperature for 5 min. The reaction was initiated by adding 20 µl of 14C-
AA to the test solutions. The enzyme in the background was inactivated by adding 10 µl 2N 
hydrochloric acid (HCL) before incubating the solution at 37 oC for 10 min. The incubation 
was stopped (after 10 min) and the reaction was terminated by adding 10 µl of 2N HCL to 
each test solution. A total of 4 µl of 0.2 mg/ml of unlabelled prostaglandin (PGE2: PGEF2α 
1:1) from Sigma-Aldrich were added to each Eppendorf as a carrier solution. Silica gel 
(particle size, 0.63-0.200 mm, Merck) was used to pack silica columns to a height of 3 cm 
using Pasteur pipettes. To separate the prostaglandins and unmetabolised AA, the test 
solution was applied to the column with 1 ml of eluent 1 [hexane: 1, 4-dioxan: glacial acetic 
acid (70:30:0.20 v/v/v)]. The AA was eluted first with 4 ml of eluent 1 and the products of 
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prostaglandin were eluted with 3 ml of eluent 2 [ethyl acetate: methanol (85:15)] and 
collected in scintillation vials. A total of 4 ml of scintillation fluid was added to each vial and 
a scintillation counter (Beckman LS 6000 LL) was used to count the disintegration per 
minute (DPM) of radioactive material. The assay was performed in replicates and repeated 
three times. The following formula was used to calculate the percentage of inhibition for the 
extracts:  
 
               ( )    {    (
(                           )
(                                 )
)}      
 
Where DPM extract, DPM background and DPM solvent blank represent the disintegrations 
per minute for extract, background and solvent blank, respectively. 
 
3.7. Results and discussions 
3.7.1. Anti-inflammatory activity 
 
A total of 68 extracts from 10 plants used for the treatment of tuberculosis and related 
symptoms in South Africa were screened for their ability to inhibit the COX-2 enzyme. 
Table 3.1 shows the results as percentage inhibition of prostaglandin synthesis by the extracts 
in the COX-2 assay. For inhibition of the enzyme by extracts, four different levels of activity 
were defined; inhibition below 20% was considered insignificant, between 20% to 40% low, 
between 40% to 70% moderate and between 70% and 100% as high (TUNÓN et al., 1995). 
The highest COX-2 inhibition was exhibited by PE extract from the roots of Pentanisia 
prunelloides (86.9%). In studies done by YFF et al. (2002) and LINDSEY et al. (1999), the 
EtOH, ethyl acetate and water extracts of Pentanisia prunelloides (leaves and roots) 
demonstrated high inhibition of COX enzyme. The roots of Pentanisia prunelloides are 
reported to be used to relieve chest pain and bacterial infection (YFF et al., 2002). The root 
EtOH extract of Pentanisia prunelloides exhibited remarkable antimicrobial activity against 
bacterial strains associated with respiratory ailments (Chapter 2, Table 2.3), and in the 
present study PE extracts of the same plant part demonstrated high COX-2 inhibition, thus, 
these findings supports the use of this plant in South African TM for treatment of 




The DCM extracts of Abrus precatorius subsp. africanus (leaves) and Ficus sur (bark) 
exhibited high COX-2 inhibition with percentages of 77.9 and 73.9, respectively. In previous 
research by KUO et al. (1995) on potent antiplatelet, anti-inflammatory and antiallergic 
properties of isoflavanquinones from the roots of Abrus precatorius subsp. africanus, 
abruquinones A, B, D and F exhibited remarkable anti-inflammatory effects. Therefore, the 
noteworthy anti-inflammatory activity exhibited by the extract from Abrus precatorius subsp. 
africanus in the present study could be from these abruquinones. 
 
Both the roots and bark of Ficus sur are used by the Zulu people of South Africa for 
traditionally treating pulmonary tuberculosis. These plant parts showed high COX-1 
inhibitory activity in a study by ELDEEN et al. (2005b) and low COX-2 inhibition. In this 
study a different solvent (DCM) from the ones used by ELDEEN et al. (2005b) (ethyl 
acetate, EtOH and water) showed the bark of Ficus sur to have high COX-2 inhibition.  
 
Out of a total of 68 extracts tested, only three exhibited high COX-2 inhibition, 14 moderate, 
20 low and the remaining 31 showed insignificant inhibition. Of 17 DCM extracts tested, two 
exhibited high COX-2 inhibition, five showed moderate and the rest showed low to 
insignificant activity. For PE extracts, only one showed high COX-2 inhibition, four showed 
moderate and the rest had low to insignificant activity. For EtOH extracts only Abrus 
precatorius subsp. africanus (leaves), Asparagus africanus (leaves), Ficus sur (roots), and 
Leonotis intermedia showed moderate COX-2 activity with percentage inhibition ranging 
from 41.4 to 50.6. The other EtOH extracts exhibited low to insignificant activity. The 
majority of the water extracts showed insignificant to low COX-2 inhibition with the 
exception of that of Asparagus africanus that showed moderate activity (56.6%). In the case 
of water extracts showing weak or no activity in these assays, it is worth mentioning that high 
dosages are frequently used in TM (McGAW et al., 1997). According to JÄGER et al. 
(1996), a species with an anti-inflammatory compound has a potential to be developed into an 
anti-inflammation product. Cyclooxygenase-2 inhibition is beneficial in clinical conditions as 
it provides therapeutic effects and its high activity is desirable (BLOBAUM and 
MARNETT, 2007). However, COX-2 inhibitors are currently regarded as dangerous, as their 
prolonged use may cause side effects in humans (BLOBAUM and MARNETT, 2007). 
 
All plant species that were evaluated in this study for inhibition of COX- 2 are frequently 
used for the treatment of tuberculosis and related symptoms. The inhibition of the tested 
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COX enzyme shown by some of the evaluated plants supports their use in South African TM 
for the treatment of pain-related ailments. Additionally, anti-inflammatory property observed 
by some of the investigated plant extracts in this study indicates the presence of bioactive 
agents that warrant further investigation. The extracts that exhibited weak or no activity 
might be active when concentrations higher than those evaluated are used. Since lipophilic 
compounds are more extractable by non-polar solvents and have far better resorption through 
the cell membrane, activity exhibited by polar solvents specifically at low concentrations is 
noteworthy (ZSCHOCKE and VAN STADEN, 2000). The high COX-2 inhibitory activity 
exhibited by the DCM leaf extracts of Abrus precatorius subsp. africanus is important for 
medicinal plant species conservation, as the leaves can be sustainable harvested while using 
the plants for medicine without threat to their survival. When treating inflammation, targeting 
the desired area is not easy as the process has many mediators and pathways that can lead to 
many pathological changes. The results obtained in this study are depended strongly on the 
test system used, therefore additional systems are needed to evaluate anti-inflammatory 
activity. Anti-inflammatory drugs with low COX-1 and high COX-2 inhibition properties are 
required. Therefore, it would be ideal to evaluate further the DCM extract of Abrus 
precatorius subsp. africanus (leaves) and Ficus sur (bark) as well as the PE extract of 
Pentanisia prunelloides (roots) for their COX-1, LOX inhibition, and to check if these plants 
inhibit these other enzymes, because high inhibition of both enzymes (COX-1 and COX-2) is 





Table 3.1: Anti-inflammatory activity (COX-2) of extracts from plants that are used for the 
treatment of tuberculosis and related symptoms in South Africa 
Plant species Plant part 
used 
Percentage inhibition of cyclooxygenase-2 
  PE DCM EtOH Water 
Abrus precatorius subsp. africanus Leaves 11.9±0 77.9±0 42.3±0 0±0 
Abrus precatorius subsp. africanus Seeds 39.0±0 26.7±1.6 8.8±0 11.8±0 
Asparagus africanus  Leaves 9.3±0 29.6±0 50.6±0 56.6±0 
Asparagus falcatus  Leaves 9.2±0 34.0±0 35.2±0 32.2±0 
Brunsvigia grandiflora  Bulbs 23.4±0 42.5±0 0±0 12.7±0.03 
Ficus sur  Bark 12.4±0 73.9±0 9.9±0 0±0 
Ficus sur Roots 44.9±0.5 55.0±0 56.3±0 0±0 
Indigofera arrecta  Leaves 24.7±2.6 28.9±1.6 0.8±0 0±0 
Indigofera arrecta Roots 52.2±0 29.3±0 0±0 12.2±0 
Leonotis intermedia Leaves 36.9±0 13.4±0 41.4±0 0±0 
Leonotis intermedia Stems 0.0±0 6.3±0.8 34.6±0 22.6±0 
Pentanisia prunelloides Leaves 2.5±0 48.4±0 16.5±0 39.4±0 
Pentanisia prunelloides Roots 86.9±0 9.1±0.7 26.2±0 0±0 
Polygala fruticosa  Whole plant 54.7±0 20.1±0 31.2±0 0±0 
Terminalia phanerophlebia  Leaves 29.0±1.1 41.9±0 0±0 0±0 
Terminalia phanerophlebia Roots 23.9±0 58.0 ±0 0±0 0±0 
Terminalia phanerophlebia Twigs 67.8±0.05 17.9±0 4.4±0 21.1±0 
Indomethacin - 79.2 - - - 











The highest inhibition of COX-2 enzyme in this study was shown by the PE extracts of 
Pentanisia prunelloides (roots) at 86.9%. The DCM extracts of Ficus sur (bark) and Abrus 
precatorius subps. africanus (leaves) exhibited high inhibition of COX-2 at inhibition 
percentages of 73.9 and 77.9 respectively. In terms of medicinal plant species conservation, the 
high COX-2 inhibition shown by the DCM leaf extracts of Abrus precatorius subsp. africanus 
was noteworthy as the leaves can be sustainably harvested while using the plants for medicine 
without threatening the survival of the plant. Anti-inflammatory activity observed for some of 
the investigated plant extracts in this study indicate the presence of bioactive agents that warrant 
further investigation. However, before biologically active compounds can be isolated from the 
plants that showed high inhibition of COX-2 in this study, it would be ideal to test the plant 
extracts for their COX-1 and LOX inhibition. Therefore, more studies (COX-1 and LOX) aimed 
at evaluating further the in vitro anti-inflammatory property of these plants is required.
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Chapter 4: Genotoxicity and cytotoxicity evaluation of biologically 
active extracts from plants used traditionally for treating 




Medicinal plants have been used since antiquity in the traditional treatment of various diseases 
and ailments (VERSCHAEVE et al., 2004). They are still used by a large proportion of the 
population in developing countries. Although medicinal plants have been used in therapy for 
many years, that does not mean that they are safe, as they may be hazardous in the long term. 
They are consumed with little or no proof or knowledge on their safety (CÂNDIDO-BACANI 
et al., 2013). Generally, plants are sessile autotrophs with the ability to adapt to challenges such 
as herbivores and pathogens (WINK and VAN WYK, 2008). They defend themselves against 
these challenges by producing a range of toxic substances that are released in response to 
specific environmental stimuli which in nature act as defence mechanisms against pathogenic 
infections, insects and herbivores. However, they can also be harmful to human beings, and thus 
medicinal plants should be used with caution (CUZZOLIN et al., 2006). 
 
Toxicity occurs when a substance exerts adverse effects on an organism and its metabolism 
(WINK and VAN WYK, 2008). Neurotoxins affect the nervous system and are the most 
poisonous substances, followed by cytotoxins and metabolic poisons that affect the liver, heart, 
kidneys, respiratory system, muscles and reproduction (WINK and VAN WYK, 2008). 
Neurotoxins affect important ion channels of neuronal cells either by permanently activating or 
deactivating them, and cytotoxins interfere with important cellular functions (WINK and VAN 
WYK, 2008). 
 
Paracelsus, “the father of toxicology”, wrote that “the dose makes the poison”, explaining that 
dose differentiates a poison from a remedy. In other words, an ordinarily harmless substance can 
be poisonous if consumed in large amounts and, conversely, substances considered toxic may be 
harmless in small doses (HAYES, 2008). A Greek pharmacist and physician, Galen, 
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demonstrated that plants do not only contain beneficial medicinal constituents, but they also have 
toxic substances (IFEOMA and OLUWAKANYINSOLA, 2013). Several studies have led to 
the validation of some traditional remedies. However, research has demonstrated that natural 
products are potentially toxic, carcinogenic and teratogenic in both in vitro and in vivo assays, 
thus they should be used cautiously (ELGORASHI et al., 2003; VERSCHAEVE et al., 2004; 
SANTIN et al., 2011). Concerns have been raised about the toxicity and side effects of 
medicinal plants in long term use. The WHO continues to encourage the use of medicinal plants 
in developing countries to supplement their healthcare program provided that they are proven to 
be non-toxic (HONG and LYU, 2011). The potential toxicity effects of some of the more 
popularly used herbal remedies are a cause for concern. It is thus necessary to assess the 
mutagenicity and cytotoxicity of traditional medicinal plants to ensure their relative safety as it 




Mutagenesis is defined as a process by which the amount or structure of genetic material of an 
organism or cell is changed in a stable, heritable manner, either in nature by the use of chemicals 
or radiation (MORTELMANS and ZEIGER, 2000; ABDELMIGID, 2013). The genome can 
be damaged either spontaneously or from exposure to genotoxic agents. Mutagens are chemicals 
responsible for induction of mutations. These changes may include a single gene, blocks of 
genes, or whole chromosomes. Clastogenicity refers to effects of agents that result in structural 
chromosome abnormalities (chromosome rearrangement or loss); and aneugenicity refers to the 
effects of agents that give rise to a change (gain or loss) in chromosome number in cells 
(ABDELMIGID, 2013).  
 
4.3. Negative effect of mutagenicity in human beings 
 
Chemicals that are capable of inducing mutations even at low exposure levels can potentially 
damage germ lines resulting in negative effects to human health. Somatic mutations occurring in 
proto-oncogenes, tumor suppressor genes and/or DNA response genes, have been reported to 
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result in cancer and various other genetic diseases (ABDELMIGID, 2013). DNA damage 
accumulation in somatic cells has been reported to play a role in accelerated aging, immune 
dysfunction, cardiovascular, and neurodegenerative diseases. Germ cell mutations can result in 
spontaneous abortions, infertility or heritable damage to offspring and possibly to subsequent 
generations (MORTELMANS and ZEIGER, 2000). Due to the adverse effects that genetic 
damage can have to human health, such as the cancer causing capability of mutagens, the 
evaluation of substances that can alter genetic potential of human beings has become an 
important procedure in safety assessment.  
 
4.4. Genotoxicity and cytotoxicity 
 
Generally, genotoxicity is defined as “the harmful action on the genetic material of a cell 
affecting its integrity”. In a broader sense, similar to mutagenicity, genotoxicity is the ability of 
compounds to interact with DNA or cellular apparatus such as spindle apparatus and 
topoisomerase enzymes which control the genome (SRIVIDYA, 2012). Substances that 
specifically cause genetic mutations in a cell are called genotoxins or genotoxic agents, and they 
are potentially carcinogenic or mutagenic. Many genotoxic events do not become evident as 
mutations, because cells have the capacity to protect themselves from potential mutagenic effects 
(SRIVIDYA, 2012). However, the ability to damage the genome is an indicator of potential 
mutagenicity. Therefore, some techniques used for genotoxicity testing may not provide direct 
evidence of heritable mutation.  
 
Cytotoxicity is defined as the negative effects that occur as a result of interferences with 
structures and processes that are vital for survival, proliferation and/or function of cells 
(RAZAK et al., 2007). These negative effects may include loss of membrane integrity, cellular 
metabolism, synthesis and degradation or release of cellular constituents, ion regulation as well 
as cell division (RAZAK et al., 2007). 
 
For any toxicological assay on medicinal plants, the main aim is to identify negative effects and 
determine the limit of exposure at which such effects can occur as well as to detect toxic plant 
extracts in early and late stages of drug discovery and development (SRIVIDYA, 2012). There 
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are many bioassays that are available for determining the genotoxicity and cytotoxicity of 
medicinal plants (RATHNASAMY et al., 2013). 
 
4.4.1. Genotoxicity testing methods 
 
Genotoxicity evaluation can be defined as in vitro or in vivo tests that are done to identify 
potential genotoxic carcinogens and germ cell mutagens (KIM et al., 2013). When doing 
genotoxicity tests, whether in vitro or in vivo, it is important to generate information on gene 
mutation, and changes to chromosomal structures and numbers, to provide comprehensive 
coverage of the mutagenic potential of a chemical (JENA et al., 2002; KIM et al., 2013). The 
main aim of genotoxicity testing is to exclude or identify potential mutagenic hazards to humans. 
In view of the fact that somatic mutational events in humans are caused by the use of plants 
whose toxicological characteristics are unknown, different techniques have been developed to 
investigate genotoxicity and antigenotoxicity (VERSCHAEVE and VAN STADEN, 2008). 
The genotoxicity test batteries that are recommended by regulatory agencies to detect genotoxic 
carcinogens both in vitro and in vivo include bacterial, yeast and mammalian studies (JENA et 
al., 2002). The Bacillus subtilis Rec-assay and the reversion assay in Salmonella typhimurium 
are the two main systems used in bacteria. The Bacillus subtilis Rec-assay was specifically 
designed to assess genotoxicity of environmental mutagens, and positive results usually indicate 
a covalent binding to DNA or a chemical breakage of DNA (TAKIGAMI et al., 2002). On the 
other hand, positive results in the Salmonella typhimurium reversion assay often parallel the 
carcinogenic potential of compounds and detect frame-shift mutations as well as base-pair 
substitutions (MARON and AMES, 1983). Numerous genotoxicity tests in yeasts have been 
developed to detect gene mutations in eukaryotes. Comparable to bacteria, some of them are 
based on reverse mutations in genetically modified yeast strains (GENG et al., 2012). However, 
others monitor the activation of DNA damage-induced over-expression of reporter genes 
including green fluorescent protein, enhanced green fluorescent protein and luciferase. The 
mammalian cell-based genotoxicity tests are often designed to detect DNA damage, gene 
mutation or cellular DNA damage responses (GENG et al., 2012). Several available mammalian 
cell-based assays are available, and they include cell lines of Chinese hamster V97 and CHO 
cells, human lymphoblastoid TK6 and mouse lymphoma L5178Y cells. Only three genetic loci 
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are validated and used widely, and these are hypoxanthine-guanine phosphoribosyltransferase, 
thymidine kinase and the cell membrane Na+/K+ ATPase gene. However, the problem is low 
sensitivity in these mammalian cell-based gene mutation assays (GENG et al., 2012). 
 
The Ames test (microsome assay) is a short-term bacterial assay that is commonly used to detect 
genotoxic carcinogens which cause gene mutation, such as base pair substitutions and small 
frame-shifts (MORTELMANS and ZEIGER, 2000; KIM et al., 2013). The test is one of the 
two assays that are recommended by the United Kingdom Expert Advisory Committee on 
mutagenicity to be appropriate as an initial screen to evaluate the genotoxicity of new chemicals 
and drugs (JENA et al., 2002). The test uses several Salmonella typhimurium strains, such as 
TA97, TA98, TA100, TA102, TA104, TA1535 and TA1537 (MORTELMANS and ZEIGER, 
2000). Each strain is genetically different, so using several strains in a test increases the 
likelihood of detecting a mutagenic chemical. Bacterial strains used in the Ames test carry a 
faulty (mutant) gene that prevents the bacteria from synthesising histidine that is needed for 
growth of colonies in the standard bacterial culture medium (MORTELMANS and ZEIGER, 
2000). Thus, the bacterial tester strains can only survive and grow on excess histidine-containing 
medium. The gene’s function can be restored when new alterations occur at the site of 
preexisting ones and allow cells to synthesise histidine. The new mutated cells can grow and 
form colonies in the absence of histidine (MORTELMANS and ZEIGER, 2000; 
ABDELMIGID, 2013). Therefore, the assay uses this principle to evaluate if the extracts or 
drugs can revert the mutations to restore the normal colony formation in the medium. 
 
4.4.2. Cytotoxicity testing methods 
 
With regard to in vitro cell culture systems, when a substance interferes with the attachment of 
cells, it alters the morphology and the rate of cell growth, or causes them to die, it is then 
considered to be cytotoxic (McGAW et al., 2014). Cytotoxicity testing allows identification and 
prioritisation of plant extracts useful for further biological evaluation. A lot of attention has been 
devoted to cytotoxicity studies as a first research step in toxicity evaluation of plant extracts and 
active compounds isolated from plants. Minimal to no toxicity is essential for bioactive purified 
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compounds or plant extracts identified for pharmaceutical use, however, high toxicity intended 
for cancerous cells is essential.  
 
Cytotoxicity can be measured in various ways, including evaluation of net change in population 
size, cell mass or metabolic activity (FOTAKIS and TIMBRELL, 2006). In general, the 
criteria for measuring viability of cell cultures can be divided in terms of the used indicator and 
evaluation method. The most commonly used assays for measuring cytotoxicity or cell viability 
following exposure to toxic substances are lactate dehydrogenase (LDH) leakage, protein 
quantification, neutral red and mitochondrial reduction (MTT) assays (MOSMANN, 1983; 
FOTAKIS and TIMBRELL, 2006). The LDH leakage assay measures LDH activity in the 
extracellular medium. This assay has been used as a cytotoxicity indicator in HepG2  cells after 
exposing them to cadmium chloride, and in toxicity studies using rat renal proximal tubular cells 
(FOTAKIS and TIMBRELL, 2006). The characteristics of the LDH leakage assay are 
reliability and speed. 
 
The neutral red assay is used to provide a quantitative measure of viable cells in cultures 
(FOTAKIS and TIMBRELL, 2006). This assay is based on the ability of living cells to take up 
neutral red and incorporate it within the lysosomes. Primary cells and cell lines from diverse 
origins are used in this assay. It is one of the most used cytotoxicity tests with many biomedical 
and environmental applications. 
 
The protein assay measures cytotoxicity indirectly by measuring protein content of viable cells 
following the exposure of exponentially growing cultures of cells to test materials (compound or 
crude extract) (FOTAKIS and TIMBRELL, 2006). 
 
The MTT assay is a rapid colorimetric test that was designed to measure only living cells 
(MOSMANN, 1983). The assay is based on the ability of mitochondrial succinate 
dehydrogenase enzymes of metabolically active cells to reduce [3-(4,5-dimethylthiazol-2-yl)-2-
5diphenyltetrazolium bromide] or MTT to a water insoluble purple formazan (MOSMANN, 
1983). Many salts are used to detect viability of cells, however, MTT is the most commonly used 
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salt. The MTT is a water soluble tetrazolium salt that is converted to formazan by cleavage of the 
tetrazolium ring by succinate dehydrogenase within the mitochondria (FOTAKIS and 
TIMBRELL, 2006). Formazan accumulates in healthy cells, and is impermeable to cell 
membranes. The results for this assay can be read on a multiwell spectrophotometer (ELISA 
reader). The MTT tetrazolium reduction assay is the first homogenous cell viability test that was 
developed for a 96 well microplate and is suitable for high throughput cytotoxicity screening 
(MOSMANN, 1983). This assay is versatile and quantitative, and is thus a “gold” standard to 
which new viability or cytotoxicity assays are compared. It requires incubation of a reagent 
(plant extract/ or compound) with a population of viable cells to convert a substrate to a colored 
product that can be detected with a microplate reader. The MTT substrate is prepared in 
physiologically balanced solution and incubated for 1 to 4 h. Only viable cells can reduce MTT, 
so the quantity of formazan reduced is directly proportional to the intensity of color and cell 
viability. As evidenced from various published articles, this assay is widely used and is popular 
in academic laboratories for cytotoxicity evaluation of plant extracts or compounds (McGAW et 
al., 2007; MUKANDIWA et al., 2012; ADEROGBA et al., 2014; MAKHAFOLA et al., 
2014).  
 
Traditional medicinal plant use and prescription in South Africa is not regulated, and this poses a 
danger of misadministration, especially if plants are toxic (FENNELL et al., 2004). In Chapter 
2, several plant extracts were reported to exhibit good antibacterial activities with MIC values 
ranging from 0.098-0.78 mg/ml against  any of the two Mycobacterium species (Mycobacterium 
aurum A+ and Mycobacterium tuberculosis) or bacterial strains associated with respiratory 
infections (Staphylococcus aureus and Klebsiella pneumoniae) tested. Based on those findings, 
further genotoxicity and cytotoxicity investigations were carried out on the antimicrobial extracts 
with MIC values ranging from 0.098-0.78 mg/ml. These tests are necessary to determine whether 
the antimicrobial as well as other biological activities of medicinal plants are due to their toxicity 
or not. Plants showing clear toxicity should be considered as potentially unsafe and must be 
tested further before their continued use can be recommended. Those with clear non-toxicity 
potential together with antimicrobial activity should be considered noteworthy for therapeutic 
use and should also be investigated further for their pharmacological properties 




4.5. Materials and methods 
4.5.1. Preparation of plant extracts for genotoxicity testing 
 
Plant materials were extracted as described in Section 2.5.2. To prepare the aliquots, biologically 
active extracts were dissolved in 10% DMSO to make a concentration of 5000 μg/ml and filter 
sterilised through 0.22 μm filters. After filter sterilisation, the 5000 μg/ml concentration of the 
sample extracts was diluted with sterile 10% DMSO to obtain lower concentrations of 500 and 
50 μg/ml. 
 
 4.5.2. In vitro genotoxicity evaluation of biologically active extracts using the 
Ames test 
 
The genotoxicity evaluation of biologically active plant extracts was done in histidine deficient 
growth medium using the Salmonella microsome assay. The Salmonella microsome assay was 
used to test mutagenicity based on the plate-incorporation procedure. The Ames test was 
performed by incorporating test extracts with Salmonella typhimurium tester strains TA98 and 
TA100 without metabolic activation. The procedure was done according to MARON and 
AMES (1983) modified by MORTELMANS and ZEIGER (2000). Bacterial stocks (100 µl) 
were incubated in 20 ml of Oxoid No.2 nutrient broth at 37 ºC on a rotary shaker for 16 h. The 
cultured bacteria (100 µl) were added to 100 µl of plant extract with 500 µl of phosphate buffer 
and 2 ml of top agar containing biotin-histidine (0.5mM). The mixture was mixed by vortexing, 
then gently poured over the surface of a minimal agar plate and incubated at 37 ºC for 48 h. The 
positive control used was 4-nitroquinoline-1-oxide (4-NQO) at a concentration of 2 µg/ml 
whereas sterile distilled water was the negative control. All the samples were tested in triplicate. 
The number of bacterial colonies was counted using a colony counter after 48 h of incubation 
and the results were expressed as the mean (±standard error) number of the revertant colonies per 
plate. The absence of toxicity was examined by observing background bacterial growth, which 




4.5.3. In vitro cytotoxicity testing of biologically active extracts using the MTT 
assay  
 
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay according to 
MOSMANN (1983) was used to evaluate viability of cells after their exposure to the test 
substances. The biologically active extracts in Chapter 2 were tested for cytotoxicity against the 
Vero (African green monkey kidney) cell line obtained from the Department of Veterinary 
Tropical Diseases, University of Pretoria.  
 
The Vero cells were cultured in sterile Minimal Essential Medium (MEM, Sigma) supplemented 
with 0.1% gentamicin (Virbac) and 5% foetal calf serum (FCS, Sigma) in a 75 cm2 flask 
incubated at 37 °C in 5% CO2. After one week of incubation, the medium was decanted, and the 
cells adhering to the bottom of the flask were washed twice with 20 ml of phosphate buffered 
saline (PBS, Sigma). Following the washing step, trypsin (3 ml) was added to the cells which 
were then incubated at 37 °C for up to 20 min to allow detachment of cells from the flask. When 
the cells had detached from the flask, MEM containing FCS was added to stop the enzymatic 
action of the trypsin. The cells were poured into centrifuge tubes and centrifuged for 2 min at 
200 x g. A Neubauer haemocytometer was used to count the number of cells per ml. Trypan blue 
was added to determine the number of viable cells as viable cells extrude the trypan blue and 
appear clear while dead cells are blue. The cells were resuspended to a concentration of 1 x 105 
cells/ml and 100 µl were added to each well of columns 2 to 11 of 96-well microtitre plates at a 
final concentration of 10 000 cells per well. Minimal Essential Medium (200 µl) was added to 
wells of columns 1 and 12 to maintain humidity. The microplates were incubated overnight at 37 
°C in a 5% CO2 incubator until the cells were in the exponential phase of growth, to allow cell 
attachment to the bottom of the microplates. The attached cells in 96 well microplates were used 
for the cytotoxicity assay.  
 
The bioactive plant extracts were resuspended in ethanol/DMSO to a concentration of 100 mg/ml 
and filter sterilised before being diluted in fresh MEM to the required concentrations. The 
concentrations tested ranged from 0.0075 to 1 mg/ml. The plant extract dilutions (100 µl) were 
pipetted into wells of the microplates in quadruplicate. Doxorubicin hydrochloride (Sigma) was 
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used as a positive control and solvent controls were also included. The microplates were 
incubated at 37 °C in a 5% CO2 incubator for 48 h. Following incubation with test extracts, the 
cells were examined using an inverted microscope to detect cytopathic effects (CPE). Minimal 
Essential Medium containing plant extracts was removed and each well was rinsed with PBS 
immediately, and fresh MEM (200 µl) without test substance was added to the wells. A 
concentration of 5 mg/ml of MTT in PBS was prepared, and 30 μl of the solution were then 
added to each well, and the plates were incubated for a further 4 h at 37 °C in 5% CO2 incubator. 
The medium was removed from the wells after 4 h incubation and 50 μl of DMSO were added to 
each well to dissolve the formazan crystals. The plates were gently shaken until the solution was 
dissolved prior to reading. The amount of MTT reduction was evaluated by measuring the 
absorbance at a wavelength of 570 nm (reference wavelength of 630 nm) in a microplate reader. 
The wells without cells which contained only the medium were used to blank the plate reader. 
The results were interpreted as a percentage of the control wells and the LC50 (lethal 
concentration 50) values were calculated. The selectivity index values for each extract were 
calculated using the following formula: 
 
Selectivity index = 




          (     )
 
 
Where LC50 stands for the concentration of a given agent (plant extract) which is lethal to 50% of 
the cells, and MIC stands for minimum inhibitory concentration. 
 
4.6. Results and discussion 
4.6.1. Genotoxicity  
 
Considering the antimicrobial results (ranging from 0.098-0.78 mg/ml) obtained in Chapter 2, 
the activity may be due to the presence of biologically active or toxic compounds. Therefore, 
genotoxicity testing was done. The results of the genotoxicity assay on plant extracts with MIC 
values less than 1.0 mg/ml are presented in Table 4.1. The Ames test without metabolic 
activation is designed only for direct mutagen detection. To designate a substance as a mutagen, 
a positive response in any single bacterial strain either with or without metabolic activation is 
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sufficient (ZEIGER, 2001). TA98 and TA100 bacterial strains are often used as they detect the 
great majority of mutagens (VERSCHAEVE and VAN STADEN, 2008). Positive results from 
Salmonella typhimurium strain TA98 detects frame-shift mutations based on spontaneous 
reversion of the Salmonella typhimurium from His- to His+ caused by crude plant extracts. 
Positive results caused by TA100 indicate base-pair substitution. The evaluated extracts must 
exhibit a dose-dependent increase in the number of revertants in order to be considered as 
genotoxic. Furthermore, the number of revertant colonies of the extracts must be equal to or 
greater than two times that of the negative control (MARON and AMES, 1983). However, in 
our study none of the tested extracts demonstrated a dose-dependent increase nor revertant 
colonies that were equal to or greater in number than twice those of the negative control. 
Therefore, the tested plant extracts lacked direct genotoxic compounds. In all cases, the values of 
the negative as well as the positive control were within normal limits and in accordance with 
literature (ELGORASHI et al., 2003).  
 
The lack of genotoxicity observed with the Ficus sur root EtOH extract against Salmonella 
typhimurium TA98 in our study is in accordance with that reported by ELDEEN et al. (2005b). 
The leaf methanol extract of Abrus precatorius subp. africanus was reported to be non-
mutagenic against Salmonella TA677 in a study by MARTINEZ et al. (2012). For more in 
depth investigations, subsequent tests should be conducted with other strains such as TA97, 
TA102, TA104, TA1535 and TA1537 (MORTELMANS and ZEIGER, 2000). 
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Table 4.1: Number of revertant colonies of Salmonella typhimurium strains TA98 and TA100 induced by extracts of some plants used as remedies 
for the treatment of tuberculosis and related symptoms in South Africa 
Plant species (part used) Bioactive extract Bacterial strains 
  TA98 TA100 
  Extract concentration in µg/ml 
  5000 500 50 5000 500 50 
Abrus precatorius subp. africanus (L)  Dichloromethane 24.33±0.33 25.00±0.58 19.33±2.33 444.00±5.51 439.33±1.76 438.67±1.76 
Abrus precatorius subp. africanus (L) Ethanol 26.33±0.88 22.67±0.33 19.00±2.08 469.67±4.33 457.00±20.21 427.67±19.23 
Abrus precatorius subp. africanus (S) Ethanol 28.33±3.33 20.33±2.40 19.00±0.58 446.67±19.47 440.00±16.37 432.67±18.99 
Asparagus africanus (L) Ethanol 26.67±0.89 27.67±1.45 19.33±0.33 462.67±6.67 467.67±6.23 474.00±4.16 
Asparagus falcatus (L) Ethanol 20.33±2.60 20.33±0.33 20.33±2.33 430.33±9.60 465.00±9.61 477.00±5.20 
Ficus sur (R) Ethanol 22.00±1.00 22.67±0.88 20.67±0.67 427.33±2.91 427.67±1.45 426.00±2.00 
Indigofera arrecta (L)  Ethanol 21.00±2.31 22.33±1.33 20.67±0.89 499.00±41.00 484.00±2.31 498.67±19.54 
Indigofera arrecta (L) Water 21.67±1.20 21.67±0.33 21.67±1.76 431.00±2.52 431.67±0.89 433.67±1.86 
Leonotis intermedia (L) Ethanol 26.00±1.15 26.67±2.33 26.00±1.53 437.67±2.84 429.67±1.20 428.33±0.88 
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Plant species (part used) Bioactive extract Bacterial strains 
  TA98 TA100 
  Extract concentration in µg/ml 
  5000 500 50 5000 500 50 
Pentanisia prunelloides (L) Ethanol 20.33±1.76 22.00±1.15 22.33±1.45 406.33±33.14 452.00±15.28 458.00±21.07 
Pentanisia prunelloides (L) Water 20.15±2.52 23.67±2.72 21.58±1.60 477.63±1.58 469.21±1.57 468.28±1.32 
Pentanisia prunelloides (R) Ethanol 26.67±1.26 24.33±1.38 24.00±1.67 432.57±1.15 435.30±1.19 433.21±1.7 
Terminalia phanerophlebia (L) Ethanol 28.00±0.57 27.00±0.58 25.67±0.33 439.67±0.67 430.00±4.58 425.00±2.52 
Terminalia phanerophlebia (L Water 25.67±2.72 26.67±1.20 25.67±0.67 467.33±14.88 472.00±7.81 461.67±5.17 
Terminalia phanerophlebia (R) Ethanol 23.00±1.15 22.67±0.67 22.33±2.73 421.33±26.69 440.67±13.38 481.00±9.84 
Terminalia phanerophlebia (R) Water 22.15±1.52 20.12±1.19 21.15±0.67 456.87±2.15 460.30±0.67 444.63±1.67 
Terminalia phanerophlebia (T) Ethanol 28.67±0.89 25.00±0.58 29.67±1.86 468.67±30.14 409.33±4.58 422.00±13.32 
Terminalia phanerophlebia (T) Water 23.67±0.89 23.33±2.19 23.67±1.89 437.67±1.60 452.00±1.05 440.67±1.20 
Water  21.00±1.05 - - 427.00±0.86 - - 
4NQO  133.00±1.21 - - 789.33±1.45 - - 




4.6.2. Cytotoxicity  
 
Cytotoxicity results of 18 biologically active crude extracts (in Chapter 2) from eight plant 
species are presented in Table 4.2. The selectivity index is the ratio of cytotoxicity to biological 
activity. When a plant extract has a selectivity index value greater than one, it is more active 
against the target bacterial strain and less toxic to the mammalian cells used in the cytotoxicity 
assay. When its selectivity index value is less than one, it is more toxic and less active. In our 
study the selectivity index values for the tested extracts ranged between 0.04 to 16.43. The leaf 
water extract of Terminalia phanerophlebia showed the highest selectivity index value of 16.43, 
which was noteworthy as the extracts from this plant part showed good antimicrobial activity. 
For Terminalia phanerophlebia, it was disturbing that the EtOH and water extracts of each plant 
part differed to a large extent in their toxicity. However, the leaf EtOH extracts of Terminalia 
phanerophlebia were reported to have selective toxicity when tested against human kidney 
epithelial cells in a study done by SIBANDZE (2009). The results indicate that even if both 
extractants are highly polar, it does not necessarily mean that the EtOH extracts would be as safe 
as water extracts that are used traditionally. 
  
For Pentanisia prunelloides leaf and root extracts, the selectivity index values were greater than 
one for all the bioactive extracts tested, ranging from 1.05 to 3.38. This means that the extracts 
showed more activity against the bacterial strains and less toxicity to the mammalian cells. The 
crude extract of Pentanisia prunelloides roots was reported to have more potency and less 
toxicity when studied using brine shrimp lethality tests (MPOFU, 2013).  
 
The EtOH extracts of Abrus precatorius subsp. africanus (leaves) and Asparagus africanus 
(leaves) demonstrated lower toxicity and more antimicrobial activity with a selectivity index 
values ranging from 1.05 to 4.97. The leaves of Abrus precatorius subsp. africanus were 
reported to have caused spastic paralysis and death of chickens within 24 h; therefore this plant 
should be administered with caution (MARTINEZ et al., 2012). 
 
The seed EtOH extracts of Abrus precatorius subsp. africanus demonstrated greatest toxicity out 
of all the extracts tested with a selectivity index value of 0.04. This is not surprising as 
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MARTINEZ et al. (2012) reported poisonous effects of extracts from the seeds of Abrus 
precatorius subsp. africanus in an in vivo study. A total of 20 crushed seeds of Abrus precatorius 
subsp. africanus mixed with water and taken orally by adult males were reported to have caused 
vomiting of blood, pain in the eyes and burning of ears (ROSS, 2003). Seeds of Abrus 
precatorius subsp. africanus were reported to be poisonous due to the presence of abrin, a toxic 
protein, and an alkaloid hypaphorine (SINGH et al., 1998). Bruquinone G previously isolated 
from the aerial parts of Abrus precatorius subsp. africanus were reported to have demonstrated 
mild toxicity (LIMMATVAPIRAT et al., 2004). Therefore caution must be taken when using 
this plant species.  
 
This study demonstrated a lack of safety for Abrus precatorius subsp. africanus (seed EtOH and 
leaf DCM extracts), Asparagus falcatus, and Indigofera arrecta (leaf EtOH extract) with 
selectivity index values lower than one, ranging from 0.04 to 0.95. Leonotis intermedia (leaves) 
and Ficus sur (roots) EtOH extracts showed some toxicity with selectivity index values of 0.33 
and 0.96 respectively. Therefore caution should be exercised when using these plants for 
medicinal purposes. However, in an in vivo study by NYARKO et al. (1999) the leaf extracts of 
Indigofera arrecta were reported to be devoid of acute and subchronic toxicity. Ficus sur was 
also reported to be devoid of cytotoxicity against brine shrimp (MOSHI et al., 2007). Therefore, 
more toxicity studies are required to evaluate the safety of these plants. 
 
Some of the plant extracts tested demonstrated selectivity index values lower than 1. However, it 
should be noted that in vitro toxicity does not always equate to in vivo toxicity because of the 
difference in microenvironment and pharmacodynamic interactions in live animals and tissue 
culture (FRESHNEY, 2000). Metabolism is one of the critical factors in toxicology as some 
substances demonstrating non-toxicity initially may produce toxic metabolites after being 
exposed to liver enzymes, while other substances that are toxic in vitro may become detoxified 
(McGAW et al., 2014). Generally, in in vitro toxicity evaluation, toxic responses are determined 
by measuring the changes in cell survival or metabolism, therefore models that are more closely 
related to tissue or systemic toxicity should be considered. It should be taken into consideration 
that in vivo toxicity might be due to a tissue response, probably caused by an inflammatory 
reaction. The low cytotoxicity observed against Vero cells for some of the biologically active 
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extracts tested in this study were noteworthy, and more tests are required to verify the lack of 




Table 4.2: Average LC50, and selectivity index values of bioactive plant extracts 







concentration values (mg/ml) 
Selectivity index values 
 Vero cells  K. p S. a M. a A+ M. tb 
H37R 
 
K. p S. a 
 
 




Abrus precatorius subsp. 
africanus (L) 
EtOH 0.97 ± 0.04 na na 0.195 na - - 4.97 - 
Abrus precatorius subsp. 
africanus (L) 
DCM 0.16 ± 0.01 na na 0.78 0.78 - - 0.21 0.21 
Abrus precatorius susbsp. 
africanus (S) 
EtOH 0.03 ± 0.00 na na 0.78 na - - 0.04 - 
Asparagus africanus (L) EtOH 0.46 ± 0.00 na na 0.39 na - - 1.18 - 
Asparagus falcatus (L) EtOH 0.28 ± 0.01 na na 0.39 na - - 0.72 - 
Ficus sur (R)  EtOH 0.75 ± 0.03 0.78 0.195 na 0.78 0.96 3.85 - 0.96 
Indigofera arrecta (L) EtOH 0.37 ± 0.03 0.78 0.39 0.39 na 0.47 0.95 0.95 - 
Indigofera arrecta (L) Water >1.00 ± 0.00 na na 0.78 na - - >1.28 - 












concentration values (mg/ml) 
Selectivity index values 








Pentanisia prunelloides (R)  EtOH 0.82 ± 0.18 0.39 0.78 0.78 0.78 2.10 1.05 1.05 1.05 
Pentanisia prunelloides (L)  Water >1 ± 0.00 na 0.39 na na - >2.56 - - 
Pentanisia prunelloides (L) EtOH 0.66 ± 0.06 na 0.195 0.39 na - 3.38 1.69 - 
Terminalia phanerophlebia (L) EtOH 0.08 ± 0.01 0.195 0.195 na 0.39  0.41 0.41 - 0.21 
Terminalia phanerophlebia (L) Water 1.61 ± 0.52 0.39 0.098 0.39 0.39 4.13 16.43 2.97 2.97 
Terminalia phanerophlebia (T) EtOH 0.25 ± 0.09 0.195 0.39 0.195 0.78  1.28 0.64 1.28 0.32 
Terminalia phanerophlebia (T) Water >1 ± 0.00 na na na 0.39 - - - >2.56 
Terminalia phanerophlebia (R) EtOH 0.17 ± 0.01 na 0.195 na 0.78 - 0.87 0.21 - 
Terminalia phanerophlebia (R) Water >1 ± 0.00 na 0.39 na - - >2.56 - - 
Doxorubicin   6.78 ± 0.39 - - - - - - - - 
L: leaves, R: roots, B: bark, S: seeds, T: twigs, DCM: dichloromethane, PE: petroleum ether, EtOH: ethanol, K. p: Klebsiella pneumoniae, 
S. a, Staphylococcus aureus, M. a A+, Mycobacterium aurum A+, M. tb H37Ra, Mycobacterium tuberculosis, na, extract not active (MIC 
value greater than 1 mg/ml) against a particular strain and  selectivity index value (-) not determined. Doxorubicin hydrochloride in µg/ml 
(positive control), Minimum inhibitory concentration values of extracts (mg/ml) from Chapter 2, LC50 = Lowest concentration of extract 
which is lethal to 50% of the cells.  
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The low toxicity (genotoxicity and cytotoxicity) and promising antimicrobial results 
demonstrated by Pentanisia prunelloides in this study endorse the traditional therapeutic use 
of this plant species in South Africa. It is evident that more tests are necessary for the 
investigation of the toxic effects of extracts from the plants tested in this study and their 




Non-genotoxic activity demonstrated by the evaluated plant extracts does not confirm that 
they are completely safe for consumption as their metabolites could be genotoxic. It confirms 
that the substance is not genotoxic to a particular bacterial strain against which it is tested, 
and for the genetic end point tested. Non-genotoxicity in the extracts of interest in this study 
is a positive step forward in determining their safe use in the treatment of tuberculosis and 
related symptoms. Lack of cytotoxic effects to Vero cells at the highest concentration tested 
of 1 mg/ml of some of the bioactive extracts was noteworthy. Abrus precatorius subsp. 
africanus, Asparagus falcatus, Leonotis intermedia, Ficus sur, Indigofera arrecta as well as 
Terminalia phanerophlebia should be administered with caution as some of their selectivity 
index values were lower than one in this study. However, more studies are required to verify 
lack of genotoxicity and more in depth cytotoxicity tests against other cell lines are needed 
prior to venturing into investigation of in vivo toxicity. 
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Chapter 5: Isolation and characterisation of antimicrobial 





An emergency “situation” was declared by the WHO in 2005, for urgent action to stop the 
worsening epidemic of tuberculosis in Africa (FYHRQUIST et al., 2014). According to the 
WHO estimations, between 1990 and 2005, in African countries the average incidence of 
tuberculosis had more than doubled (WHO, 2010). Tuberculosis epidemics are aggravated by 
the emergence of drug resistance and HIV coinfection. To counteract this problem, there is a 
need to find new and effective tuberculosis treatments that will fight challenges such as 
toxicity, drug-resistance, as well as coinfection and will reduce the duration of treatment to 
cure the disease. GUPTA et al. (2014) reported that, diverse compounds with potent 
antimicrobial activity were isolated from higher plants. Therefore, drugs that might act as an 
effective treatment of tuberculosis could be found in medicinal plants.  
 
The family Combretaceae is placed in the Myrtales and comprises of approximately 20 
genera and 600 species of trees, shrubs and lianas (ELOFF et al., 2008; DAWE et al., 
2013). Plant species belonging to the Combretaceae are widespread in tropical and 
subtropical regions of the world specifically in forests, grassland and mangroves, mostly in 
Africa and India (TILNEY, 2002; ELOFF et al., 2008; DAWE et al., 2013). Genera of the 
Combretaceae family includes: Anogeissus, Buchenavia, Bucida, Calopyxis, Calycopteris, 
Combertum, Conocarpus, Dansiea, Guiera, Languncularia, Lumnitzera, Macropteranthes, 
Melostemon, Pteleopsis, Quisqualis, Stace, Strephonema, Terminalia and Thiola. In southern 
Africa, the Combretaceae is represented by seven genera and these include Combretum, 
Lumnitzera, Meiostemon, Stace, Pteleopsis, Quisqualis and Terminalia (TILNEY, 2002). 
Combretum and Terminalia are the largest two genera in the Combretaceae. 
 
Several species in the Combretaceae family are used in many regions of the world to cure 
various diseases and ailments. Some of the uses include: treatment of tuberculosis, 
pneumonia, coughs, colds, fever, cancer, abdominal disorders, acute enteritis, dysentery, 
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diarrhoea, hook worm, constipation, gastric ulcers, bilharzia, venereal disease, eye diseases, 
heart diseases, urinary system cleansing, syphilis, beriberi, toothache, jaundice, leprosy, 
malaria, gingivitis and temporary insanity (TILNEY, 2002).  
 
The genus Terminalia consists of approximately hundred species that are distributed in the 
tropical regions of the world (KUETE et al., 2010b). Approximately 30 of the Terminalia 
species are distributed in Africa and 11 are from the southern region of the continent. The 
plants range from shrubs to big trees occurring in dry woodlands and rainforests 
(FYHRQUIST et al., 2014). The 11 southern African species include: Terminalia pruniodes 
M.A. Lawson, Terminalia randii Baker f., Terminalia stuhlmannii Engl., Terminalia 
brachymstemma Welw. ex Hiern, Terminalia sericea Burch. ex DC., Terminalia trichopoda 
Diels, Terminalia gazensis Baker f., Terminalia phanerophlebia Engl. & Diels, Terminalia 
molli Exell, Terminalia sambesiaca Engl. & Diels and Terminalia stenostachya Engl. & 
Diels (ELOFF et al., 2008). Species of Terminalia are widely used as medicinal plants both 
in Africa as well as in Asia and several are reported to exhibit biological activities 
(MASOKO and ELOFF, 2005). Several studies on the pharmacological activities of 
Terminalia have proven the plant species from this genus to contain antimicrobial, antiviral, 
anti-inflammatory, antioxidant and anthelmintic activities (MASOKO and ELOFF, 2005). 
 
5.2. Traditional uses and pharmacological studies of Terminalia 
phanerophlebia  
 
Different parts (roots, barks and leaves) of Terminalia phanerophlebia are used in TM for 
treatment of various diseases such as: pneumonia, bilharzia, hypertension, cancer, diabetes, 
stomach problems, schistosomiasis, gonorrhoea, syphilis, gynaecological conditions, 
inflammation, epilepsy, sexual transmitted diseases, wounds and skin diseases 
(NEUWINGER, 1996; VAN WYK et al., 2000, SCHMELZER and GURIB-FAKIM, 
2013). In South Africa, different cultures use roots of Terminalia phanerophlebia to treat 
witchcraft associated diseases that are believed to culminate in coughing leading to 
tuberculosis and rheumatism (MABOGO, 1990). Leaf decoctions are used in the traditional 
treatment of coughs, stomach complaints and opthalmia. The powdered leaves of Terminalia 
phanerophlebia are applied as a dressing to wounds. The widespread use of Terminalia 
phanerophlebia in indigenous medicine for the traditional treatment of different ailments 
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means that it represents a rich and readily available source of molecules with various kinds of 
biological activities, which have potential for use in pharmaceutical products. The crude 
extracts of the leaves, twigs and roots of this plant have demonstrated good antimicrobial 
activity against bacterial strains known to cause tuberculosis and opportunistic infections of 
the respiratory tract. Three compounds were reported from the stem bark of Terminalia 
phanerophlebia (NAIR et al., 2012). The compounds were identified as β-sitosterol, β-
sitostenone and stigmast-4-ene-3,6-dione. The study demonstrated β-sitosterol as an anti-
inflammatory agent. 
 
Many reports have mentioned that Terminalia contains antimycobacterial property, however 
only a few species have been investigated for their antimycobacterial constituents (McGAW 
et al. 2008a; FYHRQUIST et al., 2014). In a study by GREEN et al. (2010), Terminalia 
sericea stem bark acetone extract proved to have antimycobacterial activity as it inhibited the 
growth of both the attenuated and a clinical strain of Mycobacterium tuberculosis. The leaf 
crude extracts of Terminalia glaucescens Planch was reported to inhibit the growth of a 
revertant Mycobacterium tuberculosis strain (NVAU et al., 2011). It also showed inhibitory 
activity against other Mycobacterium species such as Mycobacterium ulcerans, 
Mycobacterium madagascariense and Mycobacterium indicus. Promising antimycobacterial 
effects were demonstrated by root extracts of Terminalia avicennoides Guill. & Perr. against 
two Mycobacterium species: Mycobacterium tuberculosis and Mycobacterium bovis 
(FYHRQUIST et al., 2014).  
 
According to SIBANDZE et al. (2009), species of Terminalia have been reported to contain 
several secondary metabolites with antibacterial property. Such compounds include 
arjunolone from Terminalia arjuna (Roxb. Ex DC.) Wight & Arn., punicalagin from 
Terminalia oblongata (Ruiz & Pav.) Steud., imberbic acid dirhamnosoid from Terminalia 
stulhmanii Engl., as well as diphenoyl-gallagylglucose and ellagitannin derivatives from 
Terminalia oblongata, Terminalia clamensae De Wild., Terminalia catappa L., and 
Terminalia cheluba Retz (ELOFF et al., 2008). Resveratrol-3-β-rutinoside, anolignan B, 
termilignan B and arjunic acid with antibacterial effects were isolated from Terminalia 
sericea (ELDEEN et al., 2005a; 2008). Ellagitannins and pentacyclic triterpenoids have 




Antimycobacterial compounds have been isolated from species of Terminalia, thus proving 
that some of the species of this genus have antimycobacterial effects. Compounds such as 
3,4'-di-O-methylellagic acid 3'-O-β-D-xylopyranoside and 4'-O-galloy-3,3'-di-O-methyllegic 
acid 4-O-β-D-xylopyranoside isolated from stem bark extract of Terminalia superba Engl. & 
Diels exhibited good antimycobacterial activity against four strains of mycobacteria 
(KUETE et al. (2010b). Pentacyclic triterpenoid and fridelin isolated from the leaf extracts 
of Terminalia avicennoides showed promising inhibitory activity against Mycobacterium 
bovis (FYHRQUIST et al., 2014). Acetyl rhamnosides of 1.3-hydroxylated pentacyclic 
triterpernoids from Terminalia stulhmanii showed good inhibition of Mycobacterium 
fortuitum (MANN et al., 2011). More studies on the isolation of compounds with 
antimycobacterial compounds from Terminalia species are needed as some of the plants from 
this genus have proven to have antimycobacterial constituents. 
 
In the current studies, on in vitro antimicrobial and antimycobacterial, anti-inflammatory as 
well as genotoxicity evaluation of extracts from plants used traditionally in South Africa to 
treat tuberculosis and related symptoms, several plant species reported to have exhibited good 
antibacterial activity against Mycobacterium species and other bacterial strains associated 
with respiratory infections. Terminalia phanerophlebia was one of them (MADIKIZELA et 
al., 2013b; 2014). Terminalia phanerophlebia leaf extracts showed considerable 
antimicrobial activities against bacterial strains tested and exhibited non-genotoxicity against 
Salmonella typhimurium strains. Thus, the aims of this study were to isolate and identify 
active antimicrobial compounds from Terminalia phanerophlebia. 
 
5.3. Materials and methods 
5.3.1. Bioassay guided fractionation of 80% methanol extracts of 
Terminalia phanerophlebia leaves  
 
In isolating bioactive compounds, different methods of separation are commonly used to 
obtain pure compounds, such methods include, thin layer chromatography (TLC), column 
chromatography using silica gel or Sephadex, flash chromatography, and high performance 
liquid chromatography (HPLC) (SASIDHARAN et al., 2011). Thin layer chromatography is 
a procedure that reveals the number of components in a mixture, after viewing the plate with 
the sample under the ultraviolet light (254 or 366 nm) or can be used as an analytic 
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fingerprint of a plant extract (AZMIR et al., 2013). The different isolation techniques have a 
common objective: to isolate compounds (AZMIR et al., 2013). When pure compounds are 
obtained after isolation, they are then used for structure and biological activity determination. 
 
Plant extracts usually occur as a combination of various types of bioactive compounds or 
phytochemicals with different polarities. As a result, their separation remains a big challenge 
for the process of identification and characterisation of bioactive compounds. The unmatched 
availability of chemical diversity of plant extracts either as pure compounds or as 
standardised extracts provides unlimited opportunities for new drug discoveries. Bioassay-
guided fractionation is a vital process in the isolation and identification of compounds with 




All TLC analyses were performed at room temperature using pre-coated plates (MERCK, 
silica gel 60 F254 0.2 thickness). Detection of spots was done by viewing under ultraviolet 
light (254 and 366 nm). Open column chromatography was carried out using silica gel (230–
400 mesh) and Sephadex LH-20. Nuclear magnetic resonance (NMR) data such as 1H, 13C, 
DEPT, COSY, NOESY, HSQC and HMBC spectra were obtained using a Bruker AV400 
spectrometer or Brucker 500 MHz spectrometer. Chemical shifts are expressed in parts per 
million (ppm).  
 
5.3.3. Plant material-collection and authentication 
 
The leaves of Terminalia phanerophlebia were collected in February, 2013 from the UKZN 
botanical garden, Pietermaritzburg, South Africa. The plant was identified by Alison Young 
(UKZN, Horticulturist) and the voucher specimen (BALUNGI 37) was deposited in UKZN 
Herbarium (NU) (Pietermaritzburg, South Africa) for botanical authentication. The collected 
leaves were separated from stalks and oven dried at 50 ºC. When completely dried, the leaves 
were ground into powder and kept in airtight containers until use. 
 




The powdered plant material (1 kg) was extracted with 8 l of 80% methanol (MeOH) at room 
temperature for 24 h with occasional shaking and filtered through Whatman No.1 filter paper. 
The filtrate was concentrated under reduced pressure using a rotary evaporator at 40 ºC. This 
afforded a crude extract (166.60 g) from the leaves of Terminalia phanerophlebia. 
 
5.3.5. Solvent partitioning of the crude extracts 
 
The crude extract was suspended in 500 ml water: MeOH (9:1) mixture, and then partitioned 
sequentially with hexane (3 × 800 ml), dichloromethane (DCM) (3 × 800 ml), ethyl acetate 
(EtOAc) (3×800 ml) and butanol (500 ml). The solvent fractions (hexane, DCM, EtOAc and 
butanol) were concentrated to dryness using a rotary evaporator and afforded four fractions. 
The mass of each fraction was 1.82 g (hexane), 2.59 g (DCM), 16.45 g (EtOAc) and 23.62 g 
(butanol) respectively. All the extracts were subsequently assayed for antimicrobial activity. 
 
5.3.6. Isolation of compounds from Terminalia phanerophlebia ethyl acetate 
fraction 
 
The most active fraction (EtOAc fraction, 16.45 g) was fractionated on a silica gel (230-400 
mesh) column. The column was filled with silica gel by pouring it directly on top of a small 
cotton wool stopper that was first inserted in the column. The column with the silica gel was 
then washed with 100% hexane twice, 100% DCM and then finally DCM: MeOH (9:1) 
before adding the extract. The EtOAc extract was dissolved in a DCM: MeOH (9:1) solvent 
mixture. The dissolved EtOAc extract was added to silica gel dropwise. The resultant silica 
gel was subsequently stirred using a mortar and pestle to evaporate the solvent until the 
extract was completely adsorbed on silica gel. Then silica gel adsorbed extract was added 
into the column using a funnel and a spatula. A cotton wool stopper was soaked in DCM: 
MeOH (9:1) solution and then placed on top of the sample in the column, to avoid disturbing 
the sample surface in the column when introducing different solvents. Elution of the sample 
was started with 100% DCM followed by an increasing gradient of EtOAc up to 100%. This 
was then in turn followed by an increasing gradient of MeOH in EtOAc up to 20%. Thirteen 





A total of 171 test tubes of 20 ml each were collected and analysed on TLC plates using 
DCM/MeOH (9:1 and 4:1) as solvent systems. These analyses yielded 10 fractions (F1-F10). 
An antimicrobial assay, on the fractions collected, was performed following the same 
procedure described in Section 2.7 to determine the MIC values of the collected fractions. 
Fraction 1 and Fraction 5 showed good activity against all tested bacterial strains. Fraction 1 
(37.4 mg) from test tubes 61 to 63 was purified by fractional crystallisation; 100% DCM was 
added to the sample and left to stand for an hour. The impurities dissolved into the DCM and 
the sample settled. The solvent containing impurities was carefully decanted and discarded. 
The same procedure was repeated three times and the sample was allowed to dry. The dried 
sample yielded compound 1 (27.10 mg) after analysis on TLC plates using DCM/MeOH 
(9:1). Fraction 5 (71.00 mg) from test tubes 96 to 105 was subjected to column 
chromatograph on Sephadex LH 20 using EtOAc/MeOH (9:1) as an eluent followed by an 
increasing gradient of MeOH from 10% up to 20%. The TLC plate analysis of the test tube 
fractions using DCM: MeOH (5:1) solvent mixtures yielded compound 2 (3.50 mg). The 
isolation scheme for compound 1 and 2 is presented in Figure 5.1. 
 
 
Table 5.1: Solvent systems used in column chromatography 
Solvent mixture  Percentage 
Dichloromethane 100 
Dichloromethane: ethyl acetate 90:10 
Dichloromethane: ethyl acetate 80:20 
Dichloromethane: ethyl acetate 70:30 
Dichloromethane: ethyl acetate 60:40 
Dichloromethane: ethyl acetate 50:50 
Dichloromethane: ethyl acetate 40:60 
Dichloromethane: ethyl acetate 30:70 
Dichloromethane: ethyl acetate 20:80 
Dichloromethane: ethyl acetate 10:90 
Ethyl acetate 100 
Ethyl acetate: methanol 90:10 
Ethyl acetate: methanol 80:20 
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Dried plant material (1 kg) 
                                              Extracted with 80% methanol, 
                                       and concentrated  
 
80% methanol extracts (166.60 g) 
                                                                        (Suspended in water: methanol; 9:1 v/v)  
Liquid-liquid partitioning  
 
                 Hexane                              Dichloromethane             Ethyl acetate (16.45 g) Butanol 
 
                                                            Fractions on silica gel (DCM/EtOAc/MeOH) 
                                                                      Fractions  
  
 1 (37.40 mg) 2        3           4             5 (71.00 mg) 6           7              8             9            10 
  Fractional crystallisation                            Purification on Sephadex LH 20 (EtOAc/MeOH) 
Compound 1 (27.10 mg)                           Compound 2 (3.50 mg) 
Figure 5.1: Fractionation scheme of the crude extracts from the leaves of Terminalia 
phanerophlebia 
 
5.3.7. Structure elucidation of isolated compounds 
 
Structure elucidation of the isolated compounds was carried out using NMR spectroscopic 
techniques: 1H (500 MHz) and 13C NMR (125 MHz), and DEPT together with 2D 
experiments (GCOSY, GHSQC and GHMBC). The compounds were identified as:  
Methyl gallate (methyl-3,4,5-trihydroxybenzoate) (Figure 5.14), 1H NMR (MeOD) δ: 3.81 
(3H, s, –OCH3), 7.05 (2H, s, H-2,H-6). 13C NMR (125 MHz, MeOD) δ: 121.6 (C-1), 110.2 
(C–H,C-2), 146.6 (C-3), 139.9 (C-4), 146.6 (C-5), 110.2 (C–H, C-6), 169.1 (C=O), 52.3 (–
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OCH3). The 1HNMR, 13C NMR, DEPT, GCOSY, GHSQC and GHMBC spectrum of 
methyl-3,4,5-trihydroxybenzoate are presented in Figures 5.2 to 5.6. The spectra data are in 
good agreement with that of methyl-3,4,5-trihydroxybenzoate in the literature 
(MADIKIZELA et al., 2013a). 
Compound 2: It was determined to be 1,6-di-O-coumaroyl glucopyranoside (Figure 5.14) 
from its spectroscopic data, NMR (1H and 13C), Table 5.2. 
 
5.3.8. Antimicrobial assay procedure 
 
The MIC values of the crude extracts, four solvent fractions, column fractions obtained from 
the EtOAc sample, and isolated compounds from Terminalia phanerophlebia leaves were 
determined using the broth microdilution method in 96 well microtitre plates against 
Staphylococcus aureus and Klebsiella pneumoniae as described by ELOFF (1998a). The 
REMA and broth microdilution method according to JADAUN et al. (2007) modified by 
GREEN et al. (2010) were used to determine the antimycobacterial activity of the extracts 
against Mycobacterium tuberculosis H37Ra and Mycobacterium aurum A+. All the 
procedures were followed as described in Section 2.4 and 2.5.  
 
5.4. Results and discussion  
5.4.1. Characterisation of compounds 1 and 2 
 
Bioassay guided fractionation of the EtOAc fraction of Terminalia phanerophlebia led to the 
isolation of two bioactive compounds that were identified by NMR (1D and 2D) 
spectroscopic methods as methyl-3,4,5-trihydroxybenzoate (1) and 1,6-di-O-coumaroyl 
glucopyranoside (2). 
 
The 1H NMR (MeOD) of compound (2) indicated the presence of two separate AA'BB' 
aromatic systems, two trans-olefinic groups and sugar signals with anomeric proton at δ 5.61 
(1H, d, J=7.7 Hz). The 13C and DEPT (MeOD) spectra of the compound showed seven pairs 
of almost identical signals assigned to the two coumaroyl groups along with six sugar peaks, 
Table 5.2. The positions of the attachment of two coumaroyl were assigned to C1 and C6 of 
the sugar using 2D NMR as indicated in Figure 5.13. Compound (2) was characterised as 
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1,6-di-O-coumaroyl glucopyranoside (phenyl propanoid glycoside ) from its NMR spectra 
data in Figures 5.7 to 5.12. To the best of my knowledge, the complete NMR data of this 
compound is presented for the first time. However, it has previously been identified as a 
constituent of strawberry leaf material by semi-preparative HPLC fractionation and H NMR. 
This is a hyphenated technique. It does not require isolation of compound but its direct 
identification from the extracts (HANHINEVA et al., 2009). Characterisation of the 
compound was carried out using 1H NMR and UPLC-qTOF-MS/MS in ES (−) technique. 
Their structural analysis could not be achieved by data obtained from the 1H NMR in the 
study. However, structure was proposed basically from the elemental composition of the 
main ion (C24H24O10), M/z = 471.13 and its subsequent fractionation in UPLC-qTOF-
MS/MS. (HANHINEVA et al., 2009). The two compounds isolated from the EtOAc fraction 
are reported for the first time from Terminalia phanerophlebia. However, methyl-3,4,5-
trihydroxybenzoate has previously been reported from Terminalia species such as Terimalia 
chebula Retz., Terminalia macroptera Guill. & Perr., Terminalia myriocapa Van Heurck & 
Müll. Arg., Terminalia calamansanai (Blanco) Rolf., Terminalia laxiflora, Terminalia 
bellerica (Gaertn.) Roxb., Terminalia horrida Steud. and Terminalia arjuna (Roxb. ex DC.) 
Wight & Arn. (MOHAMED et al., 2002; CHEN et al., 2009; MAHAJAN and PAI, 2010; 
PHAM et al., 2011; ACHARYYA et al., 2012; EL-AMEEN et al., 2013; RASHED and 
ONO, 2013; PFUNDSTEIN et al., 2010).  
 
5.4.2. Antimicrobial assays results 
 
The results of the MIC values demonstrated by the fractions and isolated compounds from 
Terminalia phanerophlebia against Staphylococcus aureus, Klebsiella pneumoniae, 
Mycobacterium aurum A+ and Mycobacterium tuberculosis H37Ra are presented in Table 
5.3. The results were interpreted as those MIC values less than 1 mg/ml had good 
antimicrobial activity (YORK et al., 2012). The extracts showed a broad spectrum of activity 
against the selected bacteria with MIC values ranging from 0.008 to ˃1 mg/ml. All four 
solvent fractions (hexane, DCM, EtOAc and butanol) obtained from the MeOH extract 
showed good antimicrobial activity, however, the EtOAc fraction demonstrated the lowest 
inhibitory values when compared to the others against all four bacterial strains tested, with 
MIC values ranging from 0.008 to 0.125 mg/ml. The best antimicrobial activity in this study 
was demonstrated by the EtOAc fraction at a MIC value of 0.008 mg/ml against 
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Staphylococcus aureus. This led to the selection of the EtOAc fraction of Terminalia 
phanerophlebia for isolation of compounds responsible for good antimicrobial activity 
observed. Out of the 10 test tube fractions obtained from the EtOAc column fractionation, 
fractions 1 and 5 exhibited good antimicrobial activity against all four bacterial strains tested, 
and that led to their purification and isolation of compounds. The two isolated compounds in 
this study showed good antimicrobial activity against all tested bacterial strains at MIC 
values ranging from 0.063 to 0.250 mg/ml. Biological activity of 1,6-di-O-coumaroyl 
glucopyranoside (2), are reported for the first time. However, closely related compounds in 
the class phenylpropanoid glycoside exhibited significant antimicrobial activity against both 
Gram-positive and Gram-negative bacterial strains (DIDRY et al., 1999; 
KYRIAKOPOULOU et al., 2001; LIMA et al., 2003; SI et al., 2007). Good MIC values 
ranging from 0.063 to 0.125 mg/ml exhibited by 1,6-di-O-coumaroyl glucopyranoside against 
the tested bacterial strains were noteworthy. When compared to that of the crude extracts 1,6-
di-O-coumaroyl glucopyranoside exhibited activity which was three times better than that of 
the crude extracts against a strain of Mycobacterium tuberculosis. Inhibition of 
Mycobacterium tuberculosis by 1,6-di-O-coumaroyl glucopyranoside was noteworthy, as this 
bacterial strain is reported to be the leading cause of tuberculosis worldwide. Compound (2), 
1,6-di-O-coumaroyl glucopyranoside could serve as a lead compound for tuberculosis drug 
discovery. Methyl-3,4,5-trihydroxybenzoate (1) is a biochemically available medicinally 
important compound derived from numerous plant species and possesses several biological 
activities including antibacterial, antifungal, antioxidant, antiasthmatic, anti-Herpes simplex 
virus and antineoplastic properties (KANG et al., 2008; CHOI et al., 2009; TEKE et al., 
2011; MADIKIZELA et al., 2013b). Methyl-3,4,5-trihydroxybenzoate demonstrated high 
activity against Herpes simplex virus type 1 and 2 (KANE et al., 1988). This compound is 
considered as a useful antimicrobial agent. Therefore, the lower MIC values demonstrated by 
methyl-3,4,5-trihydroxybenzoate in this study were not surprising as it has demonstrated 
good antibacterial activities against both Gram-negative and Gram-positive bacterial strains. 
In in vitro studies by KANG et al. (2008), CHOI et al. (2009), and TEKE et al. (2011), 
methyl-3,4,5-trihydroxybenzoate demonstrated significant antimicrobial activity. KIM et al. 
(2008) did a study determining the effect of methyl-3,4,5-trihydroxybenzoate on intracellular 
survival of Mycobacterium fortuitum and Mycobacterium tuberculosis 5 h after phagocytosis, 
this compound significantly increased the rate of intracellular killing of both bacterial strains 
demonstrating significant efficacy. According to TEKE et al. (2011), the presence of 
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hydroxyl groups on methyl-3,4,5-trihydroxybenzoate could be responsible for the 
antimicrobial activity observed from this compound.  
 
Good antimicrobial activity exhibited by the compounds isolated from Terminalia 
phanerophlebia authenticates the traditional use of this plant in treating tuberculosis and its 
related symptoms. Further pharmacological studies on antimicrobial evaluation of these 
compounds against drug-resistant strains of bacteria as well as toxicology testing are 
required. Antimicrobial compounds isolated from plants may have better antimicrobial 
properties when combined with conventional drugs, therefore, further studies on the synergy 
between isolated compounds and antibiotics is required to confirm if there could be any 
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Table 5.3: Antibacterial activity of the crude extracts, solvent fractions, column 
fractions from ethyl acetate sample and isolated compounds from the leaves of 
Terminalia phanerophlebia 
Sample Bacterial strains tested and minimum inhibitory concentration (MIC) values (mg/ml) 
K. pneumoniae S. aureus M. aurum A+ M. tuberculosis H37Ra 
Crude 0.125 0.125 0.125 0.125 
Dichloromethane 0.250 0.016 0.250 0.250 
Hexane 0.250 0.031 0.250 0.250 
Ethyl acetate 0.125 0.008 0.125 0.125 
Butanol 0.250 0.031 0.250 0.250 
Fraction 1 0.125 0.125 0.250 0.250 
Fraction 2 0.250 0.250 > 1 > 1 
Fraction 3 0.125 0.125 > 1 > 1 
Fraction 4 0.125 0.125 > 1 > 1 
Fraction 5 0.125 0.125 0.125  0.250  
Fraction 6 0.063 0.125 > 1 > 1 
Fraction 7 0.063 0.125 > 1 > 1 
Fraction 8 0.063 0.250 > 1 > 1 
Fraction 9 0.125 0.250 > 1 > 1 








0.125 0.125 0.125 0.063 
Streptomycin - - 1.95 ×10-1 - 
Rifampicin - - - 2.4 ×10-2 
Neomycin - 3.063 ×10-3 - - 
K. pneumoniae: Klebsiella pneumoniae, S. aureus: Staphylococcus aureus, M. aurum: Mycobacterium 
aurum A+, M. tuberculosis: Mycobacterium tuberculosis H37Ra. The values highlighted in bold are 





Investigation of the EtOAc soluble fraction of Terminalia phanerophlebia leaf extract using 
bioassay guided isolation techniques afforded a phenylpropanoid glycoside identified as 1,6-
di-O-coumaroyl glucopyranoside and methyl-3,4,5-trihydroxybenzoate as its bioactive 
constituents. According to our knowledge, complete NMR spectra data of 1,6-di-O-
coumaroyl glucopyranoside are reported for the first time. Isolated compounds are also 
reported for the first time from the extracts of Terminalia phanerophlebia. Good 
antimicrobial activity exhibited by these compounds validate the use of Terminalia 
phanerophlebia in traditional treatment of tuberculosis and related symptoms in South Africa. 
Further studies on cytotoxicity testing, combination with synthetic drugs of these isolated 
compounds as well as evaluating them against drug-resistant strains of bacteria are required. 
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Chapter 6: General conclusions 
 
Respiratory tract infections ranging from common cold to life threatening infectious diseases 
such as tuberculosis are responsible for the increased mortality (7 million deaths) worldwide. 
Globally, the increasing resistance to the available range of drugs against pathogens causing 
these infections remains a major concern. South Africa is included among four countries 
estimated to have the leading number of XDR tuberculosis. Given the high possibility that 
more drug-resistant tuberculosis strains which will exhaust the current chemical defence will 
emerge in the future creates an urgent reason for counteracting the problem. New anti-
tuberculosis agents with new modes of activity and low toxicity are required to control the 
epidemic of tuberculosis and reduce the prevalence of drug-resistant tuberculosis strains. 
 
The medicinal value of plants for the treatment of various diseases and ailments was 
recognised by different cultures since the beginning of human civilisation. Besides consisting 
of great cultural diversity, South Africa is blessed with a diverse flora (more than 24 000 
plant species) which has potential for the discovery of phytochemicals that have 
pharmacological activity. Several South African plants have been documented as exhibiting 
anti-tuberculosis property, therefore there is considerable potential in discovering plants that 
can inhibit the growth or eradicate microorganisms that cause tuberculosis. In the current 
study, the crude extracts from 10 plant species were tested for antimicrobial activity against 
bacterial strains related to respiratory ailments, and the ability to inhibit the COX enzymes. 
The extracts that demonstrated noteworthy antimicrobial activity (MIC values less than 1 
mg/ml) were further investigated for their genotoxicity and cytotoxicity effects. Furthermore, 
the compounds from antimicrobial active plant extracts were isolated, identified and 
evaluated for antimicrobial activity. 
 
Different solvents including PE, DCM, 80% EtOH and water were used for extraction as they 
cover a wide polarity range. The EtOH extract of Polygala fruticosa gave the highest yield, 
whilst PE extracts of the roots of Terminalia phanerophlebia yielded the lowest mass. Some 
of the extracts from Abrus precatorius subp. africanus (leaves and seeds), Asparagus falcatus 
(leaves), Asparagus africanus (leaves), Ficus sur (roots), Indigofera arrecta (leaves), 
Leonotis intermedia (leaves), Pentanisia prunelloides (leaves and roots) and Terminalia 
phanerophlebia (leaves roots and twigs) showed noteworthy antimicrobial activity against at 
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least one bacterial strain or more. Thus, partially providing supporting evidence for their use 
in South African TM for treating tuberculosis and related symptoms. Despite being 
documented to be used in the treatment of tuberculosis and related symptoms, extracts of 
Brunsvigia grandiflora (bulb), Ficus sur (bark), Indigofera arrecta (roots), Leonotis 
intermedia (stem) and Polygala fruticosa (whole plant) did not show good antimicrobial 
activity. 
 
Several symptoms of tuberculosis are associated with the host inflammatory responses that 
occur as a result of the immune system failing to recover. The high inhibition of COX-2 
exhibited by the PE extracts of Pentanisia prunelloides (roots) and the DCM extracts of Ficus 
sur (bark) as well as Abrus precatorius subps. africanus (leaves) was noteworthy. Other 
extracts of the selected plants which showed moderate inhibition of the COX-2 enzyme were 
Asparagus africanus (leaves), Brunsvigia grandiflora (bulb), Ficus sur (roots), Indigofera 
arrecta (roots), Leonotis intermedia (leaves), Pentanisia prunelloides (leaves), Polygala 
fruticosa (whole plant), and Terminalia phanerophlebia (leaves, roots and twigs). These 
findings were remarkable as they demonstrate that some of the plants besides having 
antimicrobial activity also possess anti-inflammatory property.  
 
Although determination of the biological activities of medicinal plants is important, their 
safety evaluation is crucial and necessary. The genotoxicity results revealed that all the 
selected antimicrobial extracts were non-genotoxic against the bacterial strains tested. The 
non-genotoxicity effects of tested plants coupled with the noteworthy antimicrobial activity 
of some extracts from these plants necessitates further anti-tuberculosis research.  
 
Extracts with noteworthy antimicrobial activity were further evaluated for their safety using 
the MTT assay against monkey kidney Vero cells. The highest selectivity index value (16.43) 
was demonstrated by the water extract of Terminalia phanerophlebia (leaves). Water is the 
commonly used solvent in the extraction of plant constituents in TM, so the high selectivity 
index value of the water extracts of Terminalia phanerophlebia (leaves) and good 
antimicrobial activity of the extracts from this plant part warrants further studies. Pentanisia 
prunelloides (leaf and root), Abrus precatorius subsp. africanus (leaves), and Asparagus 
africanus (leaves) extracts also demonstrated noteworthy selectivity index values which were 
greater than one for the biologically active extracts tested. Some of the extracts of Abrus 
precatorius subsp. africanus, Asparagus falcatus, Leonotis intermedia, Ficus sur and 
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Indigofera arrecta showed some cytotoxicity in this study, although they were non-genotoxic 
against Salmonella tester strains. Therefore, this suggests that these plants must be 
administered cautiously, and further studies using different test models are required to 
evaluate their cytotoxicity.  
 
Terminalia phanerophlebia leaf extracts demonstrated considerable antimicrobial activity 
against tested bacterial strains known to cause respiratory ailments. Thus, it was questioned 
whether the antimicrobial activity could be accredited to any specific compounds in the 
species. Methyl-3,4,5-trihydroxybenzoate and 1,6-di-O-coumaroyl glucopyranoside were 
isolated from Terminalia phanerophlebia (leaf) extracts using biological assay guided 
fractionation. Both compounds demonstrated noteworthy antimicrobial activity which 
partially authenticates the traditional use of this plant in treating tuberculosis and its related  
symptoms.  
 
This study provided a basic understanding of the efficacy of the selected medicinal plants in 
TM and management of the tuberculosis challenge. Furthermore it has confirmed the need to 
test these medicinal plants for more in vitro and in vivo pharmacological activities. With 
regards to the pharmacological results observed in this study future research should be aimed 
at isolating antimicrobial compounds from Abrus precatorius subsp. africanus, Asparagus 
africanus, Asparagus falcatus, Ficus sur, Indigofera arrecta, Leonotis intermedia, and 
Pentanisia prunelloides. Toxicity studies using different test batteries are required. The 
current findings substantiate that the pharmacologically active plants might comprise 
alternative future candidates for tuberculosis treatment. Besides contributing to anti-
tuberculosis research, this study will contribute to sustainable utilisation of Abrus precatorius 
subsp. africanus, Asparagus africanus, Asparagus falcatus, Indigofera arrecta, Leonotis 
intermedia, Pentanisia prunelloides, and Terminalia phanerophlebia as leaves can be used 
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